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ABSTRACT 
 
SRMS (Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristoylaton 
sites) is a non-receptor tyrosine kinase that belongs to the BRK family kinases (BFKs) and is 
evolutionarily related to the Src family kinases (SFKs). Like SFKs and BFKs, the SRMS protein 
comprises of two domains involved in protein-protein interactions, namely, the Src-homology 3 
domain (SH3) and Src-homology 2 domain (SH2) and one catalytic kinase domain.  Unlike 
members of the BFKs and SFKs, the biochemical and cellular role of SRMS is poorly understood 
primarily due to the lack of information on the substrates and signaling intermediates regulated by 
the kinase.  Previous biochemical studies have shown that wild type SRMS is enzymatically active 
and leads to the tyrosine-phosphorylation of several proteins, when expressed exogenously in 
mammalian cells. These tyrosine-phosphorylated proteins represent the candidate cellular 
substrates of SRMS which are largely unknown.  Further, previous studies have determined that 
the SRMS protein displays a characteristic punctate cytoplasmic localization pattern in mammalian 
cells.  These SRMS cytoplasmic puncta are uncharacterized and may provide insights into the 
biochemical and cellular role of the kinase.     
 Here, we utilized mass spectrometry-based quantitative label-free phosphoproteomics to 
(a) identify the candidate SRMS cellular substrates and (b) candidate signaling intermediates 
regulated by SRMS, in HEK293 cells expressing ectopic SRMS. Specifically, using a 
phosphotyrosine enrichment strategy we identified 663 candidate SRMS substrates and consensus 
substrate-motifs of SRMS.  We used customized peptide arrays and performed the high-throughput 
validation of a subset of the identified candidate SRMS substrates.  Further, we independently 
validated Vimentin and Sam68 as bonafide SRMS substrates.  Next, using Titanium dioxide 
(TiO2)-based phosphopeptide enrichment columns, we identified multiple signaling intermediates 
of SRMS.  Functional gene enrichment analyses revealed several common and unique cellular 
processes regulated by the candidate SRMS substrates and signaling intermediates.  Overall, these 
studies led to the identification of a significant number of novel and biologically relevant SRMS 
candidate substrates and signaling intermediates, which mapped to a number of cellular and 
biological processes primarily involved in cell cycle regulation, apoptosis, RNA processing, DNA 
iii 
 
repair and protein synthesis.  These findings provide an important resource for future mechanistic 
studies to investigate the cellular and physiological functions of the SRMS.  
 Studies towards characterizing the SRMS cytoplasmic puncta showed that the SRMS 
punctate structures do not colocalize with some of the major cellular organelles investigated, such 
as the mitochondria, endoplasmic reticulum, golgi bodies and lysosomes.  However, studies 
investigating the involvement of the SRMS domains in puncta-localization revealed that the SRMS 
SH2 domain partly regulates this localization pattern.  These results highlight the potential role of 
the SRMS SH2 domain in the localization of SRMS to these cytoplasmic sites and lay important 
groundwork for future characterization studies. 
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1. Review of the literature  
 
1.1 Tyrosine kinases 
       Tyrosine kinases (TKs) or protein tyrosine kinases (PTKs) are enzymes that catalyze the 
transfer of a phosphate group from a molecule of ATP to the tyrosine residues of proteins (Figure 
1) (Knighton et al., 1993).  The phosphorylation of tyrosine residues on proteins by tyrosine 
kinases entails many biologically important consequences in a cellular and physiological context 
(Hunter, 2014).  By phosphorylating tyrosine residues on proteins, tyrosine kinases elicit 
conformational changes in these proteins which affects their biochemical function and/or 
intermolecular binding to other proteins, which together modulates intracellular signaling  (Groban 
et al., 2006; Kimura et al., 1996).  Such phosphorylation is reversible where specific tyrosine 
phosphatases catalyze the removal of the phosphate group(s) from the tyrosine residue(s) of these 
proteins (Figure 1) (Frearson and Alexander, 1997; Stoker, 2005).  In this manner, the biochemical 
function of tyrosine kinases is regulated in cells (Frearson and Alexander, 1997; Stoker, 2005).  
With the culmination of the human genome project, a total of 90 tyrosine kinases were  found to 
  
        
 
Figure 1.1: Overview of protein tyrosine phosphorylation and dephosphorylation: Protein 
tyrosine kinases (PTKs) covalently attach a phosphate group, derived from an ATP moiety, to the 
nucleophilic hydroxyl group of a tyrosine residue on a protein. Protein tyrosine phosphatases 
(PTPs) in turn catalyze the de-phosphorylation of these residues by removing the phosphate group.   
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be coded by the human genome (Manning et al., 2002; Robinson et al., 2000).  Of these, 58 are 
receptor type and 32 are non-receptor type tyrosine kinases (Manning et al., 2002; Robinson et al., 
2000). 
 
1.1.1 Receptor tyrosine kinases 
          Receptor tyrosine kinases (RTKs) are embedded in the cell membrane and possess both, an 
extracellular domain and an intracellular domain (Lemmon and Schlessinger, 2010; Manning et 
al., 2002).  The extracellular domain is involved in binding to ligands whereas the intracellular 
portion of the RTK is comprised of the kinase domain which catalyzes the phosphorylation of 
tyrosine residues (Hubbard and Miller, 2007; Lemmon and Schlessinger, 2010).  A total of 58 
different receptor tyrosine kinases have been identified to date in the mammalian kinome (Figure 
2).  These are grouped into 20 sub-families, namely, the ErbB, IR (Insulin receptor), PDGFR 
(Platelet-derived growth factor receptor), VEGFR (Vascular endothelial growth factor receptor), 
FGFR (Fibroblast growth factor receptor), PTK7 (Protein tyrosine kinase 7), TRK (Tropomycin 
receptor kinase), ROR (RAR-related orphan receptors), MuSK, (Muscle-specific kinase), MET 
(Mesenchymal Epithelial Transition), TAM (Tyro3-Axl-Mer), TIE (Tyrosine kinase with 
immunoglobulin-like and EGF-like domains), EPH (Ephrin), RET (Rearranged during 
transfection), RYK (Related to tyrosine kinase), DDR (Discoidin domain receptor), ROS (c-Ros1), 
LMR (Lemur), ALK (Anaplastic lymphoma kinase) and STYK1 (Serine/threonine and tyrosine 
receptor kinase 1) (Figure 2) (Lemmon and Schlessinger, 2010).  The extracellular domains of 
receptor tyrosine kinases bind to their respective ligands, triggering receptor dimerization which 
results in the autophosphorylation of tyrosine residues on the intracellular kinase domains of the 
receptor (Lemmon and Schlessinger, 2010).  These phosphotyrosine residues serve as binding sites 
for specific cytoplasmic proteins which relay signaling downstream to elicit specific cellular 
functions (Pawson, 1995).  Notably, the LMR family, STYK1 family and ErbB2 kinase represent 
the only known receptor tyrosine kinases that do not possess an extracellular ligand-binding 
domain (Lemmon and Schlessinger, 2010).  Ligand stimulation-based activation of receptor 
tyrosine kinases leads to the activation of specific intracellular signaling cascades that involve a 
variety of cytoplasmic proteins.  Such proteins include, but are not limited to, cytoplasmic kinases 
and adapter or scaffolding proteins (Lemmon and Schlessinger, 2010).  The signals eventually 
culminate in the transcriptional regulation of specific genes in the nucleus and/or the modulation 
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Figure 1.2: The mammalian receptor tyrosine kinase (RTK) complement: Shown here is a 
schematic representation of the 20 receptor tyrosine kinase families encoded by the mammalian 
kinome (Lemmon and Schlessinger, 2010).  The kinase members of each family are indicated. The 
intracellular side of these transmembrane receptor tyrosine kinases comprises the catalytic/kinase 
domain (highlighted in red).  The extracellular side of these kinases represent various subunits that 
form the ligand-binding domain. These include the L (Leucine-rich), Cysteine-rich, Fibronectin 
type III, Cadherin, Discoidin, Ig (Immunoglobulin), EGF (Epithelial Growth Factor), Psi, WIF 
(Wnt Inhibitory Factor), Ephrin-binding, Fz (Frizzled), LDLa (Low-Density Lipoprotein class a) 
YWTD (tyrosine-tryptophan-threonine-aspartic acid), Acid box, Sema and MAM (Meprin/A5-
protein/PTPmu) subunits. 
 
 
of protein function in the cell thereby regulating important biological processes such as cell 
proliferation, migration, apoptosis and senescence, to name a few (Lemmon and Schlessinger, 
2010; Zwick et al., 2001).    
 
1.1.1.1 EGFR signaling pathway 
           The EGFR (Epithelial growth factor receptor) signaling pathway is one of the most well-
characterized and biologically important receptor tyrosine kinase-mediated signal transduction 
pathways that regulates growth, proliferation and differentiation in mammalian cells (Oda et al., 
2005).  The EGFR receptor belongs to the ErbB family of RTKs, whose other three members 
include ErbB2, ErbB3 and ErbB4, all of which display conserved structural and functional 
characteristics.  Several ligands such as EGF (Epidermal growth factor), TGF (Transforming 
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growth factor alpha), epiregulin, amphiregulin, epigen and betacellulin, are known to bind to 
EGFR.  EGF, however, is the major high-affinity ligand of EGFR (Oda et al., 2005).   
 Upon ligand-binding, EGFR undergoes homo- or heterodimerization with another EGFR 
monomer or monomers of other members of the ErbB family, respectively (Figure 1.3) (Oda et 
al., 2005; Yarden and Shilo, 2007).  Dimerization stimulates the activation of the cytoplasmic 
kinase domains of EGFR which results in the autophosphorylation of tyrosine residues within the 
cytoplasmic kinase domain (Yarden and Shilo, 2007).  These autophosphorylation residues are 
Y1092, Y1172, Y1197, Y1110 and Y1016 (Nogami et al., 2003).  These autophosphorylated 
residues serve as docking sites for the recruitment of various cytoplasmic proteins to the receptor 
(Figure 1.3) (Oda et al., 2005).  These proteins bind to the docking sites on EGFR via their SH2 
and/or PTB domains (Figure 1.3).   
 Following binding to EGFR, these proteins relay signaling through various intracellular 
pathways to elicit distinct cellular functions.  Notably, EGFR heterodimerization with other ErbB 
members recruit multiple other signaling proteins which considerably adds to the complexity of 
EGFR-signaling (Oda et al., 2005).  Figure 1.3 shows some of the major EGFR activation-
dependent signaling pathways.  For instance, Grb2 (Growth factor receptor-bound protein 2) is 
recruited to autophosphorylated EGFR via the Grb2 SH2 domain (Figure 1.3A) (Capuani et al., 
2015).  Grb2 then binds to the guanine nucleotide exchange factor SOS (Son of sevenless) via the 
Grb2 SH3 domains (Zarich et al., 2006).  Upon binding to Grb2, SOS becomes activated (Katz et 
al., 2007; Zarich et al., 2006).  Activated SOS leads to the activation of Ras which in turn activates 
Raf kinase activity (Katz et al., 2007).  Raf kinase phosphorylates and activates Mek1/2 thereby 
activating a MAPK (Mitogen-activated protein kinase) such as Erk1/2 (Extracellular signal-
regulated kinase 1/2) (Katz et al., 2007).  Activated Erk1/2 translocates to the nucleus to 
phosphorylate transcription factors such as Elk1 and c-myc which transactivate target genes 
implicated in cell survival and proliferation (Figure 1.3A) (Schuhmacher and Eick, 2013; Shin et 
al., 2011).   
 Likewise, JAK1/2 (Janus kinase1/2) is recruited to activated EGFR resulting in the 
phosphorylation and activation of the JAK proteins (Figure 1.3B) (Andl et al., 2004).  Activated 
JAK1/2 then phosphorylate STAT3 (Signal transducer and activator of transcription3) resulting in 
STAT3-dimerization (Andl et al., 2004).  Activated STAT3 dimers translocate to the nucleus  
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Figure 1.3: The EGFR-mediated signaling pathways.  A schematic representation of the major 
signaling pathways propagated downstream of ligand-induced activation of EGFR.  Following 
stimulation with EGF, the EGFR monomers undergo dimerization which activates the cytoplasmic 
kinase domains of the receptor.  As a result of enzymatic activation, EGFR undergoes 
autophosphorylation resulting in the formation of docking sites for the recruitment of various 
cytoplasmic adapter proteins and kinases.  These cytoplasmic proteins relay downstream signaling 
leading to the activation of various types of signaling cascades.  A. Recruitment of Grb2 to docking 
sites on activated EGFR leads to signaling through Ras, Raf and Mek1/2 resulting in Erk1/2 
activation which enhances the transcriptional activity of ELK1 and c-Myc.  B. Activated EGFR 
recruits and phosphorylates JAK1/2.  Active JAK1/2 phosphorylates STAT3, causing STAT3 
dimerization, nuclear translocation and transactivation of STAT3-target genes.  c-Src, activated 
downstream of EGFR, also directly phosphorylates STAT3 leading to STAT3-dimerization and 
activation.  C. Activation of PLC downstream of EGFR leads to the hydrolysis of PIP2 into IP3 
and DAG.  IP3 stimulates Calcium ion release from the endoplasmic reticulum thereby stimulating 
CaMK signaling.  Increase in cellular DAG concentration stimulates the activation of PKC which 
activates NFB via IKK leading to the transactivation of NFB-target genes.  D. Activated PI3K 
catalyzes the conversion of PIP2 to PIP3.  PIP3 promotes the PDK1-mediated activation of Akt 
which triggers the mTOR signaling via S6K resulting in enhanced protein synthesis.  E. c-Cbl 
attenuates membrane-bound EGFR expression and downstream signaling by promoting EGFR 
endocytosis, a process which is negatively regulated by BRK.  Further, BRK also direcly 
phosphorylates AKT leading to AKT activation.  F. Nck-binding to EGFR activates PAK which 
potentiates Jnk signaling through MEKK1 and MKK4.  Activated Jnk translocates to the nucleus 
to phosphorylate and activate, c-Fos and c-Jun.  Jnk-mediated activation of c-Fos and c-Jun results 
in the transactivation of c-Fos and c-Jun-target genes.  All EGFR-regulated transcriptional factors 
are involved in the transcriptional activation of genes broadly involved in cell survival, 
proliferation and migration. 
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where these transactivate target genes involved in cell proliferation and migration (Figure 1.3B) 
(Carpenter and Lo, 2014; Sherry et al., 2009).  c-Src is also known to be activated downstream of 
EGF signaling where activated c-Src directly phosphorylates STAT3 leading to STAT3 
dimerization (Figure 1.3) (Cao et al., 1996; Osherov and Levitzki, 1994; Schreiner et al., 2002).  
 EGFR also activates Phospholipase C which results in the hydrolysis of PIP2 
(Phosphatidylinositol-4,5-bisphosphate) to IP3 (Inositol trisphosphate) and DAG (1,2-
Diacylglycerol) (Iwabu et al., 2004; Xie et al., 2010).  IP3 causes the release of calcium ions (Ca2+) 
from the endoplasmic reticulum which activate calcium calmodulin-dependent kinase (CaMK)-
mediated signaling (Sun et al., 2011).  An increase in the cellular concentration of DAG triggers 
the activation of PKC (Protein kinase C) which in turn phosphorylates and activates IKK (IB 
kinase) (Lallena et al., 1999).  IKK activates the transcription factor NFB leading to the 
transactivation of NFB-target genes such as those involved in cell survival and growth (Figure 
1.3C) (Cheng et al., 2011; Israel, 2010).   
 One of the major downstream signaling modules of EGFR is PI3K (Phosphatidylinosit ide 
3-kinases) (Figure 1.3D) (Freudlsperger et al., 2011; Slomovitz and Coleman, 2012).  PI3K is 
recruited to and activated by EGFR upon ligand stimulation.  Active PI3K catalyzes the conversion 
of PIP2 to PIP3 (Phosphatidylinositol-3,4,5-trisphosphate).  PIP3 recruits Akt and PDK1 
(Phosphoinositide-dependent kinase1) together which allows PDK1 to phosphorylate and activate 
Akt (Freudlsperger et al., 2011; Slomovitz and Coleman, 2012).  Akt is a key regulator of several 
signaling proteins, one of which includes mTOR (Mammalian target of rapamycin) (Laplante and 
Sabatini, 2012).  Akt phosphorylates and inhibits the activity of the mTOR-inhibitor, TSC2 
(Tuberous sclerosis complex2), thereby relieving the inhibitory constraints on mTOR.  Activated 
mTOR phosphorylates and activates S6K1/2 (Ribosomal protein S6 kinase1/2) thereby promoting 
protein synthesis (Figure 1.3D) (Laplante and Sabatini, 2012).   
 EGFR signaling is also negatively regulated by the ubiquitin ligase c-Cbl, which promotes 
EGFR endocytosis and subsequent degradation via the lysosomal pathway (Ravid et al., 2004; 
Visser Smit et al., 2009).  In this context, BRK has been shown to antagonize c-Cbl-mediated 
EGFR endocytosis (Figure 1.3 E) (Li et al., 2012). Further, EGF-induced activation of EGFR has 
been shown to promote EGFR-BRK association and BRK activation.  Activated BRK further 
potentiates EGFR signaling by directly phosphorylating and activating EGFR, thereby forming a 
positive feedback loop for EGFR signaling (Li et al., 2012).   
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 Other downstream effectors of EGFR include Nck (Non-catalytic region of tyrosine kinase) 
which is recruited to the activated receptor via its SH2 domain (Figure 1.3F) (Tomar and 
Schlaepfer, 2010). Nck then binds to Pak1 via the Nck SH3 domain (Tomar and Schlaepfer, 2010).  
Nck-bound PAK1 is then activated at the membrane by binding to Rac1 and cdc42 (Lu and Mayer, 
1999).  Activated PAK1 in turn activates Jnk (c-Jun kinase) which is mediated via MEKK1 and 
MKK4 (Tomar and Schlaepfer, 2010).  Active Jnk undergoes nuclear translocation where it 
phosphorylates and activates the transcription factors c-Jun and c-Fos (Tomar and Schlaepfer, 
2010).  Both, c-Jun and c-Fos then transactivate target genes involved in cell proliferation and 
migration (Figure 1.3F) (Ye and Field, 2012).  In this way, ligand-induced activation of EGFR 
triggers multiple cytoplasmic signaling cascades that are essential for mammalian growth and 
development (Sibilia et al., 2007; Zhang et al., 2013).  
 
 
1.1.2 Non-receptor tyrosine kinases 
         Non-receptor tyrosine kinases, as the name suggests, are not membrane-bound and are 
present in the cytoplasm of cells (Neet and Hunter, 1996). There are 32 different non-receptor 
tyrosine kinases encoded by the mammalian genome and are categorized into 10 sub-families 
(Manning et al., 2002; Neet and Hunter, 1996).  These include the ABL, ACK, CSK, FAK, FES, 
SRC, BRK, JAK, SYK and TEC families (Neet and Hunter, 1996). Non-receptor tyrosine kinases 
are composed of a kinase domain that imparts catalytic activity and other specific binding domains 
that mediate interaction with various binding partners, substrates and other molecules such as DNA 
(Neet and Hunter, 1996).        
 
1.1.2.1 Src family kinases  
           The Src family kinases (SFKs) represents one of the most well-characterized non-receptor 
tyrosine kinase families encoded by the mammalian genome (Amata et al., 2014; Parsons and 
Parsons, 2004).  The family comprises nine different non-receptor tyrosine kinases, namely c-Src, 
Yes, Fyn, Fgr, Yrk, Lyn, Blk, Hck, and Lck (Amata et al., 2014; Parsons and Parsons, 2004).  v-
Src is an oncogenic orthologue of c-Src and one of the first constitutively active tyrosine kinases 
to be discovered with oncogenic properties (Hunter, 2015; Hunter and Sefton, 1980).  While v-Src 
was first identified from Rous Sarcoma virus, c-Src was discovered in mammalian cells and 
reported as a protooncogene (Hunter, 2015; Hunter and Sefton, 1980; Oppermann et al., 1979).  c-
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Src maps to chromosomal loci 1p34-p36 and 20q12-q13, both of which are pre-disposed to genetic 
re-arrangements in multiple malignancies (Le Beau et al., 1984; Parker et al., 1985).   
 SFKs possess an N-terminal myristoylation or palmitoylation signal that allows these 
kinases to anchor to the plasma membrane (Koegl et al., 1994; Patwardhan and Resh, 2010).  They 
also possess three evolutionarily conserved functional domains, namely, the SH3 (Src-homology 
3), SH2 (Src-homology 2) and kinase domains (Figure 1.4) (Eck et al., 1994; Parsons and Parsons, 
2004).  The SH3 and SH2 domains are intermolecular binding domains where the SH3 domains 
bind to polyproline motifs whereas the SH2 domains bind to phosphotyrosine-containing motifs, 
on cellular proteins (Gan and Roux, 2009; Panni et al., 2002; Pawson and Gish, 1992; Pawson and 
Schlessingert, 1993).  The kinase domain imparts catalytic activity to the enzyme and is involved 
 
            
 
Figure 1.4: The mammalian non-receptor tyrosine kinase complement: Shown here is the 
general domain-structure organization of members belonging to the ten non-receptor tyrosine 
kinase families.  The prototypical member of each non-receptor tyrosine kinase family possesses 
a kinase domain (highlighted in red) and one or several intermolecular-binding domains which 
include the SH3, SH2, DNA-binding, actin-binding, JEF (JAK, ERM, FAK), PH (Pleckstrin 
homology), Focal adhesion-binding, kinase-like and CB (Cdc42-binding) domains, as annotated 
in the figure.    
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in autophosphorylation as well as the phosphorylation of target proteins (Hubbard et al., 1998; 
Miller, 2003).  The SH3 domains in Src family kinases are known to bind to sequences displaying 
the X-P-X-X-P consensus motif while the SH2 domains generally exhibit strong specificity 
towards the P-Y-E-E-I motif (where Y represents the phosphorylated tyrosine residue) (Feng et 
al., 1994; Lim et al., 1994; Songyang et al., 1993; Yu et al., 1994).  Further, high-throughput 
kinase assays using libraries of degenerate peptides as candidate substrates have shown that the 
kinase domains of Src family kinases preferably phosphorylate sequences comprising either an 
isoleucine, leucine or valine at the -1 position and a glutamic acid or glycine at the +1 position, 
with respect to the central phosphotyrosine residue (Deng et al., 2014; Shah et al., 2018; Songyang 
et al., 1995).  Both, motif specificities of the kinase domain as well as the SH3 and/or SH2 domains 
are involved in substrate-selection by members of the Src family kinases (Miller, 2003).     
 Enzymatic activation in Src family kinases is auto-regulated by intramolecular associations 
involving the SH3, SH2 and kinase domains (Cooper et al., 1986; Liu et al., 1993; Superti-Furga, 
1995; Xu et al., 1999).  Key to this mode of enzymatic autoregulation is the phosphorylation of a 
highly conserved residue, Y530, in the C-terminal tail of Src- family kinases (Figure 1.5) (Cooper 
et al., 1986; Liu et al., 1993; Superti-Furga, 1995; Xu et al., 1999).  This C-terminal residue is a 
target for phosphorylation by c-Src kinase (CSK) (Nada et al., 1991).  Phosphorylation of this site 
by CSK triggers intramolecular rearrangements ultimately leading to the catalytical inhibition of 
SFKs (Figure 1.5) (Nada et al., 1991). Extensive structural and cell-based studies have shown that 
phosphorylation of the conserved Y527 amino acid in chicken c-Src (Y530 in human c-Src) by 
CSK results in the intramolecular binding of Y530 with the c-Src SH2 domain, thereby locking 
the enzyme in an inactive conformation (Figure 1.5) (Cooper et al., 1986; Liu et al., 1993).  This 
is followed by additional intramolecular rearrangements where the SH3 domain binds to the SH2-
kinase linker region to stabilize the enzymatically inactive conformation (Figure 1.5) (Cooper et 
al., 1986; Liu et al., 1993; Superti-Furga, 1995; Xu et al., 1999).  Accordingly, studies have shown 
that deletion of either the c-Src SH2 or SH3 domain or introducing a point-mutation at Y527 
(Y527F), disrupts the auto-inhibited conformation of the enzyme and results in enhanced catalytic 
activity of the kinase (Okada et al., 1993).  In the context of wild type c-Src however, the 
phosphatase-dependent dephosphorylation of the C-terminal tyrosine residue and/or availability 
of high-affinity SH3/SH2 interactors relieve the intramolecular binding constraints and promotes 
an active conformation of the kinase (Figure 1.5) (Roskoski, 2005; Xu et al., 1999).  A number of 
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phosphatases have been reported to target the C-terminal tyrosine residue in c-Src and Src family 
members leading to the enzymatic activation of these kinases.  These phosphatases include PTP1B, 
SHP1, CD45, RPTPα, RPTPε, and LAR (Huntington and Tarlinton, 2004; Maksumova et al., 
2005; Ponniah et al., 1999; Roskoski, 2005; Somani et al., 1997; Su et al., 1999; Vacaresse et al., 
2008; Yang et al., 2006; Zheng et al., 2000).       
 The active conformation of the Src family kinases is characterized by the 
autophosphorylation of a highly conserved activation loop-tyrosine residue (Y419 in c-Src) 
(Figure 1.5) (Xu et al., 1999).  This tyrosine residue lies in the catalytic cleft between the smaller 
N-terminal and larger C-terminal lobes of the kinase domain in c-Src.  In the inactive state resulting 
 
 
Figure 1.5: Regulation of c-Src kinase activity.  Shown here is a schematic representation of the 
conformational changes involved in the activation of c-Src.  A. The autoinhibited conformation is 
characterized by the phosphorylation of the C-terminal Y530 by CSK, leading to the 
intramolecular binding of phosphorylated Y530 (pY530) to the SH2 domain.  Furthermore, the 
SH3 domain also binds to the SH2-kinase linker region thereby packing the SH3 and SH2 domains 
against the kinase domain lobes.  This results in the activation loop adopting a partial helical 
structure which occludes access of the kinase domain to ATP for autophosphorylat ion of the 
activation loop tyrosine residue.  B. The de-phosphorylation of the C-terminal Y530 together with 
the binding of the SH3 and SH2 domains with their cellular proteins targets, comprising poly-
proline and phosphotyrosine motifs, respectively, results in an open-conformation of the enzyme.  
In this conformation, the activation loop helix becomes disordered which promotes access of the 
kinase domain to ATP.  C. Access to ATP enables the autophosphorylation of the activation loop 
tyrosine residue, Y419 which results in enzymatic activation.  Figure adapted from (Xu et al., 
1999). 
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from the intramolecular interactions of the SH2 domain with Y530, the kinase domain is oriented 
in an inflexible conformation that permits the activation loop to form a partial alpha helix.  The 
partial helical structure of the activation loop obstructs access of the catalytic site to ATP, thereby 
preventing autophosphorylation (Figure 1.5).  However, following Y530 dephosphorylation and/or 
binding of the SH3 and SH2 domains to target proteins, the activation loop becomes disordered 
which results in increased access of the catalytic cleft to the ATP substrate.  This leads to the 
autophosphorylation and enzymatic activation of c-Src (Figure 1.5) (Xu et al., 1999).  By 
interacting with and phosphorylating target cellular proteins, c-Src and other members of the Src 
family are known to be involved in regulating key cellular processes such cell survival, 
proliferation, angiogenesis, migration and apoptosis (Erpel and Courtneidge, 1995; Fresno Vara et 
al., 2001; Han et al., 2014; Park et al., 2007; Saigal and Johnson, 2008). 
 
1.1.2.2 BRK family kinases  
            BRK or PTK6 (Breast tumor kinase/Protein tyrosine kinase 6), FRK/ PTK5 (Fyn-related 
kinase/ Protein tyrosine kinase 5) and SRMS/ PTK70 (Src-related kinase lacking N-terminal 
myristoylation sites and C-terminal regulatory tyrosine residue/ Protein tyrosine kinase 70)  
represent an evolutionarily conserved lineage of the Src-family kinases (Goel and Lukong, 2015; 
Serfas and Tyner, 2003).  The genes encoding BRK and SRMS lie adjacent on the same 
chromosomal locus, 20q.13.33 whereas the FRK gene is distantly located on chromosomal loci 
6q21-q22.3 (Goel and Lukong, 2015, 2016).  At the genomic level, BRK, FRK and SRMS possess 
8 exons whereas Src family kinases possess 12 exons (Figure 1.6) (Goel and Lukong, 2015; Serfas 
and Tyner, 2003).  Given the distinct pattern of intron-exon splicing, BRK, FRK and SRMS were 
considered a distinct family of non-receptor tyrosine kinases, separate from the Src family (Goel 
and Lukong, 2015; Serfas and Tyner, 2003).  Like c-Src and other members of the Src family 
kinases, BRK, FRK and SRMS possess all three functional domains, namely, the SH3, SH2 and 
kinase domains (Figure 1.7) (Goel and Lukong, 2015, 2016).  Further, the mechanism of enzymatic 
autoregulation in BRK and FRK are conserved with the Src family.  Specifically, the 
phosphorylation of the conserved C-terminal tyrosine residue in BRK (Y447) and FRK (Y497) 
leads to the enzymatic inactivation of these kinases whereas autophosphorylation of the activation 
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Figure 1.6: Intron-Exon splicing pattern of the BRK family kinases and c-Src. Shown here is 
a schematic representation of the intron-exon architecture of the BRK family (BRK, FRK and 
SRMS) and the prototypical member of the Src family kinases, c-Src. The chromosomal loci and 
corresponding genetic location on the chromosome is annotated. The exons (highlighted in red for 
BRK family kinases and blue for Src) are numbered and the length of each exon indicated. Also 
indicated is the length of the DNA and the corresponding coding sequence (CDS). Figure obtained 
from (Goel and Lukong, 2015), with the permission and rights to reuse/reproduce. 
  
loop tyrosine residue (Y342 in BRK and Y387 in FRK) results in enzymatic activation (Figure 
1.7) (Goel and Lukong, 2015, 2016).  SRMS, however, lacks a C-terminal tail altogether, and the 
mode of enzymatic autoregulation was instead shown to be dependent on the 50-amino acid N-
terminal region (Goel et al., 2013). Further, the conserved activation loop autophosphorylat ion 
site, Y380 has been shown to be essential for SRMS enzymatic activity (Figure 1.7) (Goel et al., 
2013).  
 Both BRK and FRK represent well characterized members of the BRK family in the 
context of the signaling intermediaries regulated, and cellular role(s) played by these kinases.  For 
instance, a number of studies have shown that BRK plays a growth promoting role whereas FRK 
plays a tumor suppressor role, in breast cancers (Bagu et al., 2017; Brauer and Tyner, 2009, 2010; 
Goel and Lukong, 2015, 2016; Ogunbolude et al., 2017).  Both kinases have been shown to bind 
to and phosphorylate various cellular proteins to regulate these cellular functions (Brauer and 
Tyner, 2009, 2010; Goel and Lukong, 2015, 2016).  SRMS, on the other hand, is an understudied 
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kinase of this family.  The subsequent sections of this thesis shall review background information 
on SRMS. 
 
       
 
Figure 1.7: Protein domain-structure organization of BRK family kinases and c-Src. 
Schematic representation of the BRK family kinases (BRK, FRK and SRMS) and c-Src, showing 
the different functional protein domains present on each protein.  Like c-Src, members of the BRK 
family possess all three functional domains, namely, the SH3, SH2 and the kinase domain.  The 
amino acid positions of the various domains are indicated.  Also shown are key conserved amino 
acid residues which are implicated in the the regulation of the enzymatic activity of these proteins. 
These include the ATP-contacting lysine (K219 in BRK, K262 in FRK and K258 in SRMS), 
activation-loop autophosphorylation tyrosine residue (Y342 in BRK, Y387 in FRK and Y380 in 
SRMS) required for enzymatic ativation and a C-terminal tyrosine residue present only in BRK 
(Y447), FRK (497) and c-Src (Y530) that negatively regulates enzymatic activity. 
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1.1.2.2.1 SRMS  
               SRMS (pronounced “shrims”) is a non-receptor tyrosine kinase and a member of the 
BRK family kinases (BFKs) (Goel and Lukong, 2015).  The gene encoding SRMS was first 
discovered by Kohmura et al. in 1994 in a screen aimed at identifying novel genes that may 
potentially be involved in neural precursor cell (NPC) differentiation (Kohmura et al., 1994).  The 
gene was named SRMS as an abbreviation to its descriptive nomenclature which essentially 
denotes the characteristic sequence-specific differences observed between SRMS and Src family 
kinases (Kohmura et al., 1994).  Thus, the abbreviation expands to imply that SRMS is a “Src-
Related kinase”, “lacking a C-terminal regulatory residue and N-terminal Myristoylation sites”, 
both of which are hallmark biochemical features of the SFKs.  The study also reported that the 
murine SRMS gene is located 2.1 cM distal to chromosomal locus D2Mit25 whereas the human 
SRMS orthologue is positioned adjacent to the BRK gene on the chromosomal locus 20q13.33 
(Kohmura et al., 1994).  Kawachi et al. in 1996 reported on cloning the same gene from murine 
neonatal skin tissue.  The gene was named PTK70 (Protein tyrosine kinase 70) (Kawachi et al., 
1997).  Given the lack of a myristoylation signal and a conserved C-terminal tyrosine residue, 
Kawachi et al. proposed that SRMS is likely a part of another non-receptor tyrosine kinase family 
distinct from SFKs (Kawachi et al., 1997).  Later reports substantiated the classification of SRMS, 
BRK and FRK as a separate kinase family owing to the conserved intron-exon splicing pattern 
associated with these kinases (Goel and Lukong, 2015; Serfas and Tyner, 2003).  Therefore, 
SRMS, BRK and FRK were considered a separate family of non-receptor tyrosine kinases and 
thereafter named the BRK family kinases (Goel and Lukong, 2015; Serfas and Tyner, 2003).  
Since the discovery of SRMS in 1994, a few studies have investigated the biochemical 
enzymatic regulation and the potential cellular role of SRMS.  The subsequent sections shall 
review information from the literature relevant to SRMS biology.  
 
1.1.2.2.1.1 Biochemical regulation of SRMS enzymatic activity 
                  The SRMS cDNA encodes a 54 kDa protein spanning 488 amino acids that harbors a 
SH3, SH2 and a kinase domain; a structural framework common to BRK, FRK and SFKs (Goel et 
al., 2013) (Figure 1.6 and 1.7).  As described above, the enzymatic activity of SFKs, BRK and 
FRK is primarily regulated by phosphorylation of a conserved C-terminal tyrosine residue (Goel 
and Lukong, 2015, 2016; Goel et al., 2013; Li et al., 2007; Yeatman, 2004).  However, SRMS 
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lacks a C-terminal tyrosine residue implying that the mechanism of enzymatic regulation in SRMS 
is biochemically distinct (Goel et al., 2013) (Figue 1.8).  The highly conserved activation loop-
tyrosine residue represents the primary site of autophosphorylation in BRK, FRK and members of 
the Src family kinases and is required for enzymatic activation (Goel and Lukong, 2015, 2016; 
Goel et al., 2013).  This residue corresponds to Y380 in SRMS and site-directed mutagenesis 
studies have confirmed this to be the primary autophosphorylation site in SRMS (Goel et al., 2013) 
(Figure 1.8).  The phosphatases PTPN13 and PTEN have been shown to inhibit the catalytic 
activity of c-Src and BRK by directly dephosphorylating the activating autophosphorylation sites 
on these kinases which correspond to Y419 (c-Src)  and Y342 (BRK) (Glondu-Lassis et al., 2010; 
Wozniak et al., 2017).  No phosphatase has been reported to dephosphorylate the conserved 
activating Y380 residue in SRMS.  Therefore the role of phosphatases in regulating SRMS 
enzymatic activity is unknown.   
 Previous studies by our group characterized the enzymatic activity of SRMS and 
discovered that the presence of the 50 amino acid-long N-terminal region, preceding the SH3 
domain, is essential for SRMS tyrosine kinase activity (Goel et al., 2013) (Figure 1.8).  Deletion 
of this N-terminal region was found to abolish SRMS cellular tyrosine kinase activity.  
Additionally, an SH2-deletion mutant of SRMS showed lower tyrosine kinase activity compared 
 
 
Figure 1.8: Protein domain-structure organization of SRMS. Schematic representation of the 
protein domain-structure of SRMS, showing the SH3, SH2 and kinase domains.  The unique 50 
amino acid-long N-terminal region essential for SRMS enzymatic activity is highlighted (Goel et 
al., 2013).  Also shown is the W223 residue in the SH2-kinase linker region and the ATP-binding 
K258 and the activation loop-autophosphorylation residue Y380.  
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to wild type SRMS, indicating that the SH2 domain is potentially also involved in the 
autoregulation of SRMS catalytic activity.  The SRMS K258 residue forms part of a highly 
conserved ATP-binding pocket in tyrosine kinases (Figure 1.8).  Indeed substituting K258 with a 
methionine residue was found to abolish SRMS catalytic activity.  Furthermore, a SRMS W223A 
mutant was also generated to study the role of this residue on SRMS catalytic activity.  The SRMS 
W223 residue is conserved in BRK (W184) as well as Src family kinases and lies in the SH2-
kinase linker region (Goel et al., 2013) (Figure 1.8).  Structural studies on the Src family kinase-
member Hck have shown that the analogous residue, W260 stabilizes a catalytically inactive 
conformation of the enzyme (LaFevre-Bernt et al., 1998). Specifically, crystal structures of Hck 
revealed that the interaction of the SH3 domain with the SH2-kinase linker region allows the W260 
residue to interact with the C helix in the N-terminal lobe of the kinase domain which stabilizes 
the inactive conformation.  Accordingly, the Hck W260A mutant showed increased tyrosine kinase 
activity compared to wild type Hck demonstrating the significance of this residue in the 
autoregulation of Hck enzymatic activity (LaFevre-Bernt et al., 1998).  A previous study on BRK 
showed that substituting the conserved W184 residue with alanine resulted in significantly reduced 
kinase activity compared with wild type BRK (Kim and Lee, 2005; Qiu and Miller, 2004).  This 
indicated that unlike the Src family kinase Hck, this conserved residue in BRK likely serves to 
stabilize the active conformation of the kinase (Kim and Lee, 2005; Qiu and Miller, 2004).  
Interestingly, substituting the conserved W223 residue with alanine in SRMS was also found to 
result in significantly reduced tyrosine kinase activity compared to wild type SRMS (Goel et al., 
2013).  This suggested that the tryptophan residue plays a similiar biochemical role in maintaining 
an active conformation in both BRK and SRMS (Goel et al., 2013; Qiu and Miller, 2004).  
Analyses of the crystal structures of wild type SRMS and its inactivating mutants will further help 
in characterizing the underlying biochemical mechanisms involved in the autoregulation of SRMS 
enzymatic activity.    
 
1.1.2.2.1.2 Protein expression in mammalian cells/tissues  
                  To date, very few studies have examined the expression of SRMS protein/mRNA in 
mammalian cells and tissues.  Kohmura et al., credited with the discovery of the SRMS cDNA 
from mouse neural precursor cells (NPCs), identified two variants of the SRMS mRNA via 
Northern blotting analyses, bearing molecular sizes of 2 kb and 2.6 kb (Kohmura et al., 1994).  
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Though it is not clear whether these variants represent products of alternative splicing events, the 
expression of these variants were found to differ temporally and spatially in certain murine tissues 
examined (Kohmura et al., 1994).  For instance, while the 2.6 kb variant was found to be 
abundantly expressed in tissues derived from the murine lung, liver, spleen, ovary, kidney and 
intestines, the expression of the 2 kb variant was limited to fewer organs including the testis and 
cerebral tissues.  Lower expression levels of the 2.6 kb variant were also seen in murine heart, 
cerebrum, cerebellum and thymus tissues.  This indicates that SRMS expression is likely spatially 
altered across different murine organs where the cellular roles of the kinase are yet to be examined.  
Additionally, whereas the expression of the 2.6 kb mRNA variant was detected in the embryonic 
day 15 (E15) brain tissues, it was found to be relatively lower in the postnatal brain.  However, the 
2 kb mRNA variant was more abundant in the postnatal brain.  Interestingly, both variants were 
found to be low in the E10 brain-derived NPCs, E11 brain and adult mouse brain tissues (Kohmura  
et al., 1994).  This therefore indicates that SRMS expression is not only spatially regulated but 
potentially also temporally regulated during mammalian development.  
            A study by Kawachi et al. also identified two mRNA variants in mouse tissues which was 
speculated to result from alternate splicing events (Kawachi et al., 1997).  As with the observations 
of Kohmura et al., Kawachi and colleagues noted organ-specific differences in SRMS mRNA 
expression, though these observations were not entirely identical to those noted by the Kohmura 
group (Kohmura et al., 1994) (Kawachi et al., 1997).  Specifically, Kawachi et al. determined that 
the SRMS mRNA expression was more abundant in murine liver, lung, thymus and skin compared 
to brain, kidney, heart and spleen (Kawachi et al., 1997).  Furthermore, quantitative analyses of 
SRMS mRNA in selected skin-derived cell lines revealed a relatively higher level of SRMS 
mRNA expression in the Sq-1974 cell line compared to other cell lines tested such as the B16 
melanoma 4A5, NFSaY83 and L cell lines.  As well, SRMS mRNA levels were found to be 
significantly higher in the primary epidermal cells compared to the primary dermal fibroblast cells  
(Kawachi et al., 1997). 
 In another study, Anam et al. quantitatively assessed the mRNA expression levels of 
various receptor tyrosine kinases, non-receptor tyrosine kinases and other key signaling proteins 
in murine bone marrow cell (BMC)-derived hematopoietic stem/progenitor cells (HPSCs) as well 
as bone marrow mesenchymal stromal cells (BMMSCs) (Anam and Davis, 2013).  It was reported 
that certain members of SFKs such as Lck, Lyn, Hck and Fyn were found to be differentially 
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expressed in the HPSCs and BMMCs.  However, the expression of SRMS and another tyrosine 
kinase, Tnk1 was not detected in either cell type (Anam and Davis, 2013).  The underlying reasons 
behind the absence of SRMS expression were not reported and may potentially indicate a 
functionally redundant role of SRMS in the differentiation of bone-marrow stem cells.    
 The expression pattern of SRMS in normal or cancer-derived human cells/tissues is not 
well-characterized.  A previous study by our group reported the expression of SRMS in breast 
tissue microarrays representing breast carcinoma samples and the adjacent normal mammary tissue 
(Goel et al., 2013).  The array used comprised a small cohort of 24 tumor grade-specific invasive 
ductal carcinoma samples and matched adjacent normal samples, derived from 6 breast cancer 
patients.  Immunohistochemical analyses of the array indicated that SRMS expression was 
generally higher in the breast carcinoma tissues compared to matched adjacent normal tissues.  
Furthermore, SRMS expression was found to potentially correlate with tumor grade, with higher 
grade tumor tissue samples showing increased expression of SRMS compared with low-grade 
carcinoma tissues.  A similar observation was also made in immunoblotting studies using a panel 
of eight immortalized breast cancer cell lines.  The results showed that SRMS expression was 
relatively higher in the breast cancer cell lines compared to the immortalized normal mammary 
epithelial cell line 184B5 (Goel et al., 2013).  Breast cancer is a heterogeneous disease with 
different clinical, histopathological, and molecular characteristics (Perou et al., 2000; Sorlie et al., 
2001).  Therefore, an evaluation of SRMS mRNA and protein expression in a broader panel 
covering the various breast cancer pathological and molecular subtypes would be necessary to 
understand if SRMS expression can be statistically correlated between normal-tumor pairs.   
 
1.1.2.2.1.3 Subcellular localization 
                  Unlike SFKs, SRMS lacks a myristoylation/palmitoylation signal known to dictate 
plasma-membrane anchoring of SFKs or a nuclear localization signal such as that embedded within 
the FRK SH2 domain (Cance et al., 1994; Goel and Lukong, 2016; Goel et al., 2013; Koegl et al., 
1994; Patwardhan and Resh, 2010).  However, both the endogenous and ectopically expressed 
SRMS localize predominantly to punctate cytoplasmic structures, as studied in HEK293, HeLa 
and certain breast cancer cell lines such as MDA-MB 231, AU565 and SKBR3 (Goel et al., 2013).  
This subcellular localization pattern has not been reported for SFKs, BRK or FRK.  SFKs and 
BRK are known to exhibit varying subcellular localization patterns depending on the activation 
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status of the enzymes. For instance, endogenous and ectopically expressed active c-Src has been 
shown to localize at the plasma membrane as well as the perinuclear region of Cos-1 cells 
(Donepudi and Resh, 2008).  In the perinuclear region, active c-Src was found to co-traffic with 
EGFR in endosomes.  On the other hand, kinase-dead Src was found to localize only to the inner 
plasma membranes but not the endosomes, in Cos-1 cells (Donepudi and Resh, 2008).  
Furthermore, in mouse embryonic fibroblasts active c-Src has been shown to localize to focal 
adhesion sites on the plasma membrane (Tu et al., 2010).  Consistently, constitutively active v-Src 
has also been shown to localize predominantly in focal adhesions in rat fibroblast cells (Hayes and 
Moss, 2009).  In patient-derived breast cancer tissues, active c-Src has been reported to 
predominantly localize to the plasma membrane compared to inactive c-Src, which was largely 
found in the cytoplasm (Anbalagan et al., 2012).   
 In the case of BRK, previous studies have shown that ectopically expressed BRK displays 
a diffuse nucleo-cytoplasmic localization in HeLa and HEK293 cells (Lukong et al., 2005; Lukong 
and Richard, 2008).  Endogenous BRK, on the other hand, has been reported to colocalize with 
Sam68 in Sam68-like nuclear bodies (SNBs) as well as AKT in the plasma membrane in MCF7 
cells (Derry et al., 2000; Ostrander et al., 2010).  Furthermore, like c-Src, active BRK has been 
found to be predominantly localized to the plasma membrane of immortalized prostate cancer 
cells, breast cancer cells and patient-derived breast carcinoma tissues (Derry et al., 2003; Ostrander 
et al., 2010; Peng et al., 2014).  Therefore, the subcellular localization of Src and BRK seems to 
be regulated in a kinase-dependent manner.  Similarly, the catalytically deficient mutants of 
SRMS, namely the N-terminal-deletion or the SRMS K258M (kinase-dead) mutants, have been 
reported to display altered subcellular localization compared to wild type SRMS (Goel et al., 
2013).  Specifically, these kinase-inactive mutants show a partly diffused cytoplasmic localization 
as opposed to the predominant punctate pattern displayed by wild type SRMS (Goel et al., 2013).  
These SRMS cytoplasmic punctae are uncharacterized and it is not known whether these punctate 
structures are formed by the colocalization of SRMS with specific cytoplasmic proteins or those 
in cellular organelle(s).  
 
1.1.2.2.1.4 Substrates and binding partners 
      A number of cellular bindings partners and substrates of SFKs, BRK and FRK have 
been idenified and characterized to date.  However, little is known about the cellular targets of 
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SRMS.  Presently, Dok1 and BRK remain the only two substrates validated for SRMS (Fan et al., 
2015; Goel et al., 2013).   
 Takeda et al. described an in vitro proteomics study where several potential substrates of 
Src and BRK family kinases were reported (Takeda et al., 2010).  The proteomics study involved 
screening of a panel of 519 unique proteins against SFKs and BFKs in a high-throughput in vitro 
kinase assay.  CRK (p38) was identified as a common phosphorylated target of the kinases and 
used to rank the substrate-specificity of the other kinases.  A fair number of potential substrates 
were identified for each kinase by the study (Table 1.1).  Dok1 (Downstream of tyrosine kinase 1) 
was one of the potential SRMS substrates identified by this study (Takeda et al., 2010).  Dok1 was 
subsequently validated and characterized as the first  bonafide SRMS substrate (Goel et al., 2013).  
Notably, Dok1 has previously been characterized as a cellular substrate of BRK, Src and Abl 
kinases (Janas and Van Aelst, 2011; Miah et al., 2014; Ng et al., 2015; Woodring et al., 2004).  
 A recent study identified BRK as a substrate of SRMS (Fan et al., 2015).  SRMS was 
shown to phosphorylate the C-terminal Y447 residue in BRK via immunoprecipitation assays as 
well as direct in vitro kinase assays.  Further, SRMS was found to phosphorylate only BRK Y447 
but not the conserved Y530 in the c-Src C-terminal tail (Fan et al., 2015).  Phosphorylation of 
BRK Y447 plays an important role in the regulation of BRK kinase activity (Goel and Lukong, 
2015; Miah et al., 2012; Ostrander et al., 2010).  However, whether phosphorylation of BRK Y447 
by SRMS leads to the inhibition of BRK activity was not reported by the study and warrants further 
investigation. 
 The motif-specificity of the SRMS SH2 domain has been reported previously which has 
shed light on the the type of potential SRMS SH2 domain-dependent interactions (Liu et al., 2015; 
Zhao et al., 2013).  SH2 domains comprise a highly conserved phosphotyrosine-binding pocket 
which, in Src family kinases, is formed by the amino acid sequence  F-L-V-R-E-S (Eck, 1995; 
Ottinger et al., 1998; Wagner et al., 2013).  Mutant SH2 domains carrying point-mutations in this 
pocket have been shown to exhibit significantly reduced phosphotyrosine-binding ability 
(Campbell and Jackson, 2003; Mayer et al., 1992).  This phosphotyrosine-binding pocket in SRMS 
corresponds to the sequence, F-L-I-R-P-S.  Whereas the role of these amino acids in the SRMS 
SH2 domain have not been well-characterized in the context of phosphotyrosine-binding, high-
throughput studies have nonetheless identified SRMS SH2 domain consensus motifs (Liu et al., 
2015; Zhao et al., 2013).  Zhao et al. reported the identification of the SRMS SH2-domain 
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consensus motifs using a high-throughput peptide library-screening approach (Zhao et al., 2013).  
The study used a library of phosphotyrosine peptides randomized for amino acid residues flanking 
the central phosphotyrosine residue and screened binding-affinities to various recombinant GST-
tagged SH2 domains.  The study found that the SRMS SH2 domain selectively bound 
phosphotyrosine peptides displaying hydrophobic residues at the P+3 position (where P is the 
phosphotyrosine).  Specifically, it was noted that the SRMS SH2 domain favours motifs possessing 
a phenylalanine, methionine or a cysteine residue at the P+3 position.  Whereas at the P+1 position  
 
Table 1.1: List of potential SRMS substrates identified by Takeda et al.. Shown in this table 
are the potential SRMS substrates identified by Takeda et al., 2010 via high-throughput in vitro 
kinase assays. The potential substrates were ranked based on substrate-specificity towards the 
commonly phosphorylated substrate, CRK.    
 
 
the SRMS SH2 domain exhibited specificity towards a histidine or glutamic acid residue, the P-1 
position favoured either a histidine or a tyrosine residue (Zhao et al., 2013).  Characterization of 
S.No Genbank 
Accession 
no. 
Protein name Category Relative 
activity 
(CRK 
=1) 
Rank 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
AK303912 
AK055944 
AK315002 
BC013200 
AK314619 
BC053532 
BC001718 
BC065912 
AK075020 
AK095513 
AK295613 
AK027148 
Tom1 like 1 
Dok1 
Tom1 like 1 
Lck 
CRK-associated substrate 
CRK-associated substrate 
CRK 
ARG 
SYK 
Disabled 1 
HEF-like protein 
NEK11 
Adapter protein 
Adapter protein 
Adapter protein 
Tyrosine Kinase 
Adapter protein 
Adapter protein 
Adapter protein 
Tyrosine Kinase 
Tyrosine Kinase 
Adapter protein 
Adapter protein 
Ser/Thr kinase 
2.05 
1.68 
1.52 
1.22 
1.10 
1.05 
1.00 
0.84 
0.43 
0.39 
0.26 
0.26 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
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the SRMS SH3/SH2 ligands may provide vital cues on SRMS substrate specificity and the 
regulation of associated signaling pathways. 
 A similar study by Liu et al. examined the in vitro binding specificities of 78 different SH2 
domain-containing proteins towards tyrosine-phosphorylated peptides derived from various 
receptors proteins implicated in immune response signaling (Liu et al., 2015).  Specifically, 
compared to Src, BRK or FRK,  the SRMS SH2 domain was found to exhibit generally minimal 
binding specificity towards either the LIRB4 pY360, DSCAM pY1708, PGRFB pY797, PGRFB 
pY904, CD3E pY199, SLAF pY304, STAM1 pY371, LAY1 pY71, LY9 pY626 or CD79A pY199 
synthetic peptides (Liu et al., 2015).  This may imply that SRMS SH2-mediated intermolecular 
interactions and consequently its role as a signaling intermediate in the immune receptor network 
may be limited.  Further, the results of the study also suggest that unlike other BFK and SFK 
members, the SRMS SH2 domain potentially interacts with a highly limited and specific cohort of 
tyrosine phosphorylated proteins, which may have implications on the SRMS SH2 domain-
dependent cellular interactome and SRMS cellular functions (Liu et al., 2015).  
 
1.1.2.2.1.5 Cellular and physiological roles  
                  Information on the function and cellular role of SRMS is sparse.  The absence of 
characterized bonafide endogenous targets/subtrates of SRMS has limited our understanding of 
the function and role of the enzyme.  The identification of BRK Y447 as a target phosphorylation 
site of SRMS indicates that SRMS may potentially function as a negative regulator of BRK 
catalytic activity in vivo (Fan et al., 2015).  This may highlight the role of SRMS in the potential 
regulation of kinase-dependent cellular and physiological functions of BRK (Fan et al., 2015).  In 
one of the early discoveries relevant to SRMS, Kohumura et al. reported varying expression levels 
of SRMS in murine brains across the different embryonic developmental stages (Kohmura et al., 
1994).  Given the apparent temporal regulation of SRMS expression in the murine brain, it is 
possible that SRMS may potentially play a developmental role towards the differentiation of 
murine brain cells (Kohmura et al., 1994).  Similarly, due to the differential expression of SRMS 
mRNA in the murine epidermal and fibroblast cells, speculations of a possible role of SRMS in 
the proliferation and/or differentiation of murine keratinocytes were also reported (Kawachi et al., 
1997).    
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 Potts et al. reported the involvement of SRMS as a potential negative regulator of 
autophagy in mammalian cells (Potts et al., 2013).  Autophagy is a cellular process in which 
proteins and organelles are degraded within eukaryotic cells (Kristensen et al., 2008; Sica et al., 
2015).  In this process, the cytoplasmic material is engulfed in autophagosomes which then fuse 
with lysosomes for degradation (Kristensen et al., 2008; Sica et al., 2015).  During the induction 
of autophagy, the cytosolic form of the microtubule-associated protein 1A/1B-light chain 3 (LC3-
I) is conjugated to phosphatidylethanolamine to yield LC3-phosphatidylethanolamine conjugate 
(LC3-II) (Hansen and Johansen, 2011; Tanida et al., 2008).  LC3-II is then recruited to the outer 
membrane of autophagosomes (Hansen and Johansen, 2011; Tanida et al., 2008).  The turnover of 
LC3-II, therefore, is often regarded as a marker of autophagic induction (Tanida et al., 2008). In 
the study by Potts et al. the human colorectal cancer cell line HCT116 was used in high-throughput 
siRNA and miRNA screens to identify genes that regulate the expression of a group of six well-
characterized reporter genes namely, ACSL5, BNIP3L, ALDOC, LOXL2, BNIP3, and NDRG1 
(Potts et al., 2013).  These genes served as reporters or proxies for different cellular conditions 
including autophagy.  The genes identified from the screens were clustered based on the level of 
regulation of the proxy reporter genes.  SRMS was consequently identified in a cluster of genes 
with a well-documented role in the regulation of autophagy.  It was further shown that knockdown 
of SRMS in the human osteosarcoma cell line U2OS, engineered to express GFP-LC3 as the 
autophagic reporter, resulted in an increase in the number of LC3-positive puncta.  On the other 
hand, overexpression of SRMS was found to decrease the number of LC3-positive puncta. 
Additionally, modulating SRMS expression levels did not have implications on the mTOR 
pathway as determined by assessing p70S6K pT389 levels.  This implied that the SRMS-
dependent regulation of autophagic flux is not dependent on the mTOR pathway (Potts et al., 
2013).  Another study showed that EGFR directly phosphorylated Beclin on Y229, Y233 and Y352 
and increased Beclin1 association with Rubicon and Bcl2 but decreased Beclin1 association with 
the VPS34 kinase (Wei et al., 2013).  In this way EGFR was found to suppress nutrient depletion-
induced autophagy.  Interestingly, the same study reported that unlike EGFR, recombinant SRMS 
did not phosphorylate Beclin1 in in vitro kinase assays, indicating that the SRMS does not regulate 
autophagy by phosphorylating Beclin1 (Wei et al., 2013).   
 In an effort to understand the physiological significance of SRMS, Kohumura et al.  
generated a homozygous SRMS-knock out (SRMS-/-) mouse model (Kohmura et al., 1994).  These 
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transgenic mice were found to display no differences in overall phenotype compared to control 
mice (SRMS+/+).  The mice were viable, fertile and showed no apparent external or internal 
phenotypic deficits or abnormalities.  The study therefore concluded that SRMS may be 
functionally redundant and the SRMS-associated cellular and physiological roles may likely be 
compensated by other tyrosine kinases (Kohmura et al., 1994).  It may be noted that a similar 
observation was made earlier in FRK knock-out mice where no obvious differences could be 
observed in the overall murine phenotype compared to control mice (Chandrasekharan et al., 
2002).  However, characterization of the FRK knock-out mice showed that these mice had 
significantly lesser T3 thyroid hormones levels in the blood compared to control mice.  Further, 
gene expression analyses revealed increased expression of c-Src and Yes kinases in the intestine 
and colon, respectively (Chandrasekharan et al., 2002).  Likewise, other studies demonstrated that 
FRK knock-out mice displayed a significant decrease in the number of pancreatic -cells in the 
embryonic and post-natal stages (Akerblom et al., 2007).  It is therefore possible that the 
physiological role of SRMS is not entirely redundant and further in vivo investigations may be 
warranted in this regard.  
 
1.2 Phosphoproteomics analyses by mass spectrometry 
      Phosphorylation represents an important post-translational modification (PTM) that is integral 
to the regulation of signal transduction in mammalian cells (Corwin et al., 2017; Day et al., 2016).  
Phosphoserine, phosphothreonine and phosphotyrosine represent the most studied 
phosphorylation events in the mammalian proteome (Santos and Lindner, 2017; Wang et al., 
2015).  A number of studies have also reported the identification of a small number of eukaryotic 
phosphohistidine, phosphoarginine and phospholysine sites on cellular proteins (Ciesla et al., 
2011; Klumpp and Krieglstein, 2002).  However, consensus among various phosphoproteomics 
studies indicate that phosphoserine constitutes nearly 80% of the total phosphoproteome followed 
by phosphothreonine (15%) and phosphotyrosine (4%) (Cesaro and Pinna, 2015). 
 Given the importance of phosphorylation signal transduction, a paramount task in cell 
biology remains to identify substrates of the different kinases in mammalian cells (Corwin et al., 
2017).  This is especially important in the context of tyrosine kinases where the vast pool of cellular 
substrates for the majority of the tyrosine kinases have been unexplored.  Non-receptor tyrosine 
kinases represent roughly only 6% of the mammalian kinome (Manning et al., 2002).  Several 
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studies have shown that non-receptor tyrosine kinases like SFKs and BRK, for instance, regulate 
a number of essential cellular processes linked to growth and proliferation by interacting with and 
phosphorylating target cellular proteins (Abram and Lowell, 2008; Brauer and Tyner, 2010; Goel 
and Lukong, 2015; Yeatman, 2004).  The identification of the cellular substrates and signalling 
intermediates of the other non-receptor tyrosine kinases are therefore key to understanding the 
greater role and significance of these enzymes in mammalian cells.   
 Mass spectrometry (MS) is an analytical technique that measures the mass to charge (m/z) 
ratio and intensity of ions in the gas-phase (Grebe and Singh, 2011).  This principle can be applied 
to identify and quantify unknown peptides in any biological sample (Grebe and Singh, 2011).  
Tandem mass spectrometry (referred to as MS/MS) involves the determination of the mass/charge 
ratio of an intact peptide (referred to as the MS1 scan) followed by fragmentation of the peptide 
(referred to as the MS2 scan) to determine its amino acid sequence (McLafferty, 1981; Syka et al., 
2004; Wells and McLuckey, 2005).  The mass of an intact peptide alone does not provide enough 
information to precisely and unambiguously identify a peptide (Olsen and Mann, 2004; Peng and 
Gygi, 2001).  Therefore, fragmentation of the precursor peptide in an MS2 scan is necessary to 
correctly and unambiguously assign sequence-specific identity to the peptide (Olsen and Mann, 
2004; Peng and Gygi, 2001).  In modern mass spectrometry analyses, the selection of peptides for 
fragmentation is data-driven and completely automated through the use of dedicated MS 
instrument software (Bauer et al., 2014; Hu et al., 2016).  In the data-dependent acquisition (DDA) 
mode, a fixed number of highly abundant precursor peptides from MS1 are selected by the software 
for fragmentation to obtain the MS2 profile of the peptides (Bateman et al., 2014; Mann et al., 
2001).  This is helpful in eliminating noise from undesired MS1 profiles corresponding to non-
peptide moieties in the sample.     
 In a typical proteome-wide (global) phosphoproteomics experiment, the total cellular 
proteins are first extracted from the sample of choice (cells/tissues) and subjected to digestion 
using endoproteinases such as trypsin and/or Lys-C (Figure 1.9).  From the crude tryptic peptides, 
phosphorylated peptides are selectively enriched using either metal-ion affinity-based techniques 
such Titanium dioxide (TiO2) or antibody affinity-based enrichment techniques utilizing 
immunoprecipitation assays (Fila and Honys, 2012; Macek et al., 2009; Nilsson, 2012) (Figure 
1.9).  The TiO2-based enrichment technique utilizes immobilized TiO2-coated resin for binding 
phosphopeptides in the mobile phase (Roux and Thibault, 2013; Thingholm et al., 2009).  This 
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technique is suited for primarily enriching phosphoserine and phosphothreonine peptides and to a 
lesser extent, phosphotyrosine peptides (Possemato et al., 2017; Thingholm et al., 2009).  The 
enrichment of phosphotyrosine peptides is ideally performed using well-characterized 
phosphotyrosine antibodies via immunoprecipitation assays (Thingholm et al., 2009; van der Mijn 
et al., 2015).  After performing the enrichment steps, the phosphopeptides are separated by liquid 
chromatography (LC) and injected into the mass spectrometer where these are ionized and 
subsequently fragmented to obtain the MS1 and MS2 profiles (Xie et al., 2011) (Figure 1.9).  The 
 
  
      
  
Figure 1.9: Outline of a general LC-MS/MS-based phosphoproteomics workflow. Total 
proteins, extracted from cells/tissue, are digested with endoproteinases such as Trypsin and/or Lys-
C and subjected to phosphopeptide enrichment, via enrichment techniqes such as TiO2-based 
phosphopeptide enrichment or phospho-specific antibody-based enrichment. The enriched 
phosphopeptides are separated by liquid chromatography followed by mass spectrometry analysis. 
Through data-dependent acquisition (DDA), user-defined precursor ions from the MS1 scan are 
selected for fragmentation in the MS2 scan. The MS2 spectra of the peptide is used for assigning 
amino acid sequence information to the identified peptide using database-search software. The 
experimentally identified spectra is searched within a database of in silico-generated theoretical 
spectra, derived from in silico-digested peptides. The database used for this search comprises of 
all species-specific protein entries. A peptide spectrum match is obtained when the theoretically-
derived spectra matches the experimentally-obtained spectra. A peptide spectrum match is used to 
assign peptide sequence and protein identity.  
DDA 
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MS1 and MS2 spectral information obtained from the mass spectrometer is then used by specific 
“search”software to determine the identity of the peptides (Wang and Wilson, 2013) (Figure 1.9).  
Popular examples of such software include Sequest, Mascot and Andromeda (Cox et al., 2011; 
Koenig et al., 2008; Sadygov, 2015).  Here, the software refers to a database of species-specific 
protein entries (Beavis and Fenyö, 2000; Ulintz et al., 2006; Yates, 1998).  From this database, 
depending on the endoproteinase used during the experimental workflow, the software generates 
a library of theoretical spectra corresponding to the mass/charge ratio of in silico-digested peptides.  
This theoretical database of spectra is matched to the experimentally obtained spectra from the 
mass spectrometry analyses (Beavis and Fenyö, 2000; Ulintz et al., 2006; Yates, 1998) (Figure 
1.9).  Consequently, a probabilistic peptide-spectrum match (PSM) is obtained from such analyses 
and used to infer identity of the experimentally obtained peptide (Frank, 2009).  In the case of a 
phosphosite-containing peptide, the presence of a phosphate group increases the mass of the 
precursor ion (in the MS1 scan) and in most cases, that of the fragmented ions (in the MS2 scan) 
(Kim et al., 2016).  This information is used to identify phosphopeptides from their non-
phosphorylated counterparts.  Importantly, PTMs other than phosphorylation are particularly 
challenging to distinguish as these exhibit highly similar mass (Kim et al., 2016).  Further, PTMs 
in general may add very little to the overall mass of a given peptide and may be difficult to 
distinguish from peptides that do not contain PTMs (Kim et al., 2016).  Conventional high-
resolution mass spectrometers such as Orbitraps offer an unprecedented sensitivity to distinguish 
between the different PTMs to assign the correct PTM to a peptide (Kim et al., 2016; Olsen et al., 
2005).  A challenge here, however, is the ability to precisely identify the correct location of the 
PTM especially in peptides containing two or more PTMs, as in the case of multiply-
phosphorylated peptides (Kim et al., 2016).  To this end, conventional software incorporate 
iteration-based scoring methodologies to score the probability for a PTM to exist at a given site on 
a given peptide (Kim et al., 2016).  For example, the Andromeda software implements an iterative 
algorithm to derive a “Localization probability” for high-confidence PTM-site assignment (Cox et 
al., 2011).  Overall, the entire experimental workflow in mass spectrometry-based 
phosphoproteomics is integrated to automated computational analyses for the identification of 
phosphoproteins and the corresponding phosphosites on these proteins. 
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1.2.1 Quantitation approaches in mass spectrometry analyses  
          In addition to providing information on the mass to charge ratio of the precursor and 
fragment ions, mass spectrometry also provides information on the intensity of the ions (Han et 
al., 2008; Pechan and Gwaltney, 2012).  Whereas the m/z ratio gives information about the identity 
of the peptide, the intensity provides quantitative information on the abundance of the parent 
peptide in the sample (Han et al., 2008; Pechan and Gwaltney, 2012).  In mass spectrometry 
analyses, relative quantitation of protein/peptide abundance can be accomplished using either 
labelling-based approaches such as SILAC (Stable isotope labelling of amino acids in culture) and 
iTRAQ (Isobaric tags for relative and absolute quantification) or label-free approaches (Mann, 
2006; Neilson et al., 2011; Wiese et al., 2007).  In the case of label-based approaches such as 
SILAC, the cells are metabolically labelled in vivo with amino acids comprising “heavy” isotopes  
such as 13C and 15N (Mann, 2006) (Figure 1.10).  In the other experimental condition, the cells are 
left unlabelled and therefore, comprise amino acids representing the corresponding natural or 
“light” isotopes such as 12C and 14N (Mann, 2006).  The proteins are then extracted from both 
experimental conditions, digested with endoproteinases and combined prior for multiplexed 
analyses on the mass spectrometer (Figure 1.10).  The peptides derived from the “heavy” isotope -
labelled samples result in a mass shift when analysed by mass spectrometry.  This is leveraged to 
obtain a relative quantitation of peptides between the “heavy” and “light” experimental conditions 
by comparing the ‘heavy” and “light” peptide precursor ion intensities in the MS1 scan (Mann, 
2006) (Figure 1.10).   
 The iTRAQ method also involves a differential chemical-labelling approach (Unwin, 
2010; Wiese et al., 2007).  However, in this case, amino acid labelling occurs in vitro and on 
peptide-digests instead of intact proteins (Rauniyar and Yates, 2014; Wiese et al., 2007) (Figure 
1.10).    The chemical labels used in iTRAQ are isobaric, implying that these chemical groups 
share a similar mass (Rauniyar and Yates, 2014; Thompson et al., 2003).  However, upon 
fragmentation in the mass spectrometer, these chemical groups yield reporter ions of different mass 
(Thompson et al., 2003; Unwin, 2010; Wiese et al., 2007).  The LC-MS/MS-based measurement 
of the abundance of the reporter ions is reflective of the abundance of the labelled peptide from 
which these ions were produced (Figure 1.10).  In this way, proteins from different samples can 
be labelled with different isobaric chemical groups and relative quantification of each protein  
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Figure 1.10: Overview of metabolic/chemical labelling of amino acids as a quantification 
strategy in mass spectrometry analyses. The upper panel depicts a schematic representation of 
the SILAC labelling workflow for two experimental conditions. In one experimental condition, 
the cellular proteins are labelled in vivo during cell culture using amino acids comprised of “heavy” 
isotopes of carbon (C) and nitrogen (N) such as 13C and 15N. In the other experimental condition, 
the cellular proteins are left unlabelled and comprise naturally ocuring “light” 12C and 14N.  Total 
proteins are extracted from both experimental samples and mixed prior to LC-MS/MS analyses. 
Quantification is achieved by comparing the MS1 intensities of the “light” (unlabelled) and 
“heavy” (labelled) peptides. The lower panel presents a schematic workflow of the iTRAQ 
quantification approach. In this case, the cellular proteins are first digested and the peptides are 
labelled in vitro with different chemical isobaric groups tags for both experimental conditions. 
Quantification is similarly achieved by comparing the MS1 intensities of the different isobaric 
reporter ions between the two experimental conditions.   
  
determined based on the abundance of the corresponding reporter ions produced (Thompson et al., 
2003; Wiese et al., 2007) (Figure 1.10).    
 Label-free quantitation, as the name suggests, does not involve chemical or metabolic 
labelling of proteins.  The label-free quantification approach is divided into two types: (i) 
quantitation based on spectral-counting or (ii) quantitation based on summed ion intensities 
(Nahnsen et al., 2013; Neilson et al., 2011) (Figure 1.11).  Spectral-counting involves measuring 
the number of MS/MS spectra identified for a given protein or peptide in two or more experimental 
conditions (Neilson et al., 2011) (Figure 1.11).  The approach assumes that high-abundance 
peptides will result in a greater number of MS/MS spectra than peptides at lower abundance, 
between two experimental samples being assessed (Neilson et al., 2011).  The other label-free 
quantitation approach involves measuring the peptide precursor ion abundances across the 
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corresponding retention times to generate a chromatographic elution profile of these peptides 
(Figure 1.11).  For a given peptide, the entire precursor ion signal across specific retention times  
referred to as the “area under the curve” (AUC), is measured between two or more experimental 
conditions for relative quantitation (Neilson et al., 2011) (Figure 1.11).  Overall, for both, label-
based and label-free approaches, dedicated software are available which incorporate raw LC-
MS/MS data to perform peptide/protein quantitation.  Examples of such software include 
MaxQuant, Progenesis QI and Proteome DiscovererTM (Qi et al., 2012; Tyanova et al., 2016a; Veit 
et al., 2016).  These software integrate peptide-identification data obtained from the “search” 
software to ultimately provide consolidated information on the name and abundance of a specific 
peptide/protein in a given sample.  For the LC-MS/MS-based phosphoproteomics analyses 
described in this thesis, label-free quantitation based on precursor ion intensity or AUC-
measurement, was used. 
 
      
 
Figure 1.11: Overview of label-free quntification strategies for mass spectrometry analyses. 
Shown here is a schematic workflow of the two different types of label-free quantification 
strategies for LC-MS/MS analysis.   The upper panel depicts the approach of quantifying peptides 
based on their precursor ion intensities over specific retention times which corresponds to the area 
under the curve (AUC) of their chromatographic elution profiles.  The samples from different 
experimental conditions are processed in parallel and analysed sequentially via LC-MS/MS.  The 
AUC or precursor ion intensities of corresponding peptides in the different experimental 
conditions are measured.  The lower panel depicts the spectral-counting approach of label-free 
quantification.  Samples from the different experimental conditions are processed in parallel and 
analysed via LC-MS/MS. Peptide quantification is achieved by counting the corresponding MS1 
spectra in the different experimental conditions. 
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2.0 Hypothesis and Objectives 
 
2.1 Rationale and Hypothesis 
       The non-receptor tyrosine kinase SRMS belongs to the BRK family kinases whose other two 
members include BRK and FRK (Goel and Lukong, 2015, 2016).  Both BRK and FRK represent 
well-studied kinases in the context of the biochemical and cellular roles played by these enzymes 
in mammalian cells (Goel and Lukong, 2015, 2016).  The identification of a number of substrates, 
binding partners and/or signalling intermediates of BRK and FRK has led to a broad mechanistic 
understanding of the cellular and/or physiological roles played by these kinases (Brauer and Tyner, 
2010; Goel and Lukong, 2015, 2016).  SRMS, on the other hand, is a relatively understudied 
member of the BRK family.  Though discovered in 1994, little or no information on the 
biochemical, cellular and physiological role of SRMS exists in the literature.  Previous biochemical 
studies on SRMS have shown that the wild-type kinase is catalytically active and can 
phosphorylate several cellular proteins when expressed ectopically in mammalian cells (Goel et 
al., 2013).  The identity of these potential SRMS cellular substrates and other signalling 
intermediates are largely unknown.  Additionally, the SRMS protein is known to display a 
characteristic punctate cytoplasmic localization in mammalian cells (Goel et al., 2013), indicating 
that SRMS biology may be regulated by its intracellular localization.  Kinases are generally known 
to play specific cellular functions by phosphorylating specific cellular proteins and the intracellular 
localization of kinases plays a key role in this process.   
 We hypothesize that SRMS regulates specific cellular processes by phosphorylating its 
cellular substrates and/or regulating specific signaling intermediates.  We further hypothesize that 
the SRMS protein is sequestered to specific cytoplasmic organelle(s) resulting in the characteristic 
cytoplasmic punctate localization pattern displayed by the kinase.   
 
2.2 Objectives    
       The overall aim of this work is to obtain a better understanding of the cellular and biochemical 
significance of SRMS by identifying the cellular substrates and signaling intermediates of the 
kinase via quantitative mass spectrometry-based phosphoproteomic analyses.  This work further 
aims to characterize the intracellular localization pattern of SRMS.  Therefore, the specific 
objectives of this work are: 
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1.  To identify and validate the potential cellular substrates of SRMS. 
2. To identify the potential signaling intermediates regulated indirectly by SRMS. 
3. To characterize the cytoplasmic punctate localization displayed by SRMS. 
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3.  Materials and methods 
 
 
3.1 Reagents and chemicals  
      The reagents and chemicals used towards the experiments described in this thesis have been 
compiled in Table 3.1.  Table 3.2 lists the addresses of the manufacturers/suppliers of these 
reagents/chemicals.  
 
Table 3.1: List of reagents and/or chemicals. This table lists all commercially procured reagents 
and chemicals used to prepare solutions or other material to perform the experiments described in 
this thesis. The names of the supplier and catalogue information related to the reagents/chemicals 
are also indicated.   
 
Reagents/ Chemicals               Supplier and Catalogue number. 
2x Laemmli       Sigma-Aldrich, S3401 
Acrylamide       Sigma-Aldrich, A5934 
Acetic Acid       Fisher Scientific, A465250  
Acetonitrile, LC-MS-grade     ThermoFisher Scientific, 51101 
Acetonitrile       EMD-Millipore, AX0145 
Agar        Fisher Scientific, BP1425-2 
Agarose       Fisher Scientific, BP1360 
Bovine serum albumin     Amresco, 0332 
Bradford's assay dye reagent concentrate    Bio-Rad, 500-0006 
Aprotinin       Sigma-Aldrich, A6279 
Ampicillin       EMD Millipore, 171255 
Ammonium Persulfate (APS)     Sigma-Aldrich, A3678 
Adenosine triphosphate (ATP) 10 mM   New England Biolabs, P0756S                
Bovine calf serum      Thermo Scientific, SH30087.02 
BCA protein assay kit      ThermoFisher Scientific, 23225              
N'N-methylenebisacrylamide     Amresco, 0172 
Boric acid       EMD Millipore, 203-667 
Chloramphenicol      Sigma-Aldrich, C0378 
4',6-diamidino-2-phenylindole (DAPI)   ThermoFisher Scientific, P36941 
Disodium phosphate (Na2HPO4)    Fisher Scientific, S375-500                                         
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Dimethyl sulfoxide (DMSO)     Fisher Scientific, TS-20684 
Dithiothreitol (DTT)      ThermoFisher Scientific, R0861                   
Dulbecco's modified Eagle's medium (DMEM)  Hyclone, SH300243.01 
EconoTaq polymerase      Lucigen, 30031-1 
Ethylenediaminetetraaceticacid (EDTA)   EMD Millipore, 324503 
Epidermal growth factor (EGF)    Millipore-Sigma, E9644 
Fetal bovine serum      ThermoFisher Scientific, 10438026 
Formic acid, LC-MS-grade     ThermoFisher Scientific, 28905 
GST-bind resin      Novagen, 70541    
Glutathione       Sigma-Aldrich, G4251                                                                                   
Gel Red       Biotium, 41002 
Glycerol       Sigma-Aldrich, G5516 
Glycine       Fisher Scientific, S80028 
Ethyl alcohol (EtOH)      Fisher Scientific, S25310 
Hydrochloric acid (HCl)     Fisher Scientific, A508-P500 
HEPES (4-(2-hydroxyethyl)- 
1-piperazineethanesulfonic acid)    Sigma-Aldrich, H3375  
Iodoacetamide, LC-MS-grade    Sigma-Aldrich, I6125                                                 
Kanamycin       EMD Millipore, 420311   
Lys-C endoproteinase (LC-MS-grade)   Wako, 129-02541                     
Methanol       EMD Millipore, MX0475 
Magnesium chloride (MgCl2)     Fisher Scientific, 232-094-6  
Manganese chloride (MnCl2)     Fisher Scientific, M87-500                                   
Monopotassium phosphate (KH2PO4)   Fisher Scientific, BP-362-500                                                                                                                                                                          
Nitrocellulose membrane     Pall Life sciences, 66489 
Phosphatase Inhibitor cocktail    ThermoFisher Scientific,78420 
Potassium chloride (KCl)     Fisher Scientific, AC193780000 
Polyethyleneimine (PEI)     Polysciences Inc., 23966-1 
Pre-stained protein ladder                                  New England Biolabs (NEB),  
        P7711S   
Protease inhibitor cocktail     ThermoFisher Scientific, 78430 
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Protein A beads      Santa Cruz Biotech, sc-2001                                       
Protein G beads      Santa Cruz Biotech, sc-2002     
PRO-Q, Diamond Phosphoprotein Stain   ThermoFisher Scientific, P33300                                                                                                      
Phenylmethylsulfonylfluoride (PMSF)   Fisher Scientific, 329-98-6 
QuikChange site-directed mutagenesis kit   Agilent, 600250 
Restriction enzymes for molecular cloning   New England Biolabs 
Retention time calibration mixture    ThermoFisher Scientific, 88321 
RNAiMAX transfection reagent     ThermoFisher Scientific, 13778030 
Sodium acetate      Sigma-Aldrich, S2889 
Sodium dodecyl sulfate (SDS)    Sigma-Aldrich, L3771 
Sodium orthovanadate (Na3VO4)    EMD Millipore, 567540       
Sodium pyrophosphate     Sigma-Aldrich, S6422                                      
Sodium azide (NaN3)      Fisher Scientific, S227-100 
T4 DNA ligase      New England Biolabs (NEB), M0202 
Terrific Broth       Fisher Scientific, BP2468-500  
N,N,N ,´N -´tetramethylethylenediamine (TEMED)  Sigma-Aldrich, T9281 
Trifluoroacetic acid (TFA), LC-MS-grade   ThermoFisher Scientific, 28904                                                                               
Tris base       Fisher Scientific, BP152-5                                   
Triton X-100       Fisher Scientific, AC215680000 
Trypsin (Cell culture grade)     Fisher Scientific, SV3003101   
Trypsin (LC-MS grade)     Worthington, LS-003744 
Tween-20       Fisher Scientific, BP337500 
Water (LC-MS grade)      Fisher Scientific, W-5 
 
 
Table 3.2: Reagent supplier addresses. This table lists the names and addresses of all 
reagent/chemical suppliers.   
 
Supplier      Address 
Agilent      Mississauga, Ontario, Canada 
Amresco     Solon, Ohio, USA  
Biotium     Burlington, Ontario, Canada 
Bio-Rad      Hercules, California, USA 
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Cell Signaling Technologies   Danvers, Massachusetts, USA 
Clontech     Mountain view, California, USA 
EMD Millipore    Danvers, Massachusetts, USA 
Fisher Scientific    Walton, Massachusetts, USA 
Hyclone     Pittsburgh, Pennsylvania, USA 
Invitrogen Life Technologies   Green Island, New York, USA 
LI-COR, Odyssey    Lincoln, Newark, USA 
Lucigen     Middleton, Wisconsin, USA 
New England Biolabs    Ipswich, Massachusetts, USA 
Novagen     Madison, Wisconsin, USA 
Paul Life Sciences    Port Washington, New York, USA 
Polysciences Inc.    Warrington, Pennsylvania, USA 
Sigma-Aldrich     St. Louis, Missouri, USA 
Santa Cruz Biotechnologies   Santa Monica, California, USA  
ThermoFisher Scientific   Logan, Utah, USA 
Waters corporation    Wilford, Massachusetts, USA 
Worthington     Lakewood, New Jersey, USA 
 
 
3.2 Expression vectors and siRNA 
3.2.1 Expression vectors 
         PCR amplifications were performed using EconoTaq polymerase supplied with Taq buffer 
and dNTP mix with the following reaction and cycling conditions: 
Reactions Components (50 µl reaction):  
10X Standard Taq Reaction Buffer with Mg2+ (1x), 10 mM dNTPs (200 µM), 10 µM Forward 
Primer (0.2 µM), 10 µM Reverse Primer (0.2 µM), Template DNA (<100 ng), Taq DNA 
Polymerase (1.25 units), Nuclease-free water (to 50 µl).  Cycling Conditions: 
1. Initial Denaturation                               95 °C (30 seconds)  
30 cycles of  
2. Final Denaturation                                95 °C (30 seconds) 
3. Annealing                                             45-68 °C (30-60 seconds)   
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4. Extension                                              72 °C  (1 minute/kb) 
5. Final extension                                     72 °C for 5 minutes 
6. Hold                                                      4°C 
 
All primers used towards PCR reactions were purchased from Invitrogen life technologies, (New 
York, USA). The full length SRMS cDNA was originally amplified from the pANT7-cGST-
SRMS plasmid, purchased from DNASU Plasmid Repository (Tempe, AZ) via PCR and cloned 
C-terminal to the GFP sequence into the HindIII and BamHI sites of the pEGFP-C1 plasmid (Goel 
et al., 2013).  In this way, plasmids encoding GFP-SRMS wild type, GFP-SRMS K258M and 
GFP-N SRMS were constructed and described in a previous study (Goel et al., 2013).  N-terminal 
FLAG-tagged wild type SRMS or SRMS K258M cDNA sequences were cloned into the Not1 and 
BamH1 restriction sites of the pQCXIH vector (Clontech, USA) using the primer pair: 5’- 
AAAAGCGGCCGCGCCACCATGGACTACAAAGACGATGACGACAAGGAGCCGTTCCT
CAGGA-3’ (FLAG-tag nucleotide sequence underlined) and 5’-
AAAAGGATCCTCAGGGGTGGCATCTGTGGATGGCGTG-3’. An alternate forward primer 
was paired with the same reverse primer to generate an untagged wild type SRMS construct using 
the pQCXIH vector backbone: 5’-AAAAGCGGCCGCATGGAGCCGTTCCTCAGGA-3’.  
cDNA encoding the SRMS kinase was amplified using the primers:  5’-
AAAAAGGATCCATGCCCCAGAAGGCCCCGAGG-3’ and 5’-
AAAAACTCGAGTCAGGGGTGGCATCTGTG-3’ and cloned into the BamH1 and Xho1 
restriction sites in-frame with the GST sequence of the pGEX-6p1 vector.  EGFP-Vimentin-7 
(referred to as GFP-Vimentin herewith) was procured from Addgene (plasmid # 56439, Addgene, 
Massachesetts, USA). The Vimentin cDNA sequence was amplified from the EGFP-Vimentin 
construct using the primers: 5’- AAAAAAAGCTTCGATGTCCACCAGGTCCGTGTCC-3’ and 
5’-AAAAAGGATCCTCATTCAAGGTCATCGTGATGCTG-3’ and cloned into the HindIII and 
BamHI restriction sites in the pmCherry-C1 vector (Clontech, USA). Vectors encoding Myc-
Sam68 and GFP-Sam68 have been described before (Lukong et al., 2005).  To generate the GST-
Vimentin construct, the Vimentin cDNA sequence was amplified using the primers: 5’-
AAAAAGGATCCATGTCCACCAGGTCCGTG-3’ and 5’-
AAAAAGTCGACTCATTCAAGGTCATCGTGATGCTG-‘3 and cloned into the BamHI and 
SalI restriction sites of the pGEX-6P1 VECTOR. Similarly, cDNA sequence encoding Sam68 was 
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amplified using primers: 5’-
AAAAAGTCGACTCATGCAGCGCCGGGACGACCCCGCCGCG-3’ and 5’-
AAAAAGCGGCCGCTCAATAACGTCCATATGGGTG-3 and cloned into the SalI and NotI 
sites of the pGEX-6p1 vector.  The amplified sequences were ligated into the respective digested 
plasmids using the T4 DNA ligase by following the manufacturer’s instructions.  The ligated 
products were used for transforming the commercially procured X-Gold ultra-competent cells 
(#200315, Agilent Technologies).  The following day, independent bacterial colonies were 
isolated, cultured and DNA extracted from the respective clonal bacterial cultures.  The presence 
of the ligated sequences was confirmed by restriction digestion and via sequencing (sequencing 
facility: NRC-PBI, University of Saskatchewan, Saskatoon).  
 
3.2.1.1 Site-directed mutagenesis  
            Site directed mutagenesis was employed to introduce point mutations in the “FLIRPS-
ESS” phosphotyrosine-binding pocket of the SRMS SH2 domain.  The primer pair used to generate 
this mutant was:  
5’-GAACCAGGGGCCGCAGCAGCAGCAGCAGCAGCAGCAGCACTCGGGGGCTAC-3’ 
and 5’GTAGCCCCCGAGTGCTGCTGCTGCTGCTGCTGCTGCTGCGGACCCTGGTCC-3’ 
The commercially available QuikChange site-directed mutagenesis kit was used according to the 
manufacturer’s protocol outlined below:   
Reaction Components (50 µl reaction): 
Standard Reaction Buffer with Mg2+ (1x), 20 ng Template DNA, 125 ng forward primer, 125 ng 
reverse primer, 200 µM dNTP mix, nuclease free water (to 50 µl) and Pfu turbo DNA polymerase 
(1.25 units).  Cycling Conditions: 
1. Initial Denaturation                                          95 °C (30 seconds)  
 20 cycles of  
2. Final Denaturation                                           95 °C (30 seconds) 
3.  Annealing                                                       55 °C (30-60 seconds)                                                                                                  
4.  Extension                                                        68 °C (1 minute/kb)  
5.  Final Extension                                               68 °C (5 minutes) 
6.  Hold                                                                4 °C 
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The PCR-mutagenesis products were incubated with the restriction enzyme DpnI at 37 °C for 1 
hour to digest the parental cDNA and the digested PCR product directly used for transforming the 
commercially procured X-Gold ultra-competent cells (#200315, Agilent, USA).  The following 
day, bacterial colonies were picked, DNA extracted from the clones and screened via sequencing 
(sequencing facility: NRC-PBI, University of Saskatchewan, Saskatoon).  
 
3.2.2 SRMS siRNA 
         The SRMS siRNA (sc-63066) targeting human SRMS mRNA and scrambled siRNA (sc-
37007) were procured from Santa Cruz Biotechnologies (Santa Cruz Biotechnologies, USA).  The 
SRMS siRNA was purchased as a pool of two duplexed siRNAs, sc-63066A (sense- 
CUUGCGCUCUAUGACUUCAtt and antisense- UGAAGUCAUAGAGCGCAAGtt) and sc-
63066B (sense- GCGAUCAAGGUCAUCAAGUtt and antisense- 
ACUUGAUGACCUUGAUCGCtt). 
 
3.3 Cell lines and cell culture: 
       HEK293, HeLa and MDA-MB 231 cells were purchased from the American Tissue Type 
Culture Collection (ATCC, USA).  All cell lines were maintained in DMEM High glucose (4.5g/L) 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum and 
cultured at 37 °C in 5% CO2.   
 The HEK293 cell line was selected for the proteomics studies described in this thesis.  
HEK293 is a normal cell line isolated from the human embryogenic kidneys and expresses very 
low level of SRMS (Goel et al., 2013).  The cell line is also relatively more amenable to exogenous 
gene expression experiments compared with other mammalian cell lines (Thomas and Smart, 
2005).  Therefore, we used this cell line as an unbiased and suitable model to investigate the 
cellular substrates of SRMS in human cells.  Further, validation studies involving ectopic 
expression of SRMS were carried out in the HEK293 and HeLa cell lines.  Both cell lines are 
known to display low endogenous/background SRMS expression and were therefore found ideal 
for ectopic SRMS expression studies purpose (Goel et al., 2013).   
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3.3.1 Plasmid/ siRNA transfections and EGF stimulation:  
         All transfections were carried out in the HEK293 and HeLa cell lines which were cultured 
as described above.  Cells cultured in 10 cm tissue culture dishes or 6 well tissue culture plates 
were transiently transfected with 10 µg or 2.5 µg DNA, respectively, using 1% Polyethyleneimine 
(PEI) as the transfection reagent.  For each well in the 6-well plate, 2.5 µg of the appropriate DNA 
was mixed with 107.5 µl of 0.15 M sterile NaCl via gentle vortexing for 10 seconds.  15 µL of PEI 
was then added to this mixture followed by another 10 seconds of gentle vortexing.  For 
transfections in a 10 cm tissue culture dish, 10 µg DNA was mixed with 430 µl of 0.15 M sterile 
NaCl.  60 µl of PEI was added and the solution vortexed for mixing.  DNA-PEI complex formation 
was allowed to take place by incubating the mixture at room temperature for 10 minutes followed 
by dispensing it dropwise into the wells or 10 cm culture dishes.  The culture dishes were gently 
swirled to allow even distribution of the DNA-PEI complex in the culture dish and incubated 
overnight in the cell culture incubator.  24 hours post transfection, transfection efficiencies were 
determined via fluorescence microscopy using the Olympus 1x51 inverted fluorescence 
microscope and cells harvested for use towards the experiment.  SRMS or scramble siRNAs were 
transfected using the RNAiMAX transfection reagent in cells cultured to 70-80% confluency in 
10 cm culture dishes.  36 µl RNAiMAX solution was mixed with 600 µl serum-free media in a 
microcentrifuge tube by gentle vortexing for 10 seconds.  In a separate microcentrifuge tube, 100 
pmol siRNA was mixed with 600 µl serum-free media by vortexing gently for 10 seconds.  The 
diluted siRNA mix was then added to the diluted RNAiMAX solution and vortexed briefly again 
for 10 seconds.  This mix was allowed to incubate for 5 minutes at room temperature and then 
dispensed dropwise in the 10 cm tissue culture dish.  The dish was gently swirled to allow even 
distribution of the siRNA-RNAiMAX complex across the dish.  24 hours post-transfections, the 
cells were lysed and immunoblotting performed to confirm SRMS-knockdown using antibodies 
against SRMS (Table 3.5).  For stimulating cells with EGF, the cells were serum starved overnight 
and treated with 100 ng/mL EGF for various times and lysed for use as total cell lysates or for 
immunoprecipitation. 
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3.4 SDS-PAGE and Western Blotting 
3.4.1 SDS-PAGE 
         For preparing whole cell lysates, the media in the tissue culture plates was first aspirated and 
residual media removed by gently rinsing the culture plates once with 1x PBS.  Whole cell lysates 
were then prepared by harvesting the cells directly in 2x Laemmli (sample buffer).  Total cell 
lysates were prepared using freshly prepared lysis buffer (Table 3.3).  2x Laemmli was added to 
the total cell lysates or immunoprecipitates in a 1:1 ratio.   Protein samples derived from either 
whole cell lysates or immunoprecipitates, were resolved via sodium dodecyl sulphate (SDS) 
Polyacrylamide gel electrophoresis (PAGE). SDS-PAGE was performed using the Mini-Protein 4 
gel electrophoresis system (#165800FC, Bio-Rad, USA).  10% polyacrylamide gels with a 1.5 mm 
thickness were cast using the appropriate glass plates provided with the gel electrophoresis pack.  
The resolving gel comprised 10% acrylamide, 0.8% bis-acrylamide, 0.4% SDS, 375 mM Tris HCl 
pH 8.8, 0.16% (w/v) APS, 0.1% TEMED and H2O.  The stacking gel comprised 4% acrylamide, 
0.8% bis-acrylamide, 0.4% SDS, 125 mM Tris HCL pH 6.8, 0.24% (w/v) APS, 0.1% (w/v) 
TEMED and H2O. 
 The protein samples and the pre-stained protein ladder were boiled at 100 °C for 5 minutes 
prior to loading onto the gels (10 wells or 15 wells). The gels were run in 1xSDS running buffer 
at a constant voltage of 150 volts for 1.5 hours or until the bromophenol blue dye front passed 
through the gel. 
 
3.4.2 Western Blotting:  
         Following electrophoresis, the gels were removed carefully from the glass plates.  The 
stacking gels were discarded. The resolving gel was overlaid on five 3 mm filter paper sheets.  The 
filter paper sheets were cut to the size of the gel and pre-soaked in transfer buffer.  Likewise, 
nitrocellulose membranes were also cut to the size of the gel and soaked in transfer buffer.  The 
wet membranes were then overlaid on the gels.  Another five sheets of 3 mm filter paper were 
placed on top of the nitrocellulose membrane to give a “sandwich”-like assembly.  This assembly 
was placed into the gel-holder cassette and the cassette inserted into the Western blotting 
electroblotting apparatus (Bio-Rad). The apparatus was filled with Western blotting transfer buffer 
(Table 3.4) up to the manufacturer’s indicated mark.  Protein transfer was allowed to proceed for 
1 hour at a constant voltage of 100 volts at 4 °C.                                                                                                                                      
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 After the completion of protein-transfer, the nitrocellulose membranes were removed from 
the cassette and subjected to blocking by incubating with 5% skim milk on a rocking platform for 
40 minutes at room temperature.  After blocking, the membranes were washed thoroughly in 1x 
PBS to remove residual skim milk.  Next, primary antibodies diluted in primary antibody buffer 
(Table 3.3) and prepared at appropriate dilutions (listed below), were added to the membrane for 
overnight incubation on a rocker at 4 °C.  The following day, the membrane was washed three 
times for 15 minutes with 1x PBST buffer.  The membranes were then incubated with the 
appropriate secondary antibody (LICOR goat anti mouse/ goat anti rabbit, as mentioned below), 
diluted in secondary antibody buffer at a dilution factor of 1:10,000.  Incubation of the membranes 
with secondary antibodies was carried out for 40 minutes on a rocker at room temperature.  The 
membranes were subsequently washed three times with 1x PBST (Table 3.4) and used for analyses 
on the LI-COR Odyssey infrared scanning instrument (LI-COR, USA).  Images were acquired 
using the Image StudioTM Lite software (LI-COR, USA) linked to the LI-COR instrument at the 
appropriate laser intensities.  All immunoblotting images acquired were transformed to greyscale 
and exported in the .tiff image format.  The Western blotting experiments were repeated at least 3 
times to ensure reproducibility.  
 
3.5 Primary and secondary antibodies  
      Phosphotyrosine antibodies, 4G10 (#05-321) and pTyr 1000 (#8954) were procured from 
EMD Millipore and Cell Signaling Technologies, respectively.  FLAG antibodies (#MA1-91878) 
were purchased from Thermo-Scientific, USA.  The well characterized Sam68 antibody, AD1, has 
been described before (Lukong et al., 2005) and was used for immunoprecipitation experiments. 
All other primary antibodies were purchased from Santa Cruz Biotechnologies.  These include 
antibodies against GFP (#sc-101525), GST (#sc-459), SRMS (#sc-374524), Myc (#sc-40), Sam68 
(#sc-1238) and -actin (#sc-47778). Secondary antibodies for Western blotting analyses namely, 
goat anti-rabbit (IR Dye-680RD IgG, #926-68071) and goat anti-mouse (IR Dye-800CW IgG, 
#926-32210), were purchased from LI-COR Odyssey, USA.  Secondary goat anti-mouse IgG-
Texas red (#sc-2781) antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, 
USA).  Secondary antibodies for Western blotting analyses namely, goat anti-rabbit (IR Dye-
680RD IgG, #926-68071) and goat anti-mouse (IR Dye-800CW IgG, #926-32210), were 
purchased from LI-COR Odyssey, USA.  The lyophilized secondary antibodies were diluted in 
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double distilled H2O at a final concentration of 1 mg/mL and aliquots of these stock antibodies 
stored at -20 °C. For immunofluorescence analyses, secondary goat anti-mouse IgG-Texas red 
(#sc-2781) antibodies were purchased from Santa Cruz Biotechnologies at a dilution of 1:200.  The 
working concentrations used for primary antibodies are described in the table 3.2. 
 
TABLE 3.3: List of primary antibodies used. Shown in this table are the names and working 
concentrations/dilutions of primary antibodies used in Western blotting (WB), 
immunoprecipitation (IP) and immunocytochemistry (IC) experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6 Expression of recombinant GST-fused proteins 
      All recombinant GST-fused proteins (GST-SRMS kinase, GST-Vimentin and GST-Sam68) 
were expressed in the E. coli RosettaTM (DE3) strain (#7094, EMD Millipore, USA). Briefly, the 
Rosetta strains transformed with the respective plasmids were cultured in ampicillin and 
chloramphenicol-containing Terrific broth (BP-2468-2, Fisher Scientific, USA) until Abs.600 ~ 0.8. 
The expression of the GST-fused proteins was induced with 0.5 mM IPTG (Isopropyl β-D-1-
thiogalactopyranoside) (Table 3.5) at 37 °C for 3 hours. Bacteria were then harvested via 
centrifugation at 7000 X g and the pellets lysed in freshly prepared lysis buffer (Bacterial cell lysis 
buffer composition described in Table 3.4).  The recombinant proteins were purified from the  
 
Primary antibody Working 
Concentration/Dilution 
Anti-SRMS (sc-374524) 0.2 µg/mL (WB), 2 µg/mL (IC) 
Anti-GST (sc-33613) 0.2 µg/mL (WB) 
Anti--actin (sc-4778) 0.2 µg/mL (WB) 
Anti-GFP (sc-101525) 0.2 µg/mL (WB) 
Anti-FLAG (MA1-91878) 4 µg (IP) 
Anti-Myc (sc-40) 4 µg (IP) 
Anti-phosphotyrosine (sc-508) 0.2 µg/mL (WB) 
Anti-Sam68 (rabbit) (AD1) 1:1000 (WB), 4 µg (IP) 
Anti-Sam68 (sc-1238) 1:1000 (WB) 
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TABLE 3.4 List of media/buffers and their composition. This table lists the names and 
composition of all media/buffers used for the experiments described in this thesis. 
 
 
 
BUFFER/ MEDIA COMPOSITION 
1x PBS (Phosphate 
buffered saline) 
137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM 
KH2PO4, pH 7.4 . 
1x PBST 1x PBS, 0.1% Tween-20 (v/v) 
 
Blocking buffer 5% Skim milk in 1x PBS buffer (5 g Skim milk in 100 mL 
PBS buffer) 
 
Primary antibody buffer  0.1% Tween-20, 5% BSA in 1x PBS 
 
Secondary antibody buffer 0.1% Tween-20, 5% BSA in 1x PBS 
 
Western blotting Transfer 
buffer 
25 mM Tris, 192 mM glycine, pH 8.3, 20% methanol. 
1X SDS PAGE Running 
buffer 
25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3. 
 
Mammalian cell lysis 
buffer for 
Immunoprecipitation 
assays 
50 mM TrisCl pH 7.5, 1 % Triton X-100, 150 mM NaCl, 
protease inhibitors: Aprotinin 0.6 μg/mL, 1 mM PMSF and 
phosphatase inhibitor: 1 mM sodium orthovanadate. 
RIPA lysis buffer 50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 1% Triton X-
100 and 0.5% sodium deoxycholate. Buffer supplemented 
with commercial protease and phosphatase inhibitor 
cocktails (Refer to Table 3.1 for commercial source 
information). 
Kinase reaction buffer 250 μM unlabeled ATP, 5 mM MOPS, pH 7. 2, 2.5 mM β-
glycerol-phosphate, 4 mM MgC12, 2.5 mM MnC12, 1 mM 
EGTA (Ethylene glycol tetraacetic acid), 0.4 mM EDTA 
and 0.5 mM DTT 
Bacterial cell lysis buffer 50 mM Tris 7.5, 150 mM NaCl, 1% Triton X-100, protease 
inhibitors: Aprotinin 5 mg/L and 0.1 mM PMSF  
Terrific broth for bacteria 
culture 
50.8 g of Terrific broth powder in 1 L double-distilled 
water. Media is autoclaved before use. Kanamycin or 
ampicillin is added to obtain a working concentration of 1 
µg/mL.  Additionally, chloramphenicol is added at a 
working concentration of 12 µg/mL.  
45 
 
TABLE 3.5 List of stock solutions of chemicals/reagents. Shown in in this table is a list of stock 
solutions of specific chemicals/reagents and their composition. 
 
 
 
crude lysates by incubating with GST-bind resin overnight at 4 °C. The beads were washed six to 
eight times with lysis buffer and GST-fusion proteins eluted with 10 mM glutathione, 50 mM Tris-
Cl pH 7.4 and 1 mM DTT. 
 
3.7 Immunoprecipitation and in vitro kinase assays  
       For immunoprecipitation assays, cells from a 10 cm dish were lysed in 1 mL lysis buffer 
comprising 50 mM Tris-Cl, 150 mM NaCl, 1% Triton X-100, 0.6 μg/mL Aprotinin, 1 mM PMSF 
and 1 mM Na3VO4, incubated on ice for 30 minutes and centrifuged at 20,000 X g at 4 °C for 10 
minutes.  The supernatant was collected and divided in three equal volumes for use towards protein 
immunoprecipitation, mock/control immunoprecipitation with IgG, or input. For 
immunoprecipitation of the desired protein, 4 μg of the appropriate primary antibody was added 
to 330 μL of clarified lysates.  To confirm the specificity of the primary antibody-
CHEMICALS/REAGENTS 
STOCK 
COMPOSITION 
10 mg/mL Kanamycin  0.5 g 50 mL ddH2O (double distilled H2O). 
 
50 mg/mL Ampicillin 1.7 g in 50 mL ddH2O.  
34 mg/mL Chloramphenicol 0.34 g in 10 mL 100% Ethanol 
1 M IPTG (Isopropyl β-D-1-
thiogalactopyranoside) 
 
1 g IPTG dissolved in 4.2 mL ddH2O, filtered through 
0.22 μm.  
100 mM PMSF 
(Phenylmethanesulfonylfluoride) 
1.74 g PMSF in 100 mL Isopropanol. 
  
0.2 M Iodoacetamide 95 mg Iodoacetamide in 5 mL LC-MS-grade H20 
100 mM HEPES pH 8.0 23 g HEPES in 450 mL LC-MS-grade H2O, adjust pH to 
8.0 using NaOH 
1.25 M DTT 19.25 g DTT in 100 mL LC-MS-grade H2O 
1 mg/mL Trypsin  20 mg Trypsin dissolved in 1 mM HCl. 
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immunoreactivity, 4 μg of control isotype-matched IgG sera was added to an equal volume of 
clarified lysates in a separate immunoprecipitation assay.  The lysates were incubated with the 
antibody overnight at 4 °C on a gyrorotator.  The beads were centrifuged at 3500 X g for 1 minute, 
washed twice with lysis buffer and the immunoprecipitates eluted with the addition of 30 μL 2x 
Laemmli. The samples were boiled at 100 °C for 5 minutes and resolved via SDS-PAGE.  
 For in vitro kinase assays, GST-Sam68 or GST-Vimentin were incubated with GST-SRMS 
kinase in vitro with kinase reaction buffer (250 μM unlabeled ATP, 5 mM MOPS, pH 7. 2, 2.5 
mM β-glycerol-phosphate, 4 mM MgC12, 2.5 mM MnC12, 1 mM EGTA, 0.4 mM EDTA and 0.5 
mM DTT) for 30 minutes at 30 °C. The in vitro kinase reactions were quenched by the addition of 
2x sample buffer, boiled and loaded on SDS-PAGE gels.   
 
3.8 Confocal microscopy 
      For fluorescence microscopy analyses of cells expressing ectopic GFP or mCherry-fused 
proteins, cells seeded on glass coverslips were cultured in 6-well culture dishes and transfected as 
described in the previous section.  The following day, the culture media was aspirated and the cells 
fixed with 3% paraformaldehyde (PFA) for 10 minutes.  The fixed cells were then directly mounted 
on glass slides using mounting media supplemented with DAPI (4',6-diamidino-2-phenylindole) 
for imaging.  For immunofluorescence analyses, cells seeded on coverslips were fixed with 3% 
PFA and permeabilized with 0.5% Triton X-100 for 5 minutes. The fixed cells were then stained 
with the appropriate primary antibody at a concentration of 2 μg/mL in 1x PBS for 1 hour at room 
temperature. The cells were subsequently washed with 0.1% Triton X-100 in 1x PBS for 5 minutes 
followed by staining with secondary antibodies at a 1:200 dilution in 1x PBS.  The coverslips were 
then mounted on glass slides using mounting media-supplemented DAPI and used for imaging.  
For lysosomal-staining of live cells using LysoTrackerTM-Red DND-99 dye (#L7528, 
ThermoFisher Scientific, USA), cells seeded on cover slips were transfected with the indicated 
plasmids.  24-hours-post transfection, the cells were fixed with 3% PFA and mounted on glass 
slides for imaging.  Fluorescence imaging of all samples was performed using the Zeiss confocal 
laser scanning microscope (LSM) system (LSM-700, Carl Zeiss, USA).  The LSM 700 system 
was equipped with the inverted Axio Observer.Z1 SP microscope. All images were acquired using 
the Zen 2012 SP1 (64-bit, black edition) software (Carl Zeiss, USA).  Fluorescence from the EGFP 
protein was excited using the 488 nm laser (4x Pigtailed laser with single-mode fibers, Carl Zeiss, 
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USA).  Fluorescence from the mCherry protein, Texas-red (sulforhodamine 101 acid chloride)-
conjugated antibodies or the LysoTrackerTM-Red DND-99 dye, was excited using the 555 nm laser 
(4x Pigtailed laser with single-mode fibers, Carl Zeiss, USA).  Fluorescence from the DAPI dye 
was excited using the 405 nm laser (4x Pigtailed laser with single-mode fibers, Carl Zeiss, USA).  
All images were acquired at 40x magnification (40x oil-immersion objective) with a resolution of 
1024 x 1024 pixels and a pixel-bit depth of 16 bits.  Where necessary, images were acquired using 
at least two averaging scans to enhance the signal-to-noise ratio.  Colocalization between two 
proteins with different fluorescence emissions was assessed by employing the z-stack function of 
the LSM 700 confocal microscope.  The number of z-stack scans and the spatial interval between 
each scan was appropriately defined to scan the region of interest. All fluorescence and 
immunofluorescence microscopy experiments were performed at least three times to ensure 
reproducibility. 
 For counting cells displaying the punctate localization of ectopic SRMS, cells seeded on 
coverslips were transfected with GFP-SRMS and viewed by fluorescence microscopy 24 hours-
post transfection.  The cells were visualized at 20x magnification and total transfected cells (cells 
showing punctate or diffusive localization) counted from four random microscopic fields.  Fifty 
transfected cells were counted in each field for a total of 200 transfected cells per slide.   Then the 
number of cells showing exclusively punctate localization of SRMS were counted from the same 
field.  Finally, the cells with SRMS punctae were quantified as the percentage of cells showing 
punctae in the total population of transfected cells [(Number of cells with SRMS punctae in a 
specific field/ total number of transfected cells in that field) X 100].  Quantifications obtained from 
all microscopic fields was averaged.  Data from three experimental replicates were obtained and 
presented as Mean ± SEM (Standard Error of the Mean). Statistics were performed using the 
Graphpad Prism software (Version 5.01).   
 
3.9 Sample preparation and data analysis procedures for the identification of candidate  
SRMS substrates by LC-MS/MS-based phosphotyrosine-profiling. 
Note: All solutions described in the following procedures were prepared using LC-MS-grade 
water. 
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3.9.1 Protein digestion and purification of tryptic peptides     
         HEK293 cells were cultured to nearly 85% confluency in a total of 24 x 10 cm dishes.  12 x 
10 cm dishes were transfected with plasmids encoding either GFP-SRMS wild type (SRMS-WT) 
or GFP alone as control.  24 hours post-transfection, the cells were lysed in lysis buffer comprising 
9 M urea and 20 mM HEPES pH 8.0.  The respective lysates were pooled in sterile 50 mL conical 
tubes and sonicated four times with 10-second bursts using the Virsonic 100 ultrasonic cell 
disruptor (Boston Laboratory Equipment, USA).  These were then centrifuged at 15,000 X g and 
the supernatants transferred to sterile 50 mL conical tubes.  Total protein concentration was 
determined via Bradford’s assay.  12 mg total lysate protein, each from GFP and GFP-wild type 
SRMS-expressing cells, was taken for further processing.  Proteins were reduced with 
dithiothreitol (DTT) and alkylated with iodoacetamide.  The reduced and alkylated proteins were 
diluted four-fold with 20 mM HEPES pH 8.0 and digested with LC-MS-grade trypsin at a 1:100 
enzyme to protein ratio (w/w) overnight at 37°C.  Crude tryptic digests were purified via reversed-
phase (hydrophobic) solid-phase extraction using Sep-Pak cartridges (#WAT051910, Waters 
Corporation, USA).  In this step, the purification cartridges were first equilibrated by passing 6 
mL of 0.1% TFA.  Next, the tryptic digests were loaded on the cartridges and the bound peptides 
washed three times by passing 5 mL of 0.1% trifluoroacetic acid (TFA).  The washed peptides 
were then eluted with 5 mL of a 0.1% TFA and 40% acetonitrile solution.  The purified tryptic 
peptides were lyophilized overnight and used towards enrichment of phosphotyrosine peptides.  
 
3.9.2 Enrichment of phosphotyrosine peptides 
         The enrichment of tyrosine-phosphorylated peptides was performed using the PTMScan p-
Tyr 1000 phosphotyrosine enrichment kit (#8803, Cell Signaling Technologies, USA).  The 
lyophilized peptide samples were re-suspended in 1x Immunoaffinity purification (IAP) buffer 
provided in the kit.  The diluted peptides were then centrifuged at 10,000 X g for 5 minutes at 4 
°C.  The clear supernatant was retained. The pTyr-1000 antibody-bead conjugates were then 
washed with 1x PBS and incubated with the peptide mix overnight at 4 °C on a gyrorotator.  The 
following day, the immunoprecipitates were washed twice with LC-MS-grade water and once with 
1x PBS.  The immunoprecipitated peptides were then eluted by incubating the beads with 100 μL 
of 0.1% TFA at room temperature for 10 minutes.  The eluted peptides were desalted using the 
Empore C18 solid phase extraction plate (#66875, Sigma-Aldrich, USA) as per the manufacturer’s 
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protocol.  For peptide-desalting, the C18 columns were first equilibrated by passing 50 μL of 0.1% 
TFA and 50% acetonitrile solution followed by 50 μL of 0.1% TFA alone.  Eluates from the 
phosphotyrosine immunoprecipitates were then passed through the equilibrated C18 columns.  
Next, the columns were washed twice with 50 μL of 0.1% TFA and the peptides eluted using 0.1% 
TFA and 40% acetonitrile solution.  The desalted peptides were dried in a speedvac centrifuge for 
3 hours and stored at -20 °C until ready for analyses via LC-MS/MS.     
 
3.9.3 Reversed-phase Chromatography and Mass Spectrometry 
         Samples were analyzed by nano UPLC-MS/MS with a Proxeon EASY-nLC 1000 system 
interfaced to a Thermo-Fisher Q Exactive HF mass spectrometer (Sample analyses performed by 
MSBioworks Inc., Ann Arbor, Michigan, USA).  Peptides were loaded on a trapping column and 
eluted over a 75 µm x 25 cm analytical column (Thermo-Fisher Scientific, USA) at 300 nL/min 
using a 2-hour reversed-phase gradient.  Both columns were packed with PepMap C18, 3 µM resin 
(Thermo-Fisher Scientific, USA).  Mobile phases A and B consisted of 0.1% formic acid in water 
and 0.1% formic acid in 90% acetonitrile, respectively.  Peptides were eluted from the column at 
300 nL/minute using the following linear gradient: from 2 to 25% B in 100 minutes, from 25 to 
50% B in 110 minutes, from 50 to 90% B in 112 minutes, from 90 to 2% B in 113 minutes and 
held at 2% B for an additional 7 minutes.  The spray voltage was 2.2 kV.  The mass spectrometer 
was operated in the data-dependent acquisition mode with the Orbitrap operating at 60,000 FWHM 
(Full width at half maximum) and 17,500 FWHM for MS and MS/MS respectively.  Full scans 
were acquired at a resolution of 60,000 FWHM with a maximum injection time of 120 milliseconds 
in the Orbitrap analyzer.  The 15 most abundant ions with charge states ≥ 2 were selected for 
MS/MS fragmentation by high collision-induced dissociation (HCD) and analyzed at a resolution 
of 17,500 FWHM with a maximum injection time of 60 milliseconds. 
 
3.9.4 Data processing and analysis  
         All acquired MS/MS spectra were searched against the Uniprot human complete proteome 
FASTA (Fast all) database v.02/2013 (81,213 entries) using the MaxQuant software (Version 
1.5.3.17) that integrates the Andromeda search engine.  Label-free quantitation of the data was 
performed using MaxQuant.  Enzyme specificity was set to trypsin and up to two missed cleavages 
were allowed. Cysteine carbamidomethylation was specified as fixed modification whereas serine, 
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threonine and tyrosine phosphorylation were specified as variable modifications.  Peptide 
precursor ions were searched with a maximum mass deviation of 6 ppm and fragment ions with a 
maximum mass deviation of 20 ppm.  Peptide and protein identifications were filtered at 1% FDR 
using the target-decoy database search strategy (Elias and Gygi, 2010).  Proteins that could not be 
differentiated based on MS/MS spectra alone were grouped to protein groups (default MaxQuant 
settings).  Following the principle of parsimony, each protein group was considered a single 
identified protein for further data analyses since sufficient evidence was unavailable to distinguish 
between proteins from the same protein group.  A threshold Andromeda score of 40 and a threshold 
delta score of 8 was applied to the identified phosphopeptides in accordance with parameters 
described previously (Cox and Mann, 2008; Sharma et al., 2014; Tyanova et al., 2016a).  The 
Andromeda score is a search-engine score computed by the Andromeda search software.  In order 
to assign peptide and protein identity the Andromeda search software matches the mass 
spectrometry-based experimentally derived spectra with the database/ in silico-generated peptide 
spectra and scores the peptide spectrum matches (Cox et al., 2011; Sharma et al., 2014).  This 
score, called the Andromeda score, provides a quantitative estimate of the probability that the LC-
MS/MS-identified spectra matches its corresponding database spectra.  The higher the score, the 
more likely that a given peptide spectra matches the database spectra and therefore the higher the 
accuracy in the assignment of peptide identity.  The Delta score adds to the accuracy of the peptide 
identification process (Cox et al., 2011; Sharma et al., 2014).  A given experimentally-obtained 
peptide spectra may have multiple peptide spectrum matches in a database search.  The Delta score 
is defined as the difference in the Andromeda score of one PSM and the second-best PSM.  The 
Delta score therefore gives a measure of how well a top-scoring PSM compares with the next best 
PSM.  The higher the Delta score, the greater the probability that the PSM is correct and therefore 
accurate in the context of peptide identity (Cox et al., 2011; Sharma et al., 2014).  Pearsons’s 
correlation coefficients were determined in R using log2 transformed phosphopeptide intensities, 
as described previously (Grimes et al., 2013; Mertins et al., 2012).  The MaxQuant file output 
designated “Phospho(STY)sites” was used for further analysis on the Perseus software (Version 
1.5.0.15).  Potential contaminants and reverse hits were filtered.  The resulting list of modified 
peptides was further filtered at the level of phosphosite localization using a localization probability 
threshold of 0.75 to derive all class I phosphosites, as described previously (Tyanova et al., 2016b).  
For downstream analyses, all peptides with modifications other than phosphotyrosine (pTyr) were 
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discarded.  Annotated spectra for class I phosphosites identified as statistically significant are 
provided in the supplementary material. 
 
3.9.5 Data availability in public repository 
         The mass spectrometry proteomics data (including the files for viewing the annotated 
spectra) have been deposited to the ProteomeXchange Consortium (Deutsch et al., 2017; Vizcaino 
et al., 2014) via the PRIDE (Vizcaino et al., 2016) partner repository with the dataset identifier 
PXD006809. The data can be accessed on https://www.ebi.ac.uk/pride/archive/login using the 
following reviewer account details: 
Username: reviewer22933@ebi.ac.uk 
Password: xu7lPykO 
 
3.9.6 Peptide array analyses  
         Customized peptide microarrays (PepStarTM) comprising 102 peptides were manufactured 
by JPT peptide technologies GmbH (Germany).  The peptides were immobilized on modified glass 
slides at a concentration of 100 fmol/mm2 with a maximum diametrical spot size of 150 μM on the 
glass surface. Each peptide was printed on the array in nine replicates.  The array peptides and the 
corresponding phosphosites are listed in Supplementary Table 6.  HEK293 cells cultured in four 
10 cm dishes were transfected with vectors encoding either GFP-SRMS K258M or GFP-SRMS 
wild type.  24 hours post-transfection, the cells were harvested and lysed in lysis buffer [20 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM Na3VO4, 1 mM NaF, leupeptin (1 μg/ml), aprotinin (1 μg/mL) and 1 mM 
PMSF].  The lysates were incubated on ice for 10 minutes and centrifuged in a microcentrifuge at 
14,000 X g for 10 minutes at 4 °C.  Total protein concentration in the clarified lysates was 
determined using the BCA assay kit and normalized using the appropriate volume of lysis buffer.  
An 80 μL aliquot of the supernatant was mixed with 10 μL of the activation mix [50% glycerol, 
500 μM ATP, 60 mM MgCl2, 0.05% v/v Brij-35, and 0.25 mg/mL BSA] and incubated on the 
peptide arrays for 2 hours at 37 °C in a humidity chamber.  The slides were then washed once in 
PBS-Triton (1% Triton X-100 in 1x PBS) and then stained with the PRO-Q phosphoprotein 
staining solution with agitation for 1 hour.  The arrays were then washed three times with the de-
staining solution [20% acetonitrile and 50 mM sodium acetate, pH 4.0] for 10 minutes each.  The 
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de-staining solution was replaced between each wash.  The peptide arrays were then washed once 
with double-distilled water and scanned on the GENEPIX professional 4200A microarray scanner 
(MDS Analytical Technologies, USA Analytical Technologies USA) at 532 to 560 nm with a 580 
nm filter to detect dye fluorescence.  Phosphopeptide signals were collected using the GENEPIX 
6.0 software (MDS).  Data processing, including signal normalization and relative fold-change 
differences in phosphorylation intensity associated with each peptide, was performed using the 
PIIKA2 platform (http://saphire.usask.ca/saphire/piika/) (Trost et al., 2013).   
 
3.9.7 Motif enrichment analyses 
         Phosphosites derived from candidate SRMS substrates were used to identify SRMS kinase-
specific motifs.  13 amino acid-long phosphopeptide sequences comprising a central phosphosite 
were searched for consensus motifs using the Motif-x (http://motif-x.med.harvard.edu/)  and 
MMFPh (http://www.cs.dartmouth.edu/~cbk/mmfph/) motif analyses tools (Chou and Schwartz, 
2011; Wang et al., 2012).  The data was searched against a background dataset derived from the 
IPI (International Protein Index) human proteome in both motif-analyses tools (Kersey et al., 
2004).  For a sequence to be considered as a motif, the minimum number of times that the sequence 
was required to occur in the dataset, was set to 20.  Furthermore, the required motif significance 
was set to 10E-06.   
  
3.9.8 Functional gene enrichment analyses  
         Pathway enrichment analysis of the putative SRMS substrates was performed using the 
g:Profiler software (Ver. r1741_e90_eg37) (Reimand et al., 2016). A background set of 13,505 
unique phosphorylated proteins, comprising phosphorylated proteins identified in our MS analyses 
as well as those derived from proteomics datasets available with PhosphositePlus.org (Hornbeck 
et al., 2015), was used to compute the enrichment of statistically significant cellular pathways or 
processes. We retrieved gene sets corresponding to biological processes from Gene Ontology(GO) 
with statistical enrichment among input proteins (FDR<0.05 according to the internal multiple 
testing correction method of g:Profiler). Gene sets were filtered by size (minimum size of 
functional gene set 10, maximum size of functional gene set 500, at least 3 common genes of 
pathway and input protein list). We included high-confidence annotations of biological processes 
and excluded genes with only electronic annotations in GO (Inferred from Electronic Annotations, 
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IEA). The resulting enriched pathways were visualized with the Enrichment Map software (Merico 
et al., 2010) in Cytoscape (Ver. 3.0). We used a combined overlap and Jaccard coefficient of 0.75 
for network granularity and manually annotated the resulting subnetworks of pathways for 
associated biological themes. 
 
3.10 Sample preparation and data analyses procedures for the identification of candidate  
SRMS-regulated signaling intermediates by LC-MS/MS-based global phosphopeptide 
profiling.  
Note: All solutions described in the following procedures were prepared using LC-MS-grade 
water. 
3.10.1 Protein digestion and peptide purification 
           HEK293 cells were cultured to approximately 85% in six 10 cm culture dishes.  Three 10 
cm dishes were transfected with plasmids encoding GFP-SRMS wild type and the other three 
dishes were transfected with plasmids encoding GFP alone as control.  24-hours post-transfection 
the cells were observed under a fluorescent microscope to ensure that similar and over 80-90% 
transfection efficiencies were achieved.  The transfected cells were trypsinized, washed with 1x 
PBS and lysed in RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 1% Triton X-
100 and 0.5% sodium deoxycholate) supplemented with protease and phosphatase inhibitor 
cocktails.  For complete lysis, the cells were sonicated four times with 10-second bursts using the 
Virsonic 100 ultrasonic cell disruptor (Boston laboratory equipments, USA).  The lysates were 
centrifuged at 12,000 X g for 10 minutes and the clarified lysates collected.  100 μL of total 
proteins were purified by chloroform:methanol:water precipitation in a microcentrifuge tube 
where 400 μL of methanol followed by 100 μL chloroform and 300 μL of double-distilled water 
was added with intermittent vortexing.  Next, this tube was centrifuged at 14,000 X g for 2 minutes.  
The top aqueous layer was carefully removed by pipetting.  400 μL of methanol was added to the 
mix and the tube centrifuged again for 14,000 X g for 3 minutes, resulting in an insoluble protein 
pellet.  The methanol was carefully pipetted and the residual methanol allowed to evaporate by 
air-drying.  The precipitated protein pellet was then resuspended in 8 M urea pH 8.0 containing 
400 mM ammonium bicarbonate.  Next, the proteins were reduced with 10 mM DTT and alkylated 
with 40 mM iodoacetamide followed by digestion at 37 °C with Lys-C (1:100 enzyme to protein 
ratio) for 6 hours and trypsin (1:100 enzyme to protein ratio) overnight.  The digestion reactions 
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were quenched with 0.1% formic acid and desalted using C18 MacroSpin columns (The Nest 
Group, USA) as described in the previous section.  The desalted samples were dried in a speedvac 
and dissolved in a buffer comprising 3.5% formic acid and 0.1% trifluoroacetic acid (TFA).   
 
3.10.2 Phosphopeptide enrichment 
           The samples were subjected to TiO2-based phosphopeptide enrichment using TopTip 
MicroSpin columns (Cat. #TT1TIO, Glygen Corp., USA), as described previously (Krishnan et 
al., 2012; Rich et al., 2016).  For this, the samples were first acidified with 0.5% TFA and 50% 
acetonitrile and loaded onto the TopTip columns.  The flowthrough from each sample was 
collected, dried in a speedvac and resuspended in 0.1% TFA for LC-MS analysis.  The columns 
were then washed first with 100% acetonitrile, then with 0.2 M sodium phosphate pH 7.0, 0.5% 
TFA, and finally with 50% acetonitrile.  The enriched phosphopeptides were eluted with 28% 
ammonium hydroxide, dried in a speedvac centrifuge for 3 hours and resuspended in 0.1% TFA.  
Peptide concentrations in the phosphopeptide-enriched and flowthrough samples were estimated 
from A280 absorbance using the NanoDrop 2000 instrument (ThermoFisher Scientific, USA).  The 
peptide concentrations were adjusted to 0.05 μg/μL with 0.1% TFA.  A 1:10 dilution of the 
retention Time Calibration Mixture was further added to each sample prior to LC-MS/MS 
analyses. 
 
3.10.3 Mass spectrometry analyses 
           All samples were analysed on the Q-Exactive Plus mass spectrometer (ThermoFisher 
Scientific) connected to a waters nanoACQUITUPLC system equipped with a Waters Symmetry® 
C18 180 μM x 20 mm trap column and a 1.7 μm, 75 μm x 250 mm nanoACQUITY UPLC column. 
A total of three replicates for each sample were analysed by LC-MS/MS. 5 μL of each replicate 
sample (0.05 μg/μL) was injected into the mass spectrometer.  Peptide trapping was carried out for 
3 minutes at 5 μL/min in 99% Buffer A (0.1% formic acid in water) and 1% Buffer B (0.075% 
formic acid in acetonitrile) prior to eluting with linear gradients that reached 30% Buffer B at 140 
minutes, 40% Buffer B at 155 minutes, and 85% Buffer B at 160 minutes. Two blanks (1st blank 
comprising 100% acetonitrile and 2nd blank comprising Buffer A) followed each injection to 
ensure against sample carry over. The mass spectrometer was operated in the data-dependent 
acquisition mode with the Orbitrap operating at 60,000 FWHM and 17,500 FWHM for MS and 
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MS/MS, respectively. Full scans were acquired at a resolution of 60,000 FWHM with a maximum 
injection time of 120 milliseconds in the Orbitrap analyzer. The fifteen most abundant ions with 
charge states ≥ 2 were selected for fragmentation by HCD (MS/MS) and analyzed at a resolution 
of 17,500 FWHM with a maximum injection time of 60 milliseconds.  
 
3.10.4 Data processing and analyses 
            Label-free quantitation of the raw LC-MS/MS data was performed using the Progenesis QI 
software (Version 3.0, Nonlinear Dynamics, USA) as described before (Bordner et al., 2011; Rich 
et al., 2016).  All MS/MS spectra were searched against the SWISSProt database (taxonomy 
restricted to Homo sapiens, database version dated November 2015) using the Mascot search 
engine (Version 2.0).  Data from the TiO2-enriched and flow through fractions were analyzed 
separately, and the resulting quantitative analyses were combined for the respective experimental 
conditions.  Chromatographic/spectral alignment, mass spectral peak-picking, data filtering and 
statistical analyses for the protein and peptide quantitation was performed on Progenesis QI.  Raw 
mass spectral features were aligned based on their retention time using a randomly selected 
reference run.  All other runs were automatically aligned to the reference run to minimize retention 
time variability between the runs.  Only spectra with ion signals quantified at or above three times 
the standard deviation of the noise were selected for subsequent analyses.  A normalization factor 
for each run was calculated to account for the variability in sample loading and ionization.  This 
normalization factor was determined by calculating the quantitative ratio of the reference run to 
the run being normalized, with the assumption that most proteins/peptides are not changing in the 
experiment.  The experimental set-up grouped replicates of each condition for comparative 
analyses.  The algorithm then calculated and tabulated raw and normalized abundances and 
ANOVA p-values (calculated as the mean difference and variance associated with the replicate 
data in both experimental conditions) for each quantified peptide in the dataset.  The MS/MS 
spectra was exported as a .mgf file (Mascot generic files) for database searching.  The Mascot 
search algorithm was used for database searching. Carbamidomethylation (Cysteine), 
phosphorylation (Serine, Threonine, Tyrosine), deamidation (Asparagine, Glutamine), acetylation 
(Lysine) and oxidation (Methionine) were specified as variable modifications.  Two missed tryptic 
cleavages were allowed.  The precursor mass tolerance was set to 10 ppm and the fragment mass 
tolerance was set to 0.2 Da.  Stringent conditions were set in Mascot to filter out low scoring 
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peptides by imposing a confidence probability score (p) of <0.05.  Peptide and protein 
identifications were filtered at 1% FDR using the target-decoy strategy (Elias and Gygi, 2010).  
Only phosphopeptides mapping to proteins with at least two tryptic peptides were considered for 
analyses. The Mascot search results was exported as .xml files and then imported into the 
processed dataset in Progenesis QI software where the Mascot-generated peptide identifications 
were assigned to the corresponding quantified features.  Scatterplots illustrating Pearson’s 
correlation coefficients and fold-change phosphopeptide abundance were generated in R using in-
house-developed scripts.   
 
3.1.0.5 Data availability in public repository 
            The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
consortium (Deutsch et al., 2017; Vizcaino et al., 2014) via the PRIDE partner repository 
(Vizcaino et al., 2016) with the dataset identifier PXD009234. The data can be accessed on 
https://www.ebi.ac.uk/pride/archive/login using the following reviewer account details: 
Username: reviewer12016@ebi.ac.uk 
Password: HKaGSifi 
 
3.10.6 Motif enrichment analyses 
           Phosphopeptide sequences of 13 amino acids in length that were significantly altered 
between the experimental conditions (p-value = 0.05 and 3-fold upregulation) were searched for 
consensus sequences using the Motif-x (Chou and Schwartz, 2011) and PHOSIDA (Gnad et al., 
2007) algorithms.  Motifs were searched using the IPI human proteome database as the background 
dataset (Kersey et al., 2004).  Motif-x, the minimum number of occurrences for a motif in the 
dataset and the required motif significance was set to 20 and 10E-06, respectively. On PHOSIDA, 
the minimum score for phospho-Ser/Thr/Tyr was specified as 10 and the minimum proportion of 
matching sites was set to 5%. 
 
3.10.7 Functional gene enrichment analysis 
           Genes mapped from significantly upregulated phosphopeptides were used for identifying 
cellular and molecular processes, pathways and upstream regulators using the Ingenuity Pathway 
Analysis (IPA) software (QIAGEN Redwood City, http://www.qiagen.com/ingenuity).  Genes 
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were queried against the Ingenuity knowledge database as the reference set.  The analysis was 
restricted to the documentation of experimentally observed findings on human genes.  The 
Benjamini-Hochberg (B-H) multiple testing correction (B-H corrected p-value <0.05) scoring 
method was used in the IPA tool to compute the significance for the functional enrichment 
analysis.  Activation z-scores were calculated by IPA’s z-score algorithm to predict the overall 
activation or inhibition of the identified functional cellular processes/pathways and upstream 
regulators.  A positive z-score (z-score > 0) implies an overall predicted activation of the 
process/pathway/upstream regulator whereas a negative z-score (z-score < 0) implies an overall 
predicted inhibition or downregulation of the pathway/process/upstream regulator.   z-scores ≥ 2 
or ≤ -2 are considered significant by IPA for predicted activation or inhibition, respectively.  
Cellular processes/upstream regulators with no z-scores imply that IPA was unable to generate 
prediction states for these functionalities.   
 
3.10.8 NetworKIN analyses 
          The NetworKIN tool (www.networkin.info) is well described for use towards predicting 
kinase-substrate relationships (Linding et al., 2007).  The tool has been previously used to map 
candidate kinases targeting phosphosites on known proteins identified from LC-MS/MS-based 
phosphoproteomics analyses (Durnberger et al., 2014; Hoffman et al., 2015; Karayel et al., 2018).  
The NetworKIN tool integrates the NetPhorest database which comprises information on various 
kinase-specific and phospho-binding domain-specific motifs (Linding et al., 2007; Miller et al., 
2008).  We used the NetworKIN (Version 3.0) platform to identify candidate kinases upstream of 
the phosphosites identified in our global phosphoproteomics analyses.  All upregulated 
phosphosites [Log2 (SRMS/control) ≥ 1.584] identified in the SRMS-regulated phosphoproteome 
were used for analyses.  The resulting predicted annotations were filtered using a NetworKIN 
confidence score cut-off of 3.0 and a NetworKIN score-difference cut-off of 4.0.  The score-
difference defines the maximum difference between the best prediction and the second-best 
prediction.  The NetworKIN data was presented in an Excel file.  The identified kinases were 
plotted on a mammalian kinome dendogram generated using the KinMap tool (www.kinhub.org) 
(Eid et al., 2017).   
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4.0 Results 
4.1 Identification of novel candidate substrates of SRMS  
      The results described in this section have been published in the journal Molecular and Cellular 
Proteomics (MCP).  As part of the “License to Publish” agreement between the authors and the 
Journal, ownership of the copyright remains with the authors.  The authors reserve the right to use 
all or part of the published work for non-commercial purposes including theses/dissertations.  As 
per the “License to Publish” agreement, I am required to cite the publication, as below, for use in 
this thesis. 
This research was originally published in Molecular and Cellular Proteomics.    
Raghuveera Kumar Goel, Marta Paczkowska, Jüri Reimand, Scott Napper and Kiven Erique 
Lukong. Phosphoproteomics analysis identifies candidate substrates of the non-receptor tyrosine 
kinase, SRMS. Molecular and Cellular Proteomics, 2018, Paper in Press. © Goel et al. 
 
NOTE: The Supplementary Tables (Supplementary Tables 1-8) referenced in this section as well 
as legends to these tables can be accessed using the following weblink, as mentioned in Appendix 
A: 
http://www.mcponline.org/content/early/2018/03/01/mcp.RA118.000643/suppl/DC1  
 
4.1.1 Summary 
         SRMS (Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal 
myristoylation sites), also known as PTK 70 (Protein tyrosine kinase 70), is a non-receptor tyrosine 
kinase that belongs to the BRK family of kinases (BFKs).  To date little is known about the cellular 
role of SRMS primarily due to the unidentified substrates or signaling intermediates regulated by 
the kinase.  In this study, we used phosphotyrosine antibody-based immunoaffinity purification in 
large-scale label-free quantitative phosphoproteomics to identify novel candidate substrates of 
SRMS.  Our analyses led to the identification of 1258 tyrosine-phosphorylated peptides which 
mapped to 663 phosphoproteins, exclusively from SRMS-expressing cells.  DOK1, a previously 
characterized SRMS substrate, was also identified in our analyses.  Functional enrichment analyses 
revealed that the candidate SRMS substrates were enriched in various biological processes 
including protein ubiquitination, mitotic cell cycle, energy metabolism and RNA processing, as 
well as Wnt and TNF signalling.  Analyses of the sequence surrounding the phosphosites in these 
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proteins revealed novel candidate SRMS consensus substrate motifs.  We utilized customized 
high-throughput peptide arrays to validate a subset of the candidate SRMS substrates identified in 
our MS-based analyses.  Finally, we independently validated Vimentin and Sam68 as bona fide 
SRMS substrates through in vitro and in vivo assays.  Overall, our study identified a number of 
novel and biologically relevant SRMS candidate substrates, which suggests the involvement of the 
kinase in a vast array of unexplored cellular functions.  
 
4.1.2 Introduction 
         Though non-receptor tyrosine kinases constitute only about 6% of the total kinases encoded 
by the human genome (Manning et al., 2002), these kinases play physiologically significant roles 
linked to mammalian growth and development (Casaletto and McClatchey, 2012; Nurmio et al., 
2011).  Like serine/threonine kinases, tyrosine kinases phosphorylate various substrate proteins to 
regulate specific intracellular signaling pathways which ultimately elicit specific cellular and 
physiological functions (Hunter, 2009).  The catalytic activity of tyrosine kinases is highly 
regulated in eukaryotic cells and involve biochemically distinct mechanisms of autoregulation 
(Hubbard, 2002; Hubbard et al., 1998; Nolen et al., 2004).  Further, these kinases are known to 
exhibit distinct biochemical substrate-motif specificities which are believed to impart specificity 
to the cellular functions regulated by these kinases (Amanchy et al., 2011; Mok et al., 2010; 
Ubersax and Ferrell, 2007).  To date, high-throughput phosphoproteomics approaches have been 
applied to identify the cellular substrates of very few non-receptor tyrosine kinases (Amanchy et 
al., 2009; Amanchy et al., 2008; Xue et al., 2013).  Thus, key questions remain unanswered 
regarding the cellular roles and biochemical specificities of other non-receptor tyrosine kinases.  
We previously noted that the expression of wild type SRMS in HEK293 cells induced the tyrosine 
phosphorylation of several endogenous proteins (Goel et al., 2013).  These proteins represent the 
potential cellular substrates of SRMS and are largely unidentified.  The identity of these candidate 
cellular substrates of SRMS would be essential for a better understanding of the role of SRMS in 
mammalian cell biology.  
Mass spectrometry-based interrogation of the cellular phosphoproteome has afforded high-
throughput and robust identification of various serine/threonine and tyrosine kinase substrates and 
associated signaling intermediates (Amanchy et al., 2009; Amanchy et al., 2008; Bian et al., 2013; 
Courcelles et al., 2013; Hsu et al., 2011; Xue et al., 2013).  Over the years, the technology has 
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been used to precisely quantify multiple phosphorylation events occurring dynamically in the 
cellular phosphoproteome (Larance and Lamond, 2015; Roux and Thibault, 2013).  
 In the present study, we quantitatively probed the tyrosine-phosphoproteome of HEK293 
cells upon the exogenous introduction of wild type SRMS and identified 663 candidate substrates 
of the kinase.  Motif analyses revealed novel SRMS substrate consensus sequences among the 
candidate SRMS substrates.  We used customized high-throughput peptide arrays and validated a 
subset of the candidate SRMS substrates.  We finally independently validated Vimentin and 
Sam68, as bona fide SRMS substrates via immunoprecipitation analyses as well as direct in vitro 
kinase assays. 
 
4.1.3 Results 
4.1.3.1 SRMS induces kinase-dependent tyrosine phosphorylation of cellular proteins  
            We previously reported wild type SRMS as a catalytically active tyrosine kinase whose 
enzymatic activity is primarily regulated by the first 50 amino acids in the N-terminal region of 
the protein (Goel et al., 2013).  We observed that the exogenous expression of wild type SRMS 
and not N-SRMS (N-terminal deletion) or SRMS-K258M mutants resulted in increased tyrosine 
phosphorylation of cellular proteins (Goel et al., 2013).  We confirmed this finding by ectopically 
expressing GFP-tagged constructs encoding either wild type SRMS, N-SRMS or SRMS-K258M 
in HEK293 cells (Figure 4.1A).  We used general phosphotyrosine antibodies to probe the levels 
of tyrosine-phosphorylated proteins in the whole cell lysates derived from these cells. Our results 
confirmed that the ectopic expression of wild type SRMS but not N-SRMS or SRMS-K258M 
lead to the tyrosine-phosphorylation of several endogenous proteins in these cells (Figure 4.1B). 
The lysates were also probed with antibodies against GFP to ensure that the SRMS variants were 
expressed at similar levels in these cells (Figure 4.1B). The tyrosine-phosphorylated proteins 
observed in wild type SRMS-expressing cells represent the potential substrates of SRMS. We 
previously reported DOK1 as one of the proteins that is tyrosine phosphorylated in SRMS-
overexpressing HEK293 cells (Goel et al., 2013). However, the identity of the other tyrosine -
phosphorylated proteins in these cells and the specific tyrosine residues potentially targeted by 
SRMS remains unknown.  
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Figure 4.1: SRMS induces the tyrosine phosphorylation of several cellular proteins .  A. 
Shown here are the domain-structure representations of the wild type SRMS protein, the kinase-
dead SRMS mutant (K258M) and the N-terminal-deleted SRMS mutant (N-SRMS) which lacks 
the first 50 amino acids in the N-terminal region of SRMS.  Y380 represents the highly conserved 
autophosphorylation site within the activation loop of the SRMS kinase domain and K258 
represents the conserved ATP-contacting residue in the ATP-binding pocket of the SRMS kinase 
domain.  B. GFP-tagged SRMS constructs, namely, wild type SRMS, kinase-dead SRMS (SRMS- 
K258M) and N-SRMS were transiently overexpressed in HEK293 cells.  Untransfected HEK293 
cells or HEK293 cells transfected with the empty vector encoding GFP alone were used as controls. 
Post-transfection, the cells were lysed and the lysates probed with antibodies against total tyrosine 
phosphorylated residues (pTyr), GFP and -actin. Immunoblotting for -actin was used as a 
control for protein loading.  The asterisk (“*”) represents the approximate position of 
autophosphorylated GFP-wild type SRMS. 
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4.1.3.2 Phosphoproteomics workflow to enrich tyrosine -phosphorylated targets by immuno-
affinity purification 
            In order to identify the cellular substrates of SRMS, we performed a label-free quantitative 
phosphoproteomics approach to profile tyrosine-phosphorylated proteins in HEK293 cells 
ectopically expressing enzymatically active wild type SRMS (Figure 4.2).  We transiently 
transfected either GFP-tagged wild type SRMS or the empty vector as a control, in HEK293 cells 
in a large-scale experiment (Figure 4.2A).  We used the empty vector-expressing cells as a control 
to represent all steady state tyrosine phosphorylation events occurring natively in cells.  A total of 
twelve 10 cm dishes were transfected with either GFP-wild type SRMS or the control vector 
backbone.  Transfection efficiencies were determined to be over 90% (Figure 4.2A).  We harvested 
the cells directly in a strong denaturing lysis buffer and performed in-solution trypsin digestion of 
total proteins (Figure 4.2B and 4.2C).  The crude tryptic peptides were desalted via reversed-phase 
solid-phase extraction, and anti-phosphotyrosine antibodies were used to enrich for tyrosine 
phosphorylated peptides from cells expressing either GFP-SRMS or the empty vector control 
(Figure 4.2C and 4.2D).  The enriched tyrosine-phosphorylated peptides from both populations of 
cells were then sequenced via LC-MS/MS (Figure 4.2E) and protein identification and quantitation 
performed using the Andromeda and MaxQuant tools, respectively (Figure 4.2F). 
 
4.1.3.3 Identification of candidate SRMS substrates  
            Using the MaxQuant-Andromeda integrated platform and the Perseus quantitative analyses 
framework, we applied quality thresholds (Cox and Mann, 2008; Cox et al., 2011; Tyanova et al., 
2016a; Tyanova et al., 2016b) to allow the identification of high-confidence phosphopeptides 
(Figure 4.3A- 4.3D).  The search parameters on MaxQuant-Andromeda were adjusted using 1% 
FDR and quality Andromeda search and Delta scores were used as minimum thresholds (Figure 
4.3A and 4.3B, Supplementary Tables 1 and 2).  Using Pearson’s correlation analysis, we observed 
good reproducibility of the phosphopeptides quantified from both biological replicates of each 
sample (R ≥ 0.8) (Figure 4.4A and 4.4B).  We finally based subsequent analyses exclusively on 
class I phosphosites that matched a reasonably stringent t-test-based statistical threshold (p-value 
< 0.05, Student’s t-test) (Figure 4.3C and 4.3D, Supplementary Table 3).  Using these criteria, our 
analyses led to the identification of a total of 1450 tyrosine- phosphorylated peptides pooled from 
both, SRMS-expressing and control cells (Figure 4.5A and Supplementary Table 3).  Of these,  
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Figure 4.2: Experimental workflow.  A label-free quantitation-based mass spectrometry 
approach was adopted to identify the candidate cellular substrates of SRMS.  A. Plasmid constructs 
encoding either GFP-tagged wild type SRMS or GFP alone (empty vector) were exogenously 
introduced in HEK293 cells.  B. 24 hours post-transfection the cells were lysed under denaturing 
conditions. C. 12 mg total protein, each from GFP alone and GFP-SRMS conditions, was trypsin-
digested and the crude tryptic peptides were desalted via reversed-phase solid-phase 
chromatography.  D. The desalted peptides were then used towards immunoprecipitation of total 
tyrosine-phosphorylated peptides.  E. The enriched tyrosine-phosphorylated peptides from each 
condition were sequenced via LC-MS/MS. All fractions were separated using a 2-hour a reversed-
phase gradient and electro-sprayed into a Q Exactive HF quadrupole instrument.  F. Protein IDs 
and phosphosite localization were determined using the MaxQuant platform which integrates the 
Andromeda search engine.  The entire workflow was performed in 2 biological replicates. 
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Figure 4.3: Flowchart depicting the  computational pipeline used to identify high confidence 
phosphopeptides.  A. The acquired raw instrument data were processed on the MaxQuant-
Andromeda platform that integrates the Perseus software for data quantitation.  Each peptide 
spectrum obtained was queried using the Andromeda search engine to generate reliable peptide -
spectrum matches (PSM) against the queried database.  Peptide sequences and protein IDs were 
assigned at 1% False Discovery Rate (FDR) based on target-decoy searches.  B. Phosphopeptides 
were quantified based on their precursor ion intensities, calculated as the area of the associated 
peak or area-under-the curve (AUC).  Phosphopeptides with an associated “Andromeda score” < 
40.0 and Delta score < 8 were discarded.  C. Class I phosphosites were selected with an 
“Andromeda “localization score” and “localization probability” threshold of 40.0 and 0.75, 
respectively.  D. Finally, a statistical t-test threshold was applied to the identified phosphopeptides.  
Only phosphopeptides with corresponding precursor ion intensities that were statistically 
significant, with a p-value ≤ 0.05 between both biological replicates, were retained.  “Threshold 
match= Yes” indicates that the phosphopeptide(s) matched the threshold for the above parameters 
and were accepted.  “Threshold match=No” indicates that the phosphopeptides failed to match the 
threshold for the parameters and were discarded.  
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Figure 4.4: Reproducibility of phosphopeptide identifications: Pearson’s correlation 
coefficients (R score) were determined for Log2-transformed phosphopeptides (matching the 
MaxQuant-Andromeda search parameters and criteria) quantified from both replicates of A. 
SRMS-expressing cells (n= 1778 phosphopeptides) and B. control (empty vector-expressing) cells 
(n=516 phosphopeptides).   
 
1258 peptides were unique and mapped to 771 distinct proteins (Figure 4.5A and Supplementary 
Table 3).  A total of 141 peptides were found to be conserved in more than one protein and such 
proteins were consequently clustered in the respective protein groups by MaxQuant 
(Supplementary Table 3).  As expected, we identified a far greater number of tyrosine -
phosphorylated peptides in SRMS-overexpressing cells compared to control cells (Figure 4.5B, 
left panel).  This observation was consistent with our findings from Figure 4.1B as well as 
additional immunoblotting analyses where we used general phosphotyrosine antibodies to assess 
total tyrosine-phosphorylated proteins in the same pool of lysates which were used towards mass 
spectrometry analyses (Figure 4B, right panel).  While SRMS-overexpressing cells readily 
exhibited a significant number of tyrosine-phosphorylated proteins, longer exposures of the 
immunoblot revealed a fair but comparatively lower number of tyrosine-phosphorylated proteins 
in the control cells as well (Figure 4.6).  This is expected since tyrosine phosphorylation occurs 
natively in cells although at a far lower biological stoichiometry compared to serine/threonine 
phosphorylation events (Conrads and Veenstra, 2005; Hunter, 1998).  
 Of the 1258 unique tyrosine-phosphorylated peptides identified between both samples, 
1129 phosphopeptides were identified exclusively in SRMS-expressing cells whereas only 117 
phosphopeptides were enriched in the control cells (Figure 4.5B, left panel and Supplementary 
Table 3).  Additionally, 99 phosphopeptides were found common to both SRMS-expressing and 
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Figure 4.5: Overview of the identified tyrosine -phosphoproteome.  A. The MaxQuant-
Andromeda platform quantified a total of 1450 redundant tyrosine-phosphorylated peptides from 
both control and SRMS-overexpressing cells.  Of these, 1258 tyrosine-phosphorylated peptides 
were unique and mapped to 771 unique proteins.  B. A Venn diagram depicts the number of 
tyrosine-phosphorylated peptides either unique to SRMS-overexpressing cells, control cells or 
common to both. Of the 1258 unique tyrosine-phosphorylated peptides identified globally, 1129 
peptides were enriched exclusively in SRMS-overexpressing cells while 117 peptides were 
identified exclusively in control cells.  99 peptides were found common to both samples (left 
panel).  The 1129 phosphopeptides identified exclusively in SRMS-expressing cells mapped to 
663 proteins.  Prior to trypsinization, 25 ug whole cell lysates derived from large-scale 
transfections of HEK293 cells, were probed with general phosphotyrosine antibodies via 
immunoblotting analyses to confirm the expression of tyrosine-phosphorylated proteins resulting 
from SRMS kinase activity (right panel).  C. The tyrosine-phosphorylated peptides were 
segregated based on multiplicity of phosphorylation (MoP). Singly- (MoP=1), doubly- (MoP=2) 
or triply- (MoP=3)-phosphorylated peptides were quantified and represented either as percent-
abundance of total tyrosine-phosphorylated peptides in each sample (pie-chart, left panel) or in 
absolute numbers (right panel). 
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Figure 4.6: SRMS-induced tyrosine phosphorylation of endogenous proteins.  cDNA 
encoding either GFP alone or GFP-tagged wild type SRMS were exogenously expressed in 
HEK293 cells in large-scale (12 x 10 m dishes each) and lysates harvested for use towards LC-
MS analyses.  25 μg total protein from each condition was used in quantitative immunoblott ing 
analyses using general phosphotyrosine antibodies.  Antibodies against -actin were used to detect 
total -actin levels in the lysates and used as loading control.  Near-infrared fluorescent dye-
conjugated secondary antibodies (800 nm) were used in immunoblotting analyses.  The 
phosphotyrosine immunoblots were scanned at various exposure levels to detect the expression of 
both, high and low-abundance tyrosine-phosphorylated proteins in the samples. 
 
 
control cells (Figure 4.5B, right panel and Supplementary Table 3).  We considered the tyrosine-
phosphorylated targets as candidate substrates of SRMS only if the corresponding 
phosphopeptides were exclusively enriched in the SRMS overexpressing cells at a p-value 
threshold of 0.05 between the replicates.  All tyrosine-phosphorylated peptides identified in the 
control cells were considered background phosphorylation events. Since none of the 
phosphopeptides identified as common to SRMS-overexpressing and control cells displayed at 
least two-fold differential abundance in phosphopeptide intensities, we reasoned that proteins 
mapped from these peptides would be less likely to represent candidate SRMS substrates and were 
therefore filtered.  Using this approach, we identified 663 candidate SRMS substrates across two 
biological replicates with a p-value <0.05 (Figure 4.5B, left panel and Supplementary Table 3).  A 
subset of the SRMS candidate substrates is listed in Table 4.1.  Importantly, our 
phosphoproteomics analyses identified DOK1 as a hyperphosphorylated target in wild type  
SRMS-expressing cells.  This was an important observation since we previously validated DOK1 
as a direct substrate of SRMS and showed that the exogenous expression of SRMS led to the 
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phosphorylation of endogenous DOK1 in HEK293 cells (Goel et al., 2013).  Our MS analyses 
therefore validated our previous findings.  The SRMS Y380 residue represents a key 
autophosphorylation site within the kinase domain activation loop and is essential for SRMS 
 
Table 4.1: List of candidate SRMS substrates identified using quantitative 
phosphoproteomics.  List of top-ranked candidate SRMS substrates identified using the label-
free quantitative phosphoproteomics approach in LC-MS/MS analyses.  The candidate substrates 
are ranked based on associated mean log2 phosphorylation intensities from both biological 
replicates. The gene name, protein name and the corresponding phosphosite(s) identified in the 
proteins are listed. The mean log2 intensities for each phosphosite are indicated in parenthesis.  
Phosphosites identified in SRMS are indicated.  Although not identified as a top-ranked candidate 
substrate, KHDRBS1/Sam68, an important Src and BRK substrate is also listed in the table.  Refer 
to Supplementary Table 3 using the journal’s weblink provided (Appendix A), to access the 
complete list of candidate SRMS substrates. 
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enzymatic activity (Goel et al., 2013).  As expected, the peptide corresponding to SRMS Y380 
was identified as one of the major phosphopeptides from our MS analyses.  Additionally, we 
identified 14 other tyrosine- phosphorylated sites in SRMS that were not previously known (Table 
4.1).  
We also assessed the multiplicity of phosphorylation associated with tyrosine residues in 
the identified tyrosine-phosphorylated peptides.  We found that the majority of the tyrosine-
phosphorylated peptides, identified between both samples, were singly phosphorylated (Figure 
4.5C).  However, the singly-phosphorylated peptides were significantly more abundant (>3-fold) 
in SRMS-expressing cells compared to control cells (Figure 4.5C).  Interestingly, doubly-
phosphorylated peptides were over 30-fold more abundant in SRMS-expressing cells compared to 
control cells (Figure 4.5C).  Additionally, though detected only as a minor proportion, triply-
phosphorylated peptides were identified in SRMS-expressing cells but not in the control cells 
(Figure 4.5C).  The greater multiplicity of phosphorylation observed on individual peptides in 
SRMS-expressing cells, indicates that SRMS likely phosphorylates its substrates on several 
tyrosine residues.  
 
4.1.3.4 In silico analyses identifies candidate SRMS substrate motifs 
           As described above, our analyses revealed 1129 non-redundant tyrosine-phosphorylated 
peptides in SRMS-overexpressing cells.  We were interested in identifying candidate SRMS 
substrate motifs to understand the pattern of substrate-specificity exhibited by the SRMS kinase 
domain.   Motif-specificities exhibited by tyrosine kinase domains are less understood compared 
to the other well-characterized modular domains such as the SH3, SH2 and PTB domains, 
primarily since the cellular substrates of several of these kinases are unknown.  To identify the 
consensus sequence(s) of SRMS substrates, we used the entire pool of unique phosphopeptides 
(n=1129) derived from the 663 candidate SRMS substrates, enriched exclusively from SRMS-
overexpressing cells. We performed motif-analyses using two well described and popular in silico 
tools, namely, Motif-x (Chou and Schwartz, 2011) and MMFPh (Maximal motif finder for 
phosphopeptides) (Wang et al., 2012).  The active site of kinases is known to recognize residues 
that are immediately N-terminal and/or C-terminal to the phospho-acceptor site, implying that 
consensus sequences are generally short (Ubersax and Ferrell, 2007).  We therefore refined the 
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length of our query phosphopeptides to 13 amino acids.  Using Motif-x, we identified six major 
classes of SRMS substrate consensus motifs at a significance threshold of 10-6 (Figure 4.7A and  
  
                            
 
Figure 4.7: Top candidate SRMS consensus motifs  identified by Motif-x and MMFPh. A. The 
in silico motif analyses tool motif-x (Chou and Schwartz, 2011) was used to assess overrepresented 
motif patterns in tyrosine-phosphorylated peptides (n=1129) derived from 663 candidate SRMS 
substrates. Six candidate consensus motifs are represented in individual motif logos and in the 
order of their fold-enrichment (left panel). A representative motif logo of all candidate SRMS 
consensus motifs was generated using the Phosphosite motif analyses tool 
(http://www.phosphosite.org/sequenceLogoAction) (right panel). The size of the amino acid letter, 
in the motif logo (left and right panels), is proportional to the magnitude of overrepresentation of 
this residue in the pool of queried peptides. B. The tables represent statistical information on the 
top three SRMS candidate consensus motifs identified using either the Motif-x (Chou and 
Schwartz, 2011) or MMFPh (Wang et al., 2012) tools. Foreground matches indicate the number 
of queried peptides that correspond to the identified motif. Background size indicates the 
background pool of phosphopeptides used as reference. The algorithmically determined scores 
associated with each motif are indicated. 
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Supplementary Table 4).  Interestingly, the top three consensus sequences identified by Motif-x 
were also reported as overrepresented by the other in silico tool, MMFPh (Figure 4.7B).  
Additionally, both Motif-x and MMFPh identified 3 unique consensus motifs among the 
phosphosites derived from candidate SRMS substrates (Figure 4.8A- 4.8C and Supplementary 
Table 4). 
         
 
Figure 4.8: All candidate SRMS consensus motifs  identified by Motif-x and MMFPh. 
Tyrosine-phosphorylated peptides derived from 662 candidate SRMS substrates were queried 
using two in silico motif analyses tools, namely, A. Motif-x (Chou and Schwartz, 2011) and B. 
MMFPh (Wang et al., 2012). All identified motifs and the associated statistical information is 
presented. Foreground matches indicate the number of queried peptides that correspond to the 
identified motif. Background size indicates the background pool of phosphopeptides used as 
reference. The algorithmically determined scores associated with each motif is indicated. C. Six 
candidate SRMS substrate consensus motifs, identified as significantly enriched by the MMFPh 
tool, are represented in individual motif logos. The size of the amino acid letter, in the motif logo 
is proportional to the overrepresentation of this residue in the pool of queried peptides. 
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Overall, motif-analyses using these two programs revealed that top SRMS candidate consensus 
sequences predominantly displayed a lysine residue at either the -2 (KxY, where Y represents the 
phosphorylated tyrosine residue at position “0” and “x” is any amino acid residue) or -4 position 
(KxxxY) (Figure 4.7 and 4.8).  Another overrepresented candidate consensus motif displayed a 
glycine at the +1 position (YG) (Figure 4.7 and 4.8).  Other enriched motifs contained either a 
lysine residue at +6 (YxxxxxK), valine at -1 (VY) or a glutamic acid at +1 (YE) positions, 
respectively (Figure 4.8).  We also examined the possibility that the more rigorous SRMS substrate 
consensus motifs would likely be represented by a subset of phosphopeptides enriched at 
significantly higher relative abundances.  To address this, we performed motif-analyses using 86 
phosphopeptides corresponding to candidate SRMS substrates, that were quantified with average 
log2 ion intensities of at least 24.0.  Using the Motif-x tool, we consistently identified the KxY 
motif as the most overrepresented consensus sequence among the queried phosphopeptides, 
implying that this may likely represent one of the major SRMS kinase consensus motifs               
(Figure 4.9).  
       
Figure 4.9: Analyses of candidate SRMS consensus motifs from phosphopeptides identified 
at higher relative abundance: A. The in silico motif analyses tool Motif-X (http://motif-
x.med.harvard.edu/) was used to assess overrepresented motif patterns in 86 tyrosine -
phosphorylated peptides corresponding to candidate SRMS substrates with LC-MS/MS ion 
intensities ≥ 24.0. The overrepresented motif, as identified by Motif-x, is shown in the motif logo. 
B. Statistical information relevant to the identified consensus motif is presented. 
 
 
73 
 
4.1.3.5 Functional gene enrichment analysis of candidate SRMS substrates  
The cellular and physiological role of SRMS is poorly understood.  To gain insights into the 
biological function of SRMS, we performed pathway enrichment analyses on the candidate SRMS 
substrates using the g:Profiler software (Reimand et al., 2016).  In order to complete a high-
confidence pathway analysis and restrict our enrichment analysis solely to phosphoproteins, we 
used a custom background set of all reported phosphoproteins curated with the PhosphositePlus 
database (Hornbeck et al., 2015).  This increased the stringency at the level of the expected number  
of proteins associated with every Gene Ontology (GO)-annotated pathway identified.  We further 
filtered low-confidence GO annotations of genes that had been only derived from automated 
computational analysis. Our analysis revealed 176 significantly enriched biological pathways and 
processes (FDR<0.05) that associated with a large fraction (411/663 proteins or 62%) of the 
candidate SRMS substrates (Figure 4.10 A and 4.10B and Supplementary Table 5). We 
constructed an enrichment map visualization (Merico et al., 2010) and manually annotated 
subnetworks of similar pathways as functional themes (Figure 4.10B). We found that the top 
pathways and processes associated with the candidate SRMS substrates included themes such as 
proteolysis and protein ubiquitination (e.g., negative regulation of protein ubiquitinat ion, 
FDR=5x10-11, 31 proteins), mitotic cell cycle (e.g., cell cycle phase transition, FDR=3x10-11, 66 
proteins), cellular energy metabolism (e.g., ATP metabolic process, FDR=4x10-8, 36 proteins) and 
RNA processing (e.g., RNA catabolic process, FDR=8x10-12, 54 proteins) (Figure 4.10A and 
4.10B). Several other interesting themes with fewer pathways were also apparent, such as 
regulation of stem cell differentiation (FDR=0.03, 16 proteins) and cellular response to hypoxia 
(FDR=0.004, 21 proteins). Two themes corresponding to established signal transduction pathways 
were also significantly enriched: Wnt signaling pathway (FDR=9x10-4, 18 proteins) and tumor 
necrosis factor (TNF)-mediated signaling pathway (FDR=4x10-3, 20 proteins) (Figure 4.10A and 
4.10B). Overall, pathway enrichment analyses of our phosphoproteomics dataset revealed several 
distinct and related cellular processes potentially regulated by SRMS in a kinase-dependent 
manner.  
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Figure 4.10: Functional gene enrichment analyses of candidate SRMS substrates .  A. 
Enrichment map of significantly enriched cellular processes and pathways enriched by candidate 
SRMS substrates (FDR<0.05).  Network nodes represent enriched pathways and edges connect 
pathways with many shared genes.  Biological themes associated with groups of nodes represent 
a simplified summary of multiple related pathways and were assigned through manual curation.  
The size of each node is proportional to the number of genes involved in the given pathway or 
process.  B. Barplot shows the most significant pathways and processes and number of candidate 
SRMS substrates enriched in each pathway/process.  The p-value associated with each annotated 
process/pathway is indicated. 
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4.1.3.6 Validation of candidate SRMS substrates using peptide arrays  
Our mass spectrometry-based phosphoproteomics analyses identified 663 candidate SRMS 
substrates (Figure 4.5B).  We decided to utilize peptide microarrays in a complementary approach 
to perform high-throughput validation of a subset of the candidate SRMS substrates.  Peptide 
microarrays are robust and versatile tools that have been previously used for screening kinase-
substrates (Parikh et al., 2009), identifying kinase substrate-motifs (Leung et al., 2007) and 
investigating phosphoproteome-based signaling in eukaryotic cells (Diks et al., 2004).  We 
generated a customized peptide array comprising 102 unique peptides (Supplementary Table 6).  
Of these, 100 peptides were derived from the tyrosine-phosphorylated peptides identified in our 
MS analyses (Supplementary Table 6).  These 100 peptides included 80 test peptides 
corresponding to 58 candidate SRMS substrates that were identified exclusively in SRMS-
expressing cells at log2 intensities >20 and 20 negative control peptides that were selected 
randomly (Supplementary Table 6).  Of these 20 negative control peptides, 9 were identified in 
our MS analyses from control cells alone and 11 were common to both SRMS-expressing and 
control cells (Supplementary Table 6).  The remaining two are control peptide, a negative control 
peptide corresponding to Beclin1 Y352 that was previously reported as a direct phosphorylation 
site for EGFR but not SRMS (Wei et al., 2013), and a peptide corresponding to the BRK Y447 
residue since this was recently reported as a site that is directly phosphorylated by SRMS (Fan et 
al., 2015).  Each peptide was printed in three triplicate sets (9 peptide replicates in total) on each 
array to allow for intra-array normalization (Scholma et al., 2016; Trost et al., 2013) of the peptide 
phosphorylation intensities.   
 We used lysates derived from HEK293 cells overexpressing either GFP-SRMS wild type 
or GFP-kinase-dead SRMS to assess the phosphorylation status of the peptides on the microarrays.  
Data from our peptide microarray analyses showed that compared to arrays treated with kinase-
dead SRMS, wild type SRMS-treated arrays displayed increased phosphorylation of 52 peptides 
derived from candidate 44 candidate SRMS substrates (fold change phosphorylation > 1) 
(Supplementary Table 7).  Of these, 26 peptides, derived from 24 candidate substrates showed a 
SRMS kinase-dependent increase in tyrosine phosphorylation across all technical replicates (p-
value = 0.003-0.09) (Supplementary Table 8).  A subset of these validated targets is represented 
in Figure 4.11 and Table 2.  
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Figure 4.11: Validation of target peptides using peptide microarrays .  A scatter plot of 
differentially phosphorylated peptides between wild type SRMS-treated and kinase-dead SRMS-
treated conditions.  Peptides highlighted in red represent hyperphosphorylated targets identified in 
arrays treated with wild type SRMS (p-value range 0.003-0.09).  Peptides highlighted in green 
represent hypophosphorylated targets identified in arrays treated with wild type SRMS.  Selected 
hyperphosphorylated peptides are labelled in the scatter plot.  
 
As expected, none of the 21 control peptides, including Beclin1 Y352, showed increased 
phosphorylation in the wild type SRMS-treated arrays compared to kinase-dead SRMS-treated 
arrays (Supplementary Table 7 and 8).  Importantly, we observed an increase in the 
phosphorylation of the peptide corresponding to DOK1 Y337, in wild type SRMS-treated arrays 
compared to kinase-dead SRMS-treated arrays (Table 4.2 and Supplementary Tables 7 and 8).  
This again corroborates our previous findings where we identified DOK1 as a bona fide SRMS 
substrate (Goel et al., 2013).  We also observed a modest increase in the phosphorylation of the 
BRK Y447 peptide in arrays treated with lysates of cells overexpressing wild type SRMS.  The 
BRK Y447 peptide showed 1.2-fold increased phosphorylation in wild type SRMS-treated arrays 
compared to kinase-dead SRMS-treated arrays (Supplementary Tables 7 and 8).  Additionally, we 
found that the top target peptides validated in our phosphorylation assays displayed motifs that 
matched the candidate consensus motifs for SRMS (Table 4.2), as determined through in silico 
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analyses (Figure 4.7, 4.8 and 4.9).  These included motifs, RxY (VIM Y383 and MAGED1 Y505), 
VY (CDK2/3 Y19), KxY (UMPS Y326 and GRB10 Y354), KxxY (DOK1 Y337), YA (HNRNPM 
Y681 and RPS3 Y87) and YG (EIF4A3 Y50 and MCM7 Y33). 
 
Table 4.2: List of top SRMS targets validated on peptide arrays .  List of peptides that displayed 
increased phosphorylation on the central phospho-acceptor tyrosine residue (p-Tyr. site) upon 
incubation with lysates derived from HEK293 cells expressing ectopic wild type SRMS, compared 
to lysates of cells expressing the kinase-dead SRMS mutant.  Fold-change phosphorylation of each 
peptide is presented as the ratio of phosphorylation intensity corresponding to wild type SRMS-
treated versus kinase-dead SRMS-treated conditions.  The statistical significance (P-value) of 
phosphorylation was determined by PIIKA2 (Trost et al., 2013) using phosphorylation intensities 
from 9 peptide replicates on the array.  Candidate SRMS consensus motifs are indicated for the 
phosphopeptides whose phosphosite sequences match these motifs. “-” The motifs associated with 
these peptides were not enriched in our in silico motif analyses. 
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4.1.3.7 Validation of Vimentin and Sam68 as SRMS substrates  
Our peptide array analyses revealed vimentin as a top candidate substrate of SRMS (Figure 11 and 
Table 4.2).  Vimentin (VIM) is a key cytoskeletal protein and a substrate of c-Src and various 
serine/threonine kinases (Cheng et al., 2003; Eriksson et al., 2004; Ferrando et al., 2012).   
Interestingly, KHDRBS1/Sam68 was also identified as a candidate SRMS substrate from our MS 
analyses although this was not tested in our peptide microarrays.  Sam68 is a key RNA-binding 
protein implicated in cellular RNA-metabolic processes whose functions are regulated by 
phosphorylation (Feracci et al., 2016).  We have previously shown that the SRMS family member, 
BRK phosphorylates Sam68 and regulates its RNA-binding properties (Lukong et al., 2005).  To 
verify vimentin and Sam68 as in vivo SRMS substrates, we performed immunoprecipitat ion 
analyses using GFP-vimentin and Myc-Sam68 constructs.  We first co-expressed GFP-vimentin 
with either Flag-tagged wild type SRMS or SRMS K258M in HEK293 cells.  Vimentin was 
immunoprecipitated using antibodies against GFP and the immunoprecipitates and input probed 
with antibodies against GFP, Flag or total phospho-tyrosines (Figure 4.12A and 4.12B).  Firstly, 
our immunoblotting analyses using antibodies against Flag-tag showed that both wild type SRMS 
and SRMS K258M co-precipitated with ectopically expressed vimentin indicating that SRMS 
associates with vimentin in a kinase-independent manner (Figure 4.12A).  We observed the 
tyrosine-phosphorylation of vimentin only in wild type SRMS-transfected cells and not SRMS 
K258M-transfected cells, confirming that the phosphorylation of vimentin is SRMS kinase-
dependent (Figure 4.12A).  Likewise, we co-expressed Myc-Sam68 with either GFP-tagged wild 
type SRMS or SRMS-K258M.  We immunoprecipitated Sam68 using antibodies against Myc and 
probed the immunoprecipitates and input using antibodies against Myc, GFP and total 
phosphotyrosines (Figure 4.13A and 4.13B).  As seen with vimentin, we found that both wild type 
SRMS as well as SRMS K258M co-precipitated with Sam68, indicative of kinase-independent 
pattern of intermolecular association (Figure 4.13A).  Importantly, Sam68 was found to be tyrosine 
phosphorylated only upon co-expression with wild type SRMS but not kinase-dead SRMS (Figure 
4.13A).  Together, our findings concur with the results of our peptide array analyses and suggest 
that both vimentin and Sam68 are substrates of SRMS. 
 To test if vimentin and Sam68 are direct substrates of SRMS, we performed in vitro kinase 
assays using purified recombinant GST-SRMS kinase protein and GST-vimentin or GST-Sam68 
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Figure 4.12: Validation of vimentin as a SRMS substrate.  A. HEK293 cells were transiently 
transfected with constructs encoding GFP-vimentin alone or together with Flag-wild type SRMS 
(SRMS WT) or Flag-Kinase-dead SRMS (SRMS KD).  GFP-vimentin was immunoprecipitated 
using antibodies against GFP.  The immunoprecipitates (right panel) were probed with antibodies 
against GFP (top), Flag (Middle) or total phosphotyrosines (Bottom).  B. Input from the 
corresponding lysates were probed with the same antibodies and are shown in the same order  
(Right panel). 
 
proteins.  Our results showed that in the presence of ATP, SRMS kinase directly phosphorylated 
both vimentin and Sam68 in vitro (Figure 4.14A and 4.14B).  As expected, in the absence of 
SRMS, vimentin and Sam68 were not phosphorylated.  As an additional control, we incubated the 
GST protein alone with GST-SRMS kinase and observed no phosphorylation of the GST protein 
confirming that SRMS directly phosphorylates both, vimentin and Sam68 (Figure 4.14A and 
4.14B).  
 Since we found that vimentin and Sam68 co-precipitated with SRMS in our 
immunoprecipitation analyses, we asked if SRMS colocalizes with vimentin or Sam68 in vivo.  To 
examine this, we co-transfected GFP-vimentin or GFP-Sam68 with either mCherry-wild type 
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Figure 4.13: Validation of Sam68 as a SRMS substrate.  A. HeLa cells were transfected either 
individually with Myc-Sam68 or co-transfected with GFP-wild type SRMS or GFP-kinase-dead 
SRMS.  Myc-Sam68 was immunoprecipitated using anti-Myc antibodies.  The 
immunoprecipitates (left panel) were probed by Western blotting with antibodies against Myc 
(top), GFP (middle) or total phosphotyrosines (bottom).  B. Input from the corresponding lysates 
were probed with the same antibodies and are shown in the same order (Right panel). 
 
SRMS or SRMS K268M, in HEK293 cells and assessed colocalization by confocal microscopy 
analyses.  Firstly, we observed that GFP-tagged or untagged wild type SRMS localized 
predominantly to cytoplasmic punctae (Figure 4.15A and 4.15B), as we previously reported (Goel 
et al., 2013).  Vimentin was predominantly found to localize to cytoplasmic tubular networks 
(Figure 4.16A), consistent with previous reports describing these as vimentin intermediate 
filaments (VIFs) (Flynn et al., 2016; Mendez et al., 2010).  Importantly, we observed that GFP-
vimentin and mCherry-wild type SRMS colocalized in the cytoplasm of HEK293 cells (Figure 
4.16B).  We tested this co- localization reciprocally using GFP-wild type SRMS and mCherry-
vimentin constructs.  We observed that both mCherry-vimentin and GFP-SRMS colocalized in the 
cytoplasm (Figure 4.16C).  We also noted that SRMS colocalized with vimentin in VIFs 
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Figure 4.14: Validation of Sam68 and Vimentin as direct substrates of SRMS.  A. In vitro 
kinase assays were performed using purified recombinant GST-SRMS kinase and GST-Sam68. 
GST-Sam68 was incubated with or without GST-SRMS kinase and in the presence of ATP.  GST-
SRMS kinase was also incubated with GST alone as a control.  Phosphorylation of Sam68 by 
SRMS was assessed by Western blotting using general phosphotyrosine antibodies. The 
immunoblots were also probed with antibodies against GST to show the expression of the GST-
Sam68, GST-SRMS kinase and GST alone.  B. Purified recombinant GST-vimentin was incubated 
with or without GST-SRMS kinase and in the presence of ATP.  Phosphorylation of vimentin by 
SRMS was assessed by Western blotting using general phosphotyrosine antibodies.  GST-SRMS 
kinase was also incubated with GST alone as a control.  The immunoblots were also probed with 
antibodies against GST to show the expression of the respective proteins. 
 
 
rather than in the characteristic SRMS-cytoplasmic puncta, indicating that vimentin likely 
sequesters SRMS to VIFs (Figure 4.16B and 4.16C).  No colocalization was observed between 
mCherry alone and GFP-vimentin, implying that the observed colocalization between SRMS and 
vimentin does not depend on the fluorescent protein tags used (Figure 4.16D).  Although Sam68 
is known to localize predominantly to the nucleus (Lukong et al., 2005; Wrighton, 2016), certain 
studies have reported a cytoplasmic localization of the RNA-binding protein (Huot et al., 2009; 
Liao et al., 2013; Paronetto et al., 2006).  Consistent with previous reports, we found that Sam68 
localized predominantly to the nucleus in cells co-expressing control vector encoding mCherry 
A B 
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alone (Figure 4.17A).  However, in a few cells we also observed a partial cytoplasmic localization 
of Sam68 (Figure 4.17B).  Co-expression of GFP-Sam68 and mCherry-SRMS revealed partial 
colocalization of both proteins where SRMS colocalized with cytoplasmic Sam68 (Figure 4.17C).  
No colocalization was observed between GFP-Sam68 and mCherry alone (Figure 4.17A and 
4.17B).  Together, our data show that both vimentin and Sam68 colocalize with SRMS in the 
cytoplasm.  
 
                   
 
Figure 4.15: Subcellular localization of wild type SRMS in cytoplasmic punctae .  HEK293 
cells were seeded on glass coverslips in 6-well culture dishes.  Vectors encoding: A. GFP-wild 
type SRMS, B. untagged wild type SRMS or C. GFP alone were exogenously introduced in the 
cells.  Transfected cells were fixed, permeabilized and ectopic untagged SRMS detected using 
primary antibodies against SRMS (mouse IgG) and secondary anti-mouse Texas red antibodies.  
Nuclei were stained with DAPI.  Images were acquired on a confocal microscope at 40x 
magnification.  Scale bar = 20 nm. 
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Figure 4.16: Colocalization of SRMS with vimentin.  A. HEK293 cells, seeded on glass 
coverslips and cultured in 6-well culture dishes, were transfected with a vector encoding GFP-
vimentin alone or B. co-transfected with vectors encoding GFP-vimentin and mCherry-SRMS 
(wild type), C. mCherry-vimentin and GFP-wild type SRMS or D. GFP-vimentin and mCherry 
alone.  Colocalization between SRMS and vimentin was determined via confocal microscopy.  
Images were acquired at 40x magnification.  Scale bar = 20 nm. 
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Figure 4.17: Colocalization of SRMS with Sam68.  A. and B. HEK293 cells, seeded on glass 
coverslips and cultured in 6-well culture dishes, were co-transfected with either GFP-Sam68 and 
mCherry alone or C. GFP-Sam68 and mCherry-wild type SRMS.  Colocalization between Sam68 
and SRMS or mCherry alone was determined via confocal microscopy.  Images were acquired at 
40x magnification.  Scale bar = 20 nm. 
 
4.1.3.8 SRMS induces the tyrosine phosphorylation of Sam68 in an EGF-dependent manner 
Sam68 is known to be frequently tyrosine phosphorylated, which is essential for the regulation of 
the RNA-binding function of the protein (Richard, 2010).  Since we found that Sam68 is a SRMS 
substrate, we checked if SRMS was required for the tyrosine-phosphorylation of Sam68 at the 
endogenous level.  We used MDA-MB 231 cells since this cell line is known to express both 
proteins at the endogenous level (Goel et al., 2013).  To determine whether endogenous SRMS 
promotes the phosphorylation of Sam68, we transiently knocked-down SRMS and 
immunoprecipitated endogenous Sam68 from either parental, scrambled siRNA or SRMS siRNA-
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transfected cells.  Firstly, we observed a significant knockdown of endogenous SRMS in the 
SRMS siRNA-transfected cells (Figure 4.18A, lower panel).  However, immunoblotting the 
Sam68 immunoprecipitates with general phosphotyrosine antibodies revealed no significant 
difference in Sam68 tyrosine-phosphorylation between SRMS-knockdown and parental or 
scramble siRNA-transfected cells (Figure 4.18A, top panel).  This implied that under steady-state 
conditions endogenous SRMS has no impact on the tyrosine-phosphorylation of endogenous 
Sam68.  Previous studies have shown that Sam68 is a downstream target of the EGFR-signaling 
pathway where Sam68 undergoes significant tyrosine-phosphorylation upon stimulation of cells 
with EGF (Lukong et al., 2005).  Additionally, BRK has been shown to modulate the EGF-
stimulated tyrosine-phosphorylation of Sam68 (Lukong et al., 2005).  We therefore tested if SRMS 
affects Sam68-phosphorylation in response to EGF-stimulation.  We first stimulated serum-
starved MDA-MB 231 cells with EGF at intervals of 5 minutes for up to 15 minutes.  We then 
immunoprecipitated endogenous Sam68 from either serum-starved or EGF-stimulated cells and 
assessed the tyrosine-phosphorylation status of Sam68 via immunoblotting with phosphotyrosine 
antibodies.  As expected, we found that EGF-stimulation led to increased tyrosine-phosphorylat ion 
of endogenous Sam68 which peaked at 10 minutes post-stimulation (Figure 4.18B).  Next, we 
stimulated control and SRMS-depleted MDA-MB 231 cells with EGF for 10 minutes and 
immunoprecipitated Sam68 to probe with phosphotyrosine antibodies.  We found that knocking 
down endogenous SRMS led to reduced EGF-stimulated tyrosine-phosphorylation of Sam68 
compared to scramble siRNA-transfected cells (Figure 4.18C).  Further, upon increased exposure 
of the immunoblot we observed a faint but noticeable amount of SRMS co-precipitating with 
Sam68 implying that both proteins are able to associate in these cells (Figure 4.18C).  Our results 
therefore show that SRMS regulates the phosphorylation of Sam68 in an EGF-dependent manner 
in MDA-MB 231 cells.  This further underscores the potential physiological significance of Sam68 
as a substrate of SRMS. 
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Figure 4.18: EGF-induced Sam68 phosphorylation mediated by SRMS. A. MDA-MB 231 
cells were transfected with either scramble siRNA or siRNA against SRMS.  Parental and siRNA-
transfected cells were lysed and Sam68 immunoprecipitated using Sam68 antibodies.  The 
immunoprecipitates were probed via Western blotting with antibodies against Sam68 and general 
phosphotyrosines.  Input from the corresponding lysates were probed with antibodies against 
SRMS and Sam68.  -actin served as a loading control.  B. Serum-starved MDA-MB 231 cells 
were either treated with 100 ng/mL EGF for the indicated duration or left untreated.  Sam68 was 
immunoprecipitated from the lysates derived from the untreated and treated cells.  The 
immunoprecipitates were probed with antibodies against Sam68 and phosphotyrosines.  Input from 
the corresponding lysates were probed with antibodies against Sam68 and -actin.  C. MDA-MB 
231 cells, transfected with either scramble siRNA or SRMS siRNA, were stimulated with 100 
ng/mL EGF for the indicated duration and lysed.  Sam68 was immunoprecipitated from the lysates 
and the immunoprecipitates probed with antibodies against Sam68, phosphotyrosine and SRMS.  
Input from the corresponding lysates were probed with antibodies against Sam68, SRMS and -
actin. 
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4.1.4 Discussion 
SRMS is a non-receptor tyrosine kinase of the BRK family kinases.  Unlike BRK and FRK, SRMS 
remains a largely understudied member of the family.  We previously characterized the enzymatic 
activity of SRMS and reported that wild type SRMS is enzymatically active and induces the 
tyrosine-phosphorylation of several proteins when exogenously expressed in mammalian cells 
(Goel et al., 2013).  Ours represents the first quantitative phosphoproteomics study to identify a 
vast pool of novel candidate SRMS substrates from mammalian cells ectopically expressing the 
wild type SRMS kinase.  Our unbiased analyses resulted in the identification of 1129 unique 
tyrosine-phosphorylated peptides in wild type SRMS-expressing cells.  These were mapped to 663 
unique proteins which were determined to be candidate SRMS substrates since the corresponding 
phosphopeptides were identified exclusively in cells expressing ectopic wild type SRMS.  
Importantly, we identified DOK1 as a hyperphosphorylated protein in SRMS-overexpressing cells.   
This confirmed our previous findings where we characterized DOK1 as a bona fide SRMS 
substrate and demonstrated that endogenous DOK1 was phosphorylated by ectopic SRMS in 
HEK293 cells.  Further, as expected, the peptide corresponding to SRMS Y380 was identified as 
one of the major phosphopeptides from our MS analyses (Table 4.1).  We also identified 14 novel 
tyrosine-phosphorylated sites in SRMS (Table 4.1) which may either represent SRMS 
autophosphorylation sites or target sites for other tyrosine kinases.  The biochemical and functional 
significance associated with these phosphosites may be worth investigating in future studies.   
Intriguingly, we found 117 tyrosine-phosphorylated peptides in control cells but not in cells 
expressing ectopic SRMS (Figure 4.3B).  Notably, of the 663 identified tyrosine-phosphorylated 
proteins in SRMS-expressing cells, 6 are tyrosine-phosphatases (PTPRA, PTPRE, PTPN6, 
PTPN11, PTPRK, PTPN18) (Supplementary Table 3).  It is possible that SRMS-mediated tyrosine 
phosphorylation may either directly or indirectly regulate the tyrosine-phosphatase activity of one 
or several of these phosphatases potentially leading to the de-phosphorylation of specific targets.  
This may at least partly explain why the 117 tyrosine-phosphorylated peptides were identified in 
the control cells but not the SRMS-expressing cells.  
It may be noted that similar earlier phosphoproteomics studies have identified candidate 
substrates from cells overexpressing specific kinases (Amanchy et al., 2008; Leroy et al., 2009; 
Wu et al., 2010; Xue et al., 2012).  However, it can be argued that such approaches offer limited 
insights into the physiological context of kinase-substrate interactions.  Native phosphorylation 
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events occurring at the cellular level, either in the presence or absence of relevant biological 
stimuli, are a more appropriate representation of physiological kinase activities.  To this end, 
alternative approaches involve the modulation of either the expression level or catalytic activity of 
native kinases to identify stoichiometric differences among phosphorylated proteins between the 
control and test conditions (Amanchy et al., 2009; Hsu et al., 2011; Poss et al., 2016; Xue et al., 
2012).  However, screening for physiological substrates of uncharacterized kinases can be 
particularly challenging.  In the case of SRMS, the expression of the kinase has been detected in 
various breast cancer cell lines (Goel et al., 2013; Potts et al., 2013).  Other groups have reported 
the expression of SRMS in various murine organs (Kawachi et al., 1997; Kohmura et al., 1994).  
However, the activation status of endogenous SRMS in these cells is not known.  The 
phosphorylation of the activation loop tyrosine is a primary indicator of enzymatic activation in 
tyrosine kinases (Hunter, 2009).  Unlike c-Src (Dong et al., 2016) and BRK (Jiang et al., 2017), 
no commercial antibodies exist to detect the phosphorylation of the SRMS activation-loop tyrosine 
residue (Y380). Additionally, whereas various specific chemical inhibitors of Src (Yeatman, 2004) 
and BRK (Jiang et al., 2017) have been characterized, to our knowledge, no such specific inhibitors 
of SRMS enzymatic activity have been reported.  Considering these technical shortcomings, we 
reasoned that the overexpression of the catalytically active wild type SRMS kinase in human cells 
may represent a reasonably viable alternative strategy to identify the cellular substrates of the 
kinase.  Additionally, we have previously reported that both endogenous and ectopic SRMS 
localizes to cytoplasmic punctate structures.  This implies that the localization and therefore the 
biochemical and cellular functions of ectopic SRMS may likely be similarly regulated.  This 
further highlights the potential biological significance of the candidate substrates that were 
identified in our study.   
 Other groups have reported the identification of high-confidence kinase substrates via 
similar phosphoproteomics approaches by correlating the identified phosphosites with known or 
well-characterized consensus substrate motifs of the kinase (Courcelles et al., 2013; Francavilla et 
al., 2017; Kettenbach et al., 2011).  Deng et al. identified xIYx and YxxV as two potential consensus 
substrate motifs of SRMS using an arrayed positional scanning peptide library (Deng et al., 2014).  
Our in silico analyses of the phosphosites derived from candidate SRMS substrates uncovered 
various overrepresented motif patterns (Figure 4.7 and 4.8).  Surprisingly, the xIYx and YxxV 
motifs were not among those identified in our analyses.  It is not clear whether the motifs we 
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identified in the present study were among the positional peptide variants tested by Deng et al.  
(Deng et al., 2014).  Further, though we identified KxY as one of the top candidate SRMS 
consensus motifs (Figure 4.7, 4.7 and 4.9), our validation analyses using peptide arrays revealed 
that the Vimentin Y383 peptide corresponding to the RxY motif displayed relatively increased 
phosphorylation compared to the other motifs (Table 4.2 and Figure 4.11).  It may be noted that 
various factors govern enzyme-substrate specificity in a cellular context.  The subcellular 
localization as well as the intermolecular interactions between the kinase and substrate proteins 
represent key factors that contribute to the enzyme-substrate specificity (Hunter, 2009).  
Additionally, when performed exclusively, in vitro studies involving peptide arrays may not 
accurately recapitulate physiologically relevant conditions favoring enzyme-substrate interactions.  
Moreover, the phosphorylation of a peptide is not entirely representative of the phosphorylation of 
the same sequence within a globular protein.  All this may partly explain why our motif analyses 
of the candidate cellular SRMS substrates did not identify the two motifs described previously 
(Deng et al., 2014).  We therefore reason that the identification of candidate kinase motifs from 
cell-based phosphoproteomics studies would likely provide rational opportunities for motif -
validation in in vitro studies, such as with peptide arrays.  
 Our analyses using peptide arrays revealed that the phosphorylation of a number of 
peptides could not be validated since these were rendered statistically insignificant.  Importantly, 
it has been noted that due to technical reasons data normalization measures tend to account for the 
loss of information from nearly 50% to 70% of peptides printed on such arrays (Scholma et al., 
2016).  Therefore, we normally use quasi-stringent t-testing (p-value < 0.1) in our analyses to limit 
the bias associated with stringent statistical thresholds (Kindrachuk et al., 2012; Napper et al., 
2015).  This method of applying a quasi-stringent t-testing threshold in peptide array analyses has 
also been described by Scholma et al. (Scholma et al., 2016).      
Using the g:Profiler platform (Reimand et al., 2016), we identified various biological 
processes/pathways enriched by the candidate SRMS substrates (Figure 4.10A and 4.10B).  RNA 
processing emerged as one of the major functional clusters associated with the candidate SRMS 
substrates (Figure 4.10A and 4.10B).  Additionally, some of the top candidate SRMS substrates 
included translation initiation factors such as EIF4G2, EIF2S3 and EIF4A3, implying a potential 
role of SRMS in protein translation.  Sam68 was one of the proteins annotated in both the RNA 
processing and regulation of protein translation clusters (Supplementary Table 5).  Sam68 is a KH 
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domain-containing RNA-binding protein (RBP) shown to regulate several processes including pre-
mRNA splicing, mRNA translation, nuclear export, RNA stability, signal transduction, and cell 
cycle progression (Lukong et al., 2005; Lukong and Richard, 2003).  Despite its predominantly 
nuclear localization, Sam68 is a major substrate of Src in the cytoplasm during mitosis (Taylor et 
al., 1995), and of BRK in the nucleus (Lukong et al., 2005).  Both the subcellular localization 
Sam68 and its RNA-binding functions are modulated by phosphorylation (Lukong et al., 2005; 
Lukong and Richard, 2003).  Other tyrosine kinases known to target Sam68 include Fyn, Lck, Tec, 
Jak3, BRK, Zap70, Btk or the insulin receptor (Di Fruscio et al., 1999; Lukong et al., 2005; 
Sanchez-Jimenez and Sanchez-Margalet, 2013).  We validated Sam68 as a bona fide SRMS 
substrate via co-immunoprecipitation analyses and direct in vitro analyses (Figure 4.13A, 4.13B 
and 4.14A).  We further demonstrated that Sam68 displays a partial cytoplasmic localization 
(Figure 4.17A and 4.17B) and that cytoplasmic Sam68 colocalizes with SRMS in vivo (Figure 
4.17C).  More importantly, we determined that SRMS plays an important role in the EGF-induced 
tyrosine-phosphorylation of Sam68 (Figure 4.18).  In a previous study it was shown that BRK 
expression is also needed for the efficient phosphorylation of Sam68 upon EGF-stimulat ion 
(Lukong et al., 2005).  Specifically, the study demonstrated that Sam68-Y440 was a major site 
targeted by BRK in vivo (Lukong et al., 2005).  Our MS analysis identified Sam68-Y167 as a 
hyperphosphorylated site in cells expressing ectopic SRMS implying that Sam68-Y167 may 
potentially be a major SRMS target site.  Taken together, since kinase functions are known to be 
tightly regulated in a temporal and spatial context (Bergeron et al., 2016; Cai et al., 2008), our 
results indicate that the biochemical and cellular functions of SRMS, with respect to Sam68, may 
be partly regulated under specific stimuli such as in response to EGF.   
Vimentin was identified as one of the top candidate SRMS substrates in our 
phosphoproteomics analyses.  We validated vimentin as a bona fide SRMS substrate via in vitro 
and in vivo assays and showed that both proteins colocalize in the cytoplasm (Figure 4.12A, 4.12B, 
4.14B and 4.16).  Vimentin is the most common intermediate filament (IF) and an essential 
component of the cytoskeleton (Jiu et al., 2017).  Vimentin is post-translationally modified by a 
variety of kinases on both Tyr (Chen et al., 2007) and Ser/Thr residues (Eriksson et al., 2004) 
leading to the structural re-arrangements of vimentin IF filaments (Hyder et al., 2008).  To our 
knowledge, the phosphosites we identified in vimentin in the present study have not been 
functionally characterized before and may warrant future studies.   
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A recent study by Potts et al. showed that knockdown of SRMS resulted in increased light 
chain 3 (LC3)-positive puncta per cell and decreased abundance of GFP-LC3 in an autophagy-
related 5 (ATG5)–dependent manner (Potts et al., 2013).  Overexpression of SRMS decreased the 
number of LC3-positive puncta per cell, suggesting that SRMS potentially inhibits autophagy 
upstream of autophagosome formation (Potts et al., 2013).  However, in our study, functional gene 
enrichment analyses of these candidate substrates did not identify any autophagy-linked cellular 
process or pathway.  Therefore, it is possible that the regulation of autophagy by SRMS, as 
reported by Potts et al., is not kinase-dependent or may likely be influenced in a tissue or cell line-
specific context.  It is possible that examining the SRMS-interacting partners may reveal proteins 
that are linked to autophagy.  
In the present study we used ectopic SRMS to identify the candidate SRMS cellular 
substrates.  A few or several of these substrates are likely to represent physiologically important 
substrates of SRMS.  This will certainly lead to a better understanding of the biochemical and 
functional specificity associated with SRMS in a physiological context.  In conclusion, our 
phosphoproteomics analyses helped uncover a vast array of novel candidate SRMS substrates 
which provides insights into the biochemical substrate motif specificities and the potentially 
diverse cellular roles played by the tyrosine kinase.  Given that SRMS is the least studied member 
of the BRK family kinases, our findings provide an important resource for future mechanistic 
studies to investigate the cellular and physiological functions of the kinase.  
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4.2 Identification of candidate signaling intermediates of SRMS 
      The results described in this section are part of a research manuscript that has been accepted 
for publication by the journal Proteome Science.  As part of the “Open access” policy 
(https://www.biomedcentral.com/about/policies/access-to-articles) implemented by the journal, 
the ownership of the copyright remains with the authors.  The authors reserve the right to use all 
or part of the published work for non-commercial purposes including theses/dissertations.  The 
manuscript and authorship details are:  
Raghuveera Kumar Goel, Mona Meyer, Marta Paczkowska, Jüri Reimand, Frederick 
Vizeacoumar, Franco Vizeacoumar, TuKiet T. Lam and Kiven Erique Lukong. Global 
phosphoproteomic analysis identifies SRMS-regulated signaling intermediates.   
NOTE: The Supplementary Tables referenced in this section (Supplementary Tables 9, 10 and 11) 
have been compressed in a single file and uploaded as an “Additional File” to the Usask Thesis 
and Dissertation submittal system.  Accessibility to this file is governed by the University of 
Saskatchewan.  The legends to Supplementary Tables 9, 10, and 11 are available in Appendix A.  
 
4.2.1 Summary 
The non-receptor tyrosine kinase, SRMS (Src-related kinase lacking C-terminal regulatory 
tyrosine and N-terminal myristoylation sites) is a member of the BRK family kinases (BFKs) 
which represents an evolutionarily conserved relative of the Src family kinases (SFKs).  Tyrosine 
kinases are known to regulate a number of cellular processes and pathways via phosphorylating 
substrate proteins directly and/or by partaking in signaling cross-talks leading to the indirect 
modulation of various signaling intermediates.  In the study described in the previous section, we 
profiled the tyrosine-phosphoproteome of SRMS and identified multiple candidate substrates of 
the kinase.  The broader cellular signaling intermediates of SRMS are unknown.  In order to 
uncover the broader SRMS-regulated phosphoproteome and identify the SRMS-regulated indirect 
signaling intermediates, we performed label-free global phosphoproteomics analysis on cells 
expressing wild-type SRMS.  Our analyses identified 60 hyperphosphorylated 
(phosphoserine/phosphothreonine) proteins mapped from 140 hyperphosphorylated peptides.  
Bioinformatics analyses identified a number of significantly enriched biological and cellular 
processes among which DNA repair pathways were found to be upregulated while apoptotic 
pathways were found to be downregulated.  Analyses of motifs derived from the upregulated  
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phosphosites identified Casein kinase 2 alpha (CK2) as one of the major potential kinases 
contributing to the SRMS-dependent indirect regulation of signaling intermediates.  Overall, our 
phosphoproteomics analyses identified serine/threonine phosphorylation dynamics as important 
secondary events of the SRMS-regulated phosphoproteome with implications in the regulation of 
cellular and biological processes.  
 
4.2.2 Introduction 
Kinase-substrate interactions are known to modulate the formation of secondary and tertiary 
protein complexes in cells (Kapoor et al., 2015; Krapivinsky et al., 2004; Wegener and 
Krappmann, 2008). Such protein complexes are implicated in the regulation of other kinases 
thereby potentiating a concerted mode of signaling, leading to the modulation of various cellular 
and biological functions (Besset et al., 2000; Ochoa et al., 2016).  Importantly, serine/threonine 
kinases constitute the majority of the mammalian kinome and evidence suggests that 
serine/threonine and tyrosine kinases are interconnected by several protein-protein interactions and 
cross-phosphorylation events, indicative of global signaling cross-talks (Bhavanasi et al., 2015; 
Colinge et al., 2014; Emkey and Kahn, 1997).  This inevitably suggests that a tyrosine kinase, for 
instance, may likely have an impact on the greater cellular phosphoproteome, extending beyond 
the direct phosphorylation of its substrates.  The identification of such secondary or effector 
phosphorylation events on signaling intermediaries is essential towards understanding the broader 
mechanisms of action of kinases. 
 Mass spectrometry has emerged as a powerful technique to identify and quantify proteins 
as well as associated post-translational modifications (PTMs) in almost any biological cell/tissue 
type (Larance and Lamond, 2015; Walther and Mann, 2010).  Label-free quantitation techniques 
offer a straightforward and cost-effective approach to reliably quantify peptide and proteins 
abundances in cells (Cox et al., 2014; Kauko et al., 2015; Neilson et al., 2011).  The technique has 
gained popularity in recent years and successfully applied to several phosphoproteomics studies 
(Bensimon et al., 2010; Dazert et al., 2016; Sharma et al., 2014; Steger et al., 2016).   
 Overall, in this study, using label-free quantitation we investigated the SRMS-regulated 
global phosphoproteome to identify potential secondary phosphorylation events involving 
phosphoserine and phosphothreonine sites.  We used the TiO2-based phosphopeptide enrichment 
strategy as a tool to preferentially identify serine/threonine phosphorylation events in cells 
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expressing wild-type SRMS.  Our analyses identified multiple significantly upregulated 
phosphosites in the SRMS phosphoproteome.  Using bioinformatics analyses, the upregulated 
proteins and phosphosites were mapped to various cellular and biological processes and cognate 
serine/threonine kinases, respectively.  Overall, our findings provide important insights on the 
cross-talks between SRMS and serine/threonine kinases in the orchestrated modulation of SRMS-
regulated cellular functions. 
 
4.2.3 Results 
4.2.3.1 Global analysis of the SRMS-regulated phosphoproteome 
Tyrosine kinases and serine/threonine kinases are known to exhibit dynamic cross-talks leading to 
a concerted mode of regulation of signaling networks (Bhavanasi et al., 2015; Colinge et al., 2014; 
Emkey and Kahn, 1997).  Evidence from large-scale database curation and high-throughput 
experimental observations indicate that such cross-talks are modulated through secondary and 
tertiary protein-protein interactions around primary kinase-substrate interaction and 
phosphorylation events (Colinge et al., 2014; Ochoa et al., 2016).  We therefore sought to study 
the SRMS-regulated serine/threonine phosphoproteome to infer cues on its contribution to the 
cellular signaling network potentially regulated SRMS.  To survey these global phosphoproteomic 
changes we performed metal-ion enrichment-based quantitative phosphoproteomics analysis on 
cells ectopically expressing wild-type SRMS.  Cells expressing the empty vector backbone served 
as control for all background phosphorylation events occurring natively in HEK293 cells.  We 
confirmed the expression of wild-type SRMS in the cells by immunoblotting the lysates with 
antibodies against GFP and SRMS (Figure 4.19).  As expected, immunoblotting with 
phosphotyrosine antibodies confirmed the enzymatic activation of wild-type SRMS in these cells 
(Figure 4.19).  The total proteins were then subjected to dual enzymatic digestion with Lys-C and 
trypsin followed by phosphopeptide enrichment using titanium dioxide (TiO2) resin prior to LC-
MS/MS analyses (Figure 4.20). The experiment was performed in three independent replicates to 
allow assessment of the statistical reproducibility of our analysis.  Collectively, we identified 995 
unique phosphosites from 1459 redundant phosphopeptides which mapped to 439 unique 
phosphoproteins, at an estimated False Discovery Rate (FDR) of 1% (Figure 4.21A, 
Supplementary Table 9).  We found significant reproducibility between the replicate datasets, as 
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reflected by a Pearson’s correlation coefficient in the range of 0.84 to 0.96 (Figure 4.21B).  We 
quantified the number of phosphoserine, phosphothreonine and phosphotyrosine sites to assess the  
 
                                                             
 
Figure 4.19: Phosphoproteomics analyses of cells expressing ectopic wild-type SRMS.  Vector 
encoding either GFP alone or GFP-SRMS wild type was exogenously introduced in HEK293 cells.  
Prior to phosphopeptide enrichment, immunoblotting analyses was performed on a portion of total 
cell lysates derived from the transfected cells.  The lysates were probed with antibodies against 
GFP, total phosphotyrosines and SRMS.  Immunoblotting with antibodies against -actin was used 
to assess the loading of total proteins. 
 
distribution of the identified phosphoproteome.  Consistent with previous studies employing metal 
ion-based phosphopeptide enrichment techniques (Gnad et al., 2016; Kuzmanov et al., 2016; 
Possemato et al., 2017), we observed that the majority of the identified phosphosites were 
represented by phosphoserine (85.2%) followed by phosphothreonine sites (13.3%) (Figure 
4.21C).  Phosphotyrosine sites represented a minor fraction (0.76%) of the identified 
phosphoproteome (Figure 4.21C).  This was an expected observation since previous studies have 
reported a similar phosphotyrosine enrichment profile using metal ion enrichment chromatography 
despite significant induction of cellular tyrosine phosphorylation, for instance, via pervanadate 
treatment (Di Palma et al., 2013; Possemato et al., 2017).  Additionally, singly phosphorylated 
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peptides were more strongly represented than doubly or triply phosphorylated peptides in our 
dataset, consistent with previous reports (Courcelles et al., 2013; Gnad et al., 2016; Pan et al., 
2008) (Figure 4.21D). 
 To gain a better understanding of the SRMS-regulated phosphoproteome, we first applied 
a p-value threshold of ≤ 0.05 to focus on phosphopeptides that displayed statistically significant 
differential regulation (up or downregulation) compared to control cells (Supplementary Table 9).   
 
 
               
Figure 4.20: Phosphoproteomics workflow.  Schematic representation of the label-free 
quantitation-based phosphoproteomics workflow using cells expressing GFP alone (the empty 
vector control) or cells expressing GFP-SRMS wild type.  The cells were lysed, and total proteins 
subjected to dual enzymatic digestion (Trypsin/Lys-C).  The crude tryptic peptides were used 
towards phosphopeptide enrichment using TiO2 resin.  Both enriched and flowthrough fractions 
were analysed by LC-MS/MS and data analyses performed using the Mascot search engine (for 
protein identification) and Progenesis QI tool (for phosphopeptide quantitation). 
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We then determined significantly regulated phosphopeptides in the wild-type SRMS 
phosphoproteome based on the differential abundance of the corresponding average precursor ion 
intensities in the control cells.  To ensure stringent analyses, phosphopeptides quantified at average 
pre-cursor ion intensities ≥ 3-fold [Log2 (SRMS/control) ≥ 1.584] compared to corresponding  
 
                   
 
FIGURE 4.21: Overview of the identified phosphoproteome.  A. The coverage of the 
phosphoproteome showing the total number of identified phosphopeptides, unique phosphosites 
and unique proteins mapping from the phosphopeptides.  B. Pearson’s correlation analyses of the 
3 replicate datasets corresponding to the vector control and wild type SRMS phosphoproteome.  
The Pearson’s correlation coefficients and associated distribution curve histograms between 
Replicate 1, 2 and 3 for both experimental conditions are reflected in a matrix format.  C. Pie-chart 
representation of the multiplicity of phosphorylation of the identified phosphopeptides indicating 
the percentage of phosphopeptides carrying either a single phosphosite, double phosphosites or 
triple phosphosites.  D. Pie-chart depiction of the proportion of phosphoserine, phosphothreonine 
and phosphotyrosine sites in the identified phosphoproteome.  
98 
 
average intensities in control cells were considered hyperphosphorylated or upregulated (Figure 
4.22A and Supplementary Table 9).  Similarly, phosphopeptides with average intensities ≤ 0.5-
fold [Log2 (SRMS/control) ≤ -1; conversely equal to 2-fold upregulation in control cells] were 
considered hypophosphorylated or downregulated (Figure 4.22A and Supplementary Table 9).  
Using these criteria, we identified 140 upregulated and 1 downregulated (NUCKS S19) 
phosphopeptides in the wild-type SRMS-regulated phosphoproteome (Figure 4.22 and 
Supplementary Table 9).  Some of the significantly upregulated phosphosites included NUCL 
S206, NUCL S184, MYH9 S1943, HS90A S263 and MARCS S147.  Overall, these 
phosphopeptides mapped to 60 upregulated and 1 downregulated proteins, respectively (Table 4.3 
and Supplementary Table 9).  We used the 0.5-fold cut-off for downregulation since our dataset 
comprised only 37 phosphopeptides below the median 1-fold differential abundance (p-value ≤ 
0.05) and most of these peptides displayed only marginal downregulation in phosphorylation  
 
                          
 
FIGURE 4.22: Identification of SRMS-regulated phosphosites.  A scatter plot showing the the 
phosphopeptide log2 fold-change (SRMS/control) plotted against the -Log10 p-value, highlight ing 
the significantly regulated phosphopeptides (ANOVA p-value ≤ 0.05; upregulation fold-change 
cut-off = Log2 ≥ 1.58 and downregulation fold-change cut-off = Log2 ≤ -1).  Upregulated 
phosphopeptides are highlighted in orange while the downregulated phosphopeptide is highlighted 
in blue.  Selected upregulated phosphoproteins and corresponding phosphosites, namely HMGA1-
S103, MARCS-S147, HMGN1-S89, ENSA-S2, HS90A-S263, MYH9-S1943 and NUCL-S206, 
are annotated in the scatter plot.  
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(SRMS/Control ~ 0.7-fold).  Additionally, we reasoned that phosphopeptides that are at least two-
fold more abundant in control than in the SRMS-regulated phosphoproteome would be likely to 
represent genuine SRMS-regulated hypophosphorylation events. 
 
Table 4.3: List of SRMS-dependent upregulated phosphoproteins . Shown here is a subset of 
the top hyperphosphorylated/upregulated proteins and corresponding phosphosites, as identified 
in the wild-type SRMS phosphoproteome.  Refer to Supplementary Table 1, using the weblink 
provided in the Bibliography section, to access the complete dataset comprising details on all 
regulated phosphosites and phosphoproteins.  
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4.2.3.2 Functional annotation of the SRMS-regulated phosphoproteome 
To better understand the cellular and biological processes mapped from the SRMS-regulated 
phosphoproteins, we performed functional gene enrichment analyses using the Ingenuity Pathway 
analyses (IPA) tool.  We increased the stringency of our analyses by restricting functional 
annotations inferred exclusively from experimental observations.  This led us to identify 30 
molecular and cellular processes (Benjamini-Hochberg multiple testing p-value < 0.05) mapped 
from the majority of the hyperphosphorylated proteins (48/60 proteins or 80%) identified in the 
SRMS phosphoproteome (Figure 4.23A and Supplementary Table 10).  These cellular processes 
broadly represented key functional categories that included protein synthesis (p-value range 1.11E-
07 to 9.87E-03), cell cycle (p-value range 8.49E-03 to 1.03E-02), RNA post-transcriptiona l 
modification (p-value range 3.49E-08 to 1.95E-04), cell death and survival (p-value range 6.30E-
06 to 2.76E-02), cell growth and proliferation (p-value range 1.35E-04 to 1.29E-02) and DNA 
replication and repair (p-value 7.05E-08 and 1.02E-04).  Importantly, our analyses also led us to 
determine the predicted activation states of four molecular and cellular processes at a significant 
activation z-score threshold of ± 2.  Specifically, cellular processes related to viral infection (20 
proteins, z-score = 3.8, p-value = 5.45E-06) and DNA repair (10 proteins, z-score = 2.18, p-value 
= 7.05E-08) were predicted with a significantly increased activation state while apoptosis (17 
proteins, z-score = -2.11, p-value = 3.94E-03) and necrosis (15 proteins, z-score = -2.48, p-value 
= 2.76E-02) were predicted to display an overall decreased activation state (Figure 4.23A and 
Supplementary Table 10).  Some of the other interesting cellular/biological themes enriched from 
the hyperphosphorylated proteins included cell movement (p-value = 1.35E-04) and catabolism of 
protein (p-value = 9.87E-03) (Figure 4.23A and Supplementary Table 10).  Analyses of the 
upstream regulators identified 5 proteins, namely, PI3K (Phosphoinositol-3-kinase), CDK9 
(Cyclin-dependent kinase 9), CK2 (Casein kinase 2), CK2 (Casein kinase 2 catalytic subunit 
alpha) and FN1 (Fibronectin) (Figure 4.23B and Supplementary Table 10).  Importantly, among 
these, two kinases were associated with significantly increased predicted activation- the tetrameric 
kinase complex, CK2 (z-score = 3.54, p-value = 7.41E-05), its monomeric catalytic subunit, CK2 
(z-score = 4.87, p-value = 9.32E-19), and CDK9 (z-score = 2.81, p-value = 7.33E-05) ) (Figure 
4.23B and Supplementary Table 10).  Further, our analyses also revealed that a small number of 
the hyperphosphorylated proteins were enriched in specific signaling pathways which included 
Telomerase signaling (-Log p-value = 2.33), PI3K/AKT signaling (-Log p-value = 2.18), Sirtuin 
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signaling (-Log p-value = 1.93) and Phospholipase C signaling (-Log p-value = 1.44) 
(Supplementary Table 10).  
 
4.2.3.3 Analyses of phosphorylation motifs and predicted kinases  
The amino acids surrounding a phosphosite constitute important recognition motifs for cognate 
kinases (Amanchy et al., 2007; Turk, 2008; Ubersax and Ferrell, 2007).  Our phosphoproteomics 
 
                   
 
FIGURE 4.23: Functional enrichment analyses of the significantly altered phosphoproteins.  
A. IPA analyses of the top cellular and molecular processes enriched from upregulated 
phosphoproteins identified in the SRMS-regulated phosphoproteome (n=60; corresponding to 
upregulated phosphopeptides; SRMS/Control Log2 ≥ 1.58-fold).  z-score indicates the predicted 
upregulation (z-score > 1) or downregulation (z-score < 0) of specific cellular and molecular 
processes.  B. IPA analyses of upstream regulators for the upregulated phosphoproteins (n=60).  z-
score indicates the predicted activation (z-score > 1) or inactivation (z-score < 0) of the indicated 
upstream proteins.  An asterisk (“*”) mark indicates cellular processes with significant z-scores 
(z-score ≥ 2 or ≤ -2)  
 
* 
* 
* 
* 
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analysis identified 140 upregulated phosphopeptides that mapped to 60 proteins in the SRMS-
regulated phosphoproteome.  We assessed the enrichment of motifs among these upregulated 
phosphopeptides using the Motif-x and PHOSIDA (Phosphorylation Site Database) motif-
enrichment tools (Chou and Schwartz, 2011; Gnad et al., 2007).  Our analyses using both the tools 
resulted in the enrichment of similar motifs (p-value = 10E-06) which primarily corresponded to 
phosphoserine sites (Figure 4.24A, 4.24B and 4.24C).  No significant phosphothreonine or 
phosphotyrosine motifs were found due to their lower abundances in our dataset.  Collectively, we 
identified four major motifs, all comprising positional variations in amino acids following the 
central phosphoserine residue.  One significantly overrepresented motif comprised a glutamic acid 
and aspartic acid residue in the +3 and +5 positions (SxxExD) (Figure 4.24A, 4.24B and 4.24C).   
 
     
 
FIGURE 4.24: Motif-enrichment analyses of SRMS-dependent upregulated 
phosphopeptides.  A. Motif-logos showing the significantly enriched motifs (p-value < 10E-06) 
identified by Motif-x (Chou and Schwartz, 2011). The positions of the amino acid residues C-
terminal or N-terminal to the central phosphoresidue (position “0”) are shown in the logos.  The 
height of the amino acid residues is proportional to their enrichment at the specific position in the 
pool of the queried phosphopeptides.  B. Table representing the scoring information relevant to 
the enriched motifs identified by Motif-x.  C. A consolidated motif-logo generated by PHOSIDA 
(Gnad et al., 2007) showing the enrichment of various amino-acid residues at specific positions 
relative to the central phosphoresidue (position “0”). 
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Other top motifs comprised either a glutamic acid and a serine residue at the +2 and +3 positions 
(SxES), a serine at +2 position (SxS) or a glutamic acid residue at +3 position (SxxE) (Figure 4.24A, 
4.24B and 4.24C). 
 We further analyzed the upregulated phosphopeptides using the NetworKIN tool (Linding 
et al., 2007) to identify candidate kinases responsible for the site-specific phosphorylation of the 
associated motifs.  The NetworKIN algorithm exploits information based on consensus motif 
recognition as well as context-specific factors such as the physical association and co-expression 
of kinases and substrates, to predict corresponding kinase-substrate relationships (Linding et al., 
2007; Van Hoof et al., 2009).  NetworKIN analyses of the hyperphosphorylated motifs identified 
25 candidate serine/threonine kinases, corresponding to 16 kinase subfamilies, at a NetworKIN 
score > 3 (Figure 4.25 and Supplementary Table 11).  Kinases found to potentially target multiple 
phosphosites included CDK1 (5 phosphosites, NetworKIN score range: 9.62-17.93), CK2 (19 
phosphosites, score range: 3.17-35.63), GSK3  (5 phosphosites, score range: 4.75-10.43), CK2 
2 (3 phosphosites, score range: 8.47-9.61), GRK2 (3 phosphosites, score range: 4.30-9.76) and 
CDK5 (2 phosphosites, score range: 3.42-14.02) (Figure 4.25 and Supplementary Table 11).  
Importantly, Casein Kinase 2  (CK2) was the among the highest scoring candidate kinases and 
found to target the maximum number of phosphosites in our dataset (Figure 4.25 and 
Supplementary Table 11).  CK2 is a functionally independent catalytic subunit of the tetrameric 
holoenzyme, CK2 (Zhou et al., 2016).  The consensus recognition motifs for the acidophilic 
kinase, CK2 are characterized by the presence of either glutamic acid or aspartic acid residues 
near the phosphorylation site (St-Denis et al., 2015; Van Hoof et al., 2009).  Indeed, the motifs we 
identified by motif enrichment analyses (SxxExD, SxE and SxxE) conform to the CK2 consensus 
recognition sequences, thereby confirming CK2 as a major upstream kinase of the upregulated 
phosphosites.  This also corroborated findings from our functional gene enrichment analyses using 
IPA where the holoenzyme CK2 and its catalytic module, CK2 were identified as major upstream 
regulatory kinases of the upregulated phosphoproteins (Figure 4.23B).  Taken together, our 
findings suggest that CK2 represents a key serine/threonine kinase that is potentially activated in 
the SRMS phosphoproteome.  This further indicates that CK2 and/or CK2 may likely represent 
key downstream targets of SRMS. 
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FIGURE 4.25: Identification of candidate kinases predicted to target the upregulated 
phosphosites in the SRMS-regulated phosphosites.  Dendogram of the human kinome, 
constructed using KinMap (Eid et al., 2017), highlighting the candidate kinases predicted to target 
the upregulated phosphosites identified in the SRMS-regulated phosphoproteome.  Candidate 
kinases were identified by NetworKIN (Linding et al., 2007) analysis.  Node size is proportional 
to the number of the phosphosites targeted by the kinase.  CK2 (node highlighted in yellow) 
represents the largest node in the kinome dendogram.  All major kinase families are annotated in 
the dendogram which include: TK (Tyrosine Kinases), TKL (Tyrosine Kinase-Like), STE (Sterile 
kinases; homologs of the yeast STE7, STE11 and STE20 kinases), CK1 (Casein Kinase 1), AGC 
(comprising Protein kinase A/ PKA, PKG and PKC kinase sub-families), CAMK 
(Calcium/Calmodulin-dependent kinases) and CMGC (comprising cyclin-dependent kinase 
(CDK), mitogen-activated protein kinase (MAPK), glycogen synthase kinase (GSK) and CDC-
like kinase (CLK)). 
 
 
4.2.4 Discussion 
Here we used quantitative mass spectrometry analyses to identify cognate serine/threonine 
phosphorylation events significantly altered in the SRMS-regulated phosphoproteome.  We 
identified 60 phosphoproteins mapped from 140 phosphopeptides which were upregulated by at 
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least 3-fold in the SRMS-regulated phosphoproteome.  To our knowledge, this represents the first 
study to investigate global serine and threonine phosphorylation changes induced by a bonafide 
non-receptor tyrosine kinase in the eukaryotic phosphoproteome.     
 Despite the ectopic expression of SRMS in cells, we identified only 1.3% phosphotyrosine 
peptides in contrast to our previous study where we reported multiple phosphotyrosine peptides 
(Goel et al., 2018) (Figure 4.21C).  The lysis of cells under less stringent conditions, such as by 
RIPA lysis buffer used in this study, and the use of TiO2 resin, known to less favourably bind to 
phosphotyrosines, are factors that may explain the lower enrichment of tyrosine-phosphorylated 
peptides.  The former may be an equally important factor since tyrosine phosphorylation is far 
more stringently regulated by phosphatase activity than serine/threonine phosphorylation (Sharma  
et al., 2014) and as such the use of denaturing conditions during cell lysis have proved useful in 
such studies (Sharma et al., 2014; Yoshida et al., 2015; Zhang et al., 2017).  The relatively lower 
selectivity of TiO2 resin towards phosphotyrosine peptides can also be demonstrated by the fact 
that we identified only 2 major phosphorylation sites on SRMS- Y299 and Y456, in this study.  
Our previous phosphotyrosine enrichment-based approach enabled the identification of several 
other phosphotyrosine sites on wild-type SRMS (Goel et al., 2018).  However, since the focus of 
this study was to identify phosphoserine and phosphothreonine events, the relatively poor 
enrichment of phosphotyrosine peptides did not pose a concern.  
 The cellular roles of SRMS have not been well characterized to date. In the present study, 
functional enrichment analyses of the upregulated phosphoproteins in the SRMS-regulated 
phosphoproteome identified apoptosis and necrosis as potentially important downregulated 
cellular processes in cells expressing ectopic SRMS.  A previous study by Potts et al. implicated 
SRMS in the potential negative regulation of autophagy (Potts et al., 2013), implying that SRMS 
may potentially be a positive regulator of stress-induced cell survival.  This is in line with our 
present findings which not only projected a downregulation of apoptotic processes but also a 
potential upregulation of cell survival and proliferative processes in cells expressing ectopic 
SRMS, as determined by a positive z-score from IPA analyses (Figure 4.23A and Supplementary 
Table 10).  Interestingly, processes related to DNA repair were also predicted to be upregulated 
(Figure 4.23A and Supplementary Table 10).  As an example, HMGA1 was among the upregulated 
proteins enriched in DNA repair processes (Supplementary Table 10).  We identified HMGA1 
S102 as a hyperphosphorylated site in cells expressing ectopic SRMS (Supplementary Table 9).  
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HMGA1 S102 is a target site for phosphorylation by CK2 and studies have shown that the 
hyperphosphorylation of HMGA1 S102 impairs the DNA-binding ability of the protein (Domizio 
et al., 1990; Palvimo and Linnala-Kankkunen, 1989; Schwanbeck et al., 2001; Wang et al., 2017).  
The dissociation of HMGA1 from the DNA in turn promotes efficient DNA repair, presumably by 
allowing various DNA repair factors to be recruited to the sites of DNA lesions, as reported 
previously (Adair et al., 2005; Maloney et al., 2007).  Taken together, our data points towards a 
potential role of SRMS in modulating cellular DNA repair processes by regulating HMGA1 S102 
phosphorylation.  Further, HMGA1 has also been shown to inhibit apoptosis by suppressing p53-
mediated transcriptional repression of apoptosis-related genes like Mdm2, Bax and p21 (Esposito 
et al., 2010).  This therefore also explains the cross-talk involving HMGA1 between cellular 
processes lined to DNA repair, apoptosis and cell proliferation in our dataset (Supplementary 
Table 10).  
 Analyses of the phosphosites using NetworKIN identified CK2 as one of the major 
candidate upstream kinases for the upregulated phosphosites identified in the SRMS-regulated 
phosphoproteome (Figure 4.25, Supplementary Table 11).  This raises the possibility that SRMS 
may potentially function upstream of CK2 and as a candidate regulator of CK2 activity. CK2 is an 
active tetrameric serine/threonine kinase composed of two catalytic subunits ( and ’) and two 
regulatory -subunits (Lee et al., 2013).  Activation of CK2 is primarily regulated in vivo by 
inositol phosphates, phospholipase D2 (PLD2) and protein kinase C (PKC) (Korolchuk et al., 
2005; Lee et al., 2013; Solyakov et al., 2004).  However, previous studies have identified c-Abl, 
BCR-Abl and Src-family kinases, Lyn and c-Fgr as regulators of CK2 activity (Donella-Deana et 
al., 2003; Heriche and Chambaz, 1998).  Specifically, the catalytic subunit of CK2, CK2, was 
identified as a substrate of these kinases where phosphorylation by c-Abl or BCR-Abl was shown 
to inhibit CK2 activity while phosphorylation by Lyn or c-Fgr was shown to increase CK2 
activity (Donella-Deana et al., 2003; Heriche and Chambaz, 1998).  Interestingly, our previous 
phosphotyrosine enrichment-based phosphoproteomics analysis found CK2 to be significant ly 
tyrosine-phosphorylated exclusively in cells expressing ectopic wild type SRMS, projecting CK2 
as a candidate SRMS substrate (Supplementary Table 11) (Goel et al., 2018).  Specifically, CK2 
Y182, Y188 and Y323 were identified as hyperphosphorylated sites (Supplementary Table 11).  
Of these, Y182 represents a key residue lying in the activation loop of the CK2 subunit and the 
trans-autophosphorylation of this site has been shown to increase CK2 activity (Donella-Deana  
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et al., 2001).  Additionally, CK2 Y188 has also been reported as another activation loop 
phosphosite contributing to CK2 activation, albeit to a lesser extent than CK2 Y182 (Donella-
Deana et al., 2001; Sarno et al., 2002).  However, findings from our previous phosphoproteomics 
study revealed that CK2 Y182/Y188 are candidate target sites of SRMS which imply that CK2 
enzymatic activity may potentially be modulated by SRMS.  This may highlight SRMS as a 
possible modulator of CK2 kinase-dependent functions.  
 CDK1/cdc2 is another upstream candidate kinase identified by NetworKIN analysis which 
was also identified as an upstream regulator by IPA analyses. Kinases Wee1, Myt1 and Lyn are 
known to regulate the activity of CDK1 by phosphorylating the inhibitory Y15 site on CDK1 
(Fattaey and Booher, 1997; Uckun et al., 1996; Watanabe et al., 1995).  Our previous 
phosphoproteomics study also identified CDK1 as a candidate target of SRMS where CDK1 Y19, 
Y270 and Y286 were found to be hyperphosphorylated (Supplementary Table 11) (Goel et al., 
2018).  However, these sites on CDK1 have not been functionally characterized.  Therefore, the 
mechanism by which CDK1 may be activated in the presence of SRMS, leading to the 
phosphorylation of the CDK1 consensus phosphosites, is not known. 
 It is important to note that the overall cellular and molecular processes mapped from the 
SRMS-regulated signaling intermediates identified in the present study were consistent with the 
major functional themes mapped from the candidate SRMS substrates in our previous study (Goel 
et al., 2018).  Some of the major functional themes enriched by the candidate SRMS substrates 
included RNA processing, viral processes, negative regulation of apoptosis, cell cycle regulation 
and protein ubiquitination (Figure 4.10 and Supplementary Table 5) (Goel et al., 2018).  These 
correlate well with the broad functional categories identified in the present study such as RNA 
post-transcriptional modifications (processing of RNA), viral infection, cell death and survival 
(apoptosis), cell cycle, and protein degradation, respectively (Supplementary Table 10).  
Collectively, our findings here indicate that some of the major cellular processes regulated by 
SRMS involve additional signaling factors characterized by serine/threonine phosphorylation 
events.  Our study therefore presents key evidence that serine/threonine phosphorylation likely 
forms part of important secondary signaling events triggered by SRMS.  
 Overall, our global phosphoproteomic profiling reveals that the non-receptor tyrosine 
kinase, SRMS can indirectly regulate multiple signaling intermediates which are characterized by 
an altered serine/threonine phosphorylation status.  The regulation of serine/threonine 
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phosphorylation events in the presence of SRMS is likely a result of SRMS-dependent direct or 
indirect modulation of serine/threonine kinase activity.  In this context, the serine/threonine kinase, 
Casein kinase 2 (CK2) may likely represent one of the major downstream targets of SRMS.  
Overall, findings from our study form an important mechanistic resource for characterizing the 
cellular role(s) of SRMS in mammalian cells.  
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4.3 Characterizing the SRMS cytoplasmic punctae 
4.3.1 Summary  
Previous studies from our laboratory revealed that endogenous as well as ectopic SRMS protein 
localize predominantly to the cytoplasm and in distinct cytoplasmic punctate structures in various 
immortalized human cell lines (Goel et al., 2013).  The reasons underlying the characteristic 
punctate localization pattern of SRMS are unknown.  SRMS possesses functional protein-protein 
binding SH3 and SH2 domains known to associate with its cellular substrates (Goel et al., 2013).  
Therefore, it is possible that SRMS is localizes to specific cytoplasmic sites by interacting with 
and/or phosphorylating specific cellular proteins.  These cellular proteins may be constituents of 
specific cytoplasmic organelles, implying that SRMS may be sequestered to and therefore 
colocalize with certain cytoplasmic organelles.  To address this, colocalization of ectopic SRMS 
with known markers of specific cellular organelles, such as the endoplasmic reticulum, 
mitochondria, lysosomes, and golgi bodies, was examined.  Further, whether the SRMS SH3, SH2 
and/or kinase domains play any role in the formation of the cytoplasmic puncta was also 
investigated by fluorescence microscopy analyses.  Overall, the data obtained showed that SRMS 
did not display significant colocalization with any of the organelles examined.  However, the 
SRMS SH2 domain was found to partly contribute to the formation of the SRMS cytoplasmic 
puncta.   
 
4.3.2 Results  
4.3.2.1 Colocalization analyses of SRMS with cellular cytoplasmic organelles    
To determine whether the SRMS cytoplasmic punctae results from the colocalization of the protein 
with specific cytoplasmic organelles, we performed immunofluorescence analyses using confocal 
microscopy.  We selected well-characterized markers of four cytoplasmic organelles, namely the 
endoplasmic reticulum (ER), mitochondria, lysosomes and golgi bodies.  GFP-tagged wild type 
SRMS or GFP alone were ectopically introduced in HEK293 cells via transient transfection.  24 
hours-post transfection the cells were prepared for immunofluorescence analyses using the 
appropriate primary and secondary antibodies.   
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4.3.2.1.1 Colocalization analysis with endoplasmic reticulum (ER) 
Primary antibodies against calnexin were used to label endoplasmic reticuli in HEK293 cells. 
Calnexin is an endoplasmic reticulum-based transmembrane chaperone protein that regulates the 
folding of glycoproteins within the ER (Ellgaard and Helenius, 2003). Firstly, in our 
immunofluorescence analyses the cytoplasmic pattern of localization of Calnexin observed was 
consistent with that reported by others as well as immunofluorescence data provided by various 
manufacturers’ on their antibody product website (Fernandez-Valdivia et al., 2006) (Figure 4.26).  
This therefore helped confirm the immunoreactive specificity of the antibody used.  Further, the 
pattern of localization of ER was reproducibly observed with each experimental replicate we  
 
                      
 
Figure 4.26: Colocalization analyses of Calnexin (endoplasmic reticulum) and wild type 
SRMS.  HEK293 cells were seeded in glass coverslips in 6-well tissue culture dishes and 
transfected with vectors encoding: A. GFP alone (top panel) and B. GFP-SRMS. 24 hours post-
transfection the cells were fixed and processed for immunofluorescence analyses.  Primary 
antibodies against Calnexin (mouse IgG) and secondary goat anti-mouse IgG-Texas red (594 nm) 
antibodies were used to label ER. DAPI was used to counter-stain the nucleus.  The cells were 
imaged at 40x magnification by confocal microscopy.  Scale bar = 20 nm. 
 
B 
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performed.  As expected, GFP-SRMS localized to characteristic cytoplasmic punctae (Figure 
4.26). However, no obvious or significant colocalization was observed between the ER and 
ectopically expressed GFP-SRMS (Figure 4.26). 
 
4.3.2.1.2 Colocalization analysis with mitochondria 
 Colocalization analysis was performed between GFP-SRMS and mitochondria using antibodies 
against the mitochondrial marker mitofilin. Mitofilin is a transmembrane protein of the inner 
mitochondrial membrane and controls the mitochondrial cristae morphology and integrity (Ding 
et al., 2015; von der Malsburg et al., 2011). A characteristic and reproducible cytoplasmic 
localization of the mitochondria was observed which was consistent with the manufacturer’s 
immunofluorescence data (Figure 4.27). No obvious or significant colocalization was observed  
                                             
 
                                                                                                                                                 
Figure 4.27: Colocalization analyses of Mitofilin (mitochondria) and wild type SRMS.  
HEK293 cells were seeded in glass coverslips in 6-well tissue culture dishes and transfected with 
vectors encoding: A. GFP alone (top panel) and B. GFP-SRMS.  24 hours post-transfection the 
cells were fixed and processed for immunofluorescence analyses.  Primary antibodies against 
Mitofilin (rabbit IgG) and secondary goat anti-rabbit IgG-Texas red (594 nm) antibodies were used 
to label the mitochondria.  DAPI was used to counter-stain the nucleus.  The cells were imaged at 
40x magnification by confocal microscopy.  Scale bar = 20 nm. 
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between mitofilin and GFP-SRMS (Figure 4.27).  
 
4.3.2.1.3 Colocalization analysis with golgi bodies  
Colocalization analysis was performed between GFP-SRMS and golgi bodies using antibodies 
against golgin p97, a marker of golgi bodies. Golgin p97, also referred to as GOLGA A1, is a 
protein that is targeted to the trans-golgi network (TGN) of the golgi bodies and is involved in 
regulating the localization of other TGN-resident proteins (Luke et al., 2005).  From our 
immunofluorescence analyses, we observed a pattern of cytoplasmic localization of golgin p97 
that was consistent with previous studies as well as with immunofluorescence data available with 
various manufacturers (Alzhanova and Hruby, 2006) (Figure 4.28).  Our analyses did not reveal  
 
                   
 
Figure 4.28: Colocalization analyses of Golgin p97 (golgi bodies) and wild type SRMS.  
HEK293 cells were seeded in glass coverslips in 6-well tissue culture dishes and transfected with 
vectors encoding: A. GFP alone (top panel) and B. GFP-SRMS.  24 hours post-transfection the 
cells were fixed and processed for immunofluorescence analyses.  Primary antibodies against 
Golgin p97 (mouse IgG) and secondary goat anti-mouse IgG-Texas red (594 nm) antibodies were 
used to label the Golgi bodies.  DAPI was used to counter-stain the nucleus.  The cells were imaged 
at 40x magnification by confocal microscopy.  Scale bar = 20 nm. 
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significant colocalization of GFP-SRMS with golgin p97 indicating that SRMS does not colocalize 
with golgi bodies (Figure 4.28). 
 
4.3.2.1.4 Colocalization with lysosomes 
 SRMS colocalization with lysosomal bodies was tested using a commercially available 
LysoTrackerTM stain that specifically and reversibly stains the cellular lysosomes of live cells.  
Weakly basic amines are known to accumulate in low-pH vesicles such as lysosomes.  The 
LysoTrackerTM stain essentially comprises weakly basic fluorescent amines that selectively 
permeate the membranes of live cells and accumulate in the lysosomes.  The LysoTrackerTM probe 
was used to stain lysosomes of live HEK293 cells expressing either GFP alone or GFP-SRMS 
(Figure 4.29).  We observed a punctae-like localization of the lysosomes which was consistent  
 
                           
                      
Figure 4.29: Colocalization analyses of lysosomes and wild type SRMS.  HEK293 cells were 
seeded on glass coverslips in 6-well tissue culture dishes and transfected with vectors encoding: 
A. GFP alone (top panel) and B. GFP-SRMS.  24 hours post-transfection 75 nM LysoTrackerTM 
stain was added directly to the culture media and the cells cultured for 2 hours.  The cells were 
then fixed, mounted on glass slides and imaged by confocal microscopy at 40x magnification.  
Scale bar = 20 nm. 
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with the manufacturer’s fluorescence microscopy data as well as other published studies (Figure 
4.29) (Fossale et al., 2004; Hashiguchi et al., 2002).  However, no significant colocalization was 
observed between GFP-SRMS and the LysoTrackerTM-stained lysosomal bodies (Figure 4.29).   
 Overall, our immunofluorescence analyses revealed that the SRMS cytoplasmic punctae 
did not display significant colocalization with either the mitochondria, endoplasmic reticulum, 
golgi bodies or lysosomes.  This implied that other factors may be involved in establishment of 
the characteristic SRMS cytoplasmic punctae.   
 
4.3.2.2 Role of SRMS functional domains in the formation of SRMS  
Since we were unable to clearly establish the role of specific subcellular organelles in sequestering 
SRMS to cytoplasmic punctae, we asked whether the SRMS functional domains play a role in 
sequestering the kinase to these punctae, possibly via intermolecular interactions with other 
cellular proteins.  We assessed the involvement of the three functional domains in SRMS, namely 
the SH3 (Src-homology 3), SH2 (Src-homology 2) and the kinase domain in promoting the 
formation of the characteristic cytoplasmic puncta displayed by the full-length protein.  cDNA 
sequences corresponding to either the SRMS SH3, SRMS SH2 or the SRMS kinase domain were 
amplified to generate GFP-fusion constructs using the pEGFP-C1 vector (Figure 4.30A).  These 
constructs were first exogenously expressed in HEK293 cells and expression of the respective 
proteins confirmed via immunoblotting analyses using antibodies against GFP (Figure 4.30B).  
The constructs were then ectopically introduced in HEK293 and subcellular localization 
determined via fluorescence microscopy (Figure 4.31).  Our analyses demonstrated that cells 
transfected with either the SRMS SH3 domain or the SRMS kinase domain displayed a 
predominantly diffuse localization pattern (Figure 4.31B, 4.31C and Figure 4.32).  This diffuse 
pattern of localization was comparable to the localization of the control GFP protein (Figure 
4.31A).  However, the SRMS SH2 domain displayed the characteristic cytoplasmic puncta-type 
localization in a significant proportion (55-60%) of transfected cells (Figure 4.31D and Figure 
4.32).  We also tested if the puncta localization displayed by the SRMS SH2 domain would be 
affected by the presence of other domains in SRMS.  Since the SRMS SH3 domain alone produced 
a diffuse localization (Figure 4.31B and Figure 4.32), we tested the influence of this domain on 
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Figure 4.30: Generation of GFP-SRMS domain constructs.  A. Shown here is a schematic 
representation of the various GFP-tagged constructs generated from the wild type SRMS cDNA 
sequence.  cDNA sequences encoding either the SRMS SH3, SRMS SH2, SRMS SH3-linker-SH2 
or the SRMS kinase domains were cloned into the pEGFP-C1 vector to generate the indicated 
GFP-tagged constructs.  B. The indicated constructs were exogenously introduced in HEK293 
cells and lysates probed via immunoblotting analyses using antibodies against GFP.  -tubulin was 
used as the loading control.   
 
the localization of the SRMS SH2 domain.  We generated a construct that encoded GFP-tagged 
SRMS SH3-linker-SH2 protein (the linker indicates the amino acid sequence between the SH3 and 
SH2 domains in SRMS).  Through fluorescence microscopy analyses, we found that the GFP-  
SH3+SH2 protein also localized to cytoplasmic puncta in roughly the same proportion of 
transfected cells as the SRMS SH2 domain (Figure 4.32E and Figure 4.33).  This implied that the 
SRMS puncta formation is at least partially driven by the SRMS SH2 domain and less likely by 
the other SRMS domains.  Further, whereas wild type SRMS displayed the puncta localization in 
90% of transfected cells, the SRMS SH2 domain alone displayed puncta localization in only 55-
60% cells.  This indicates that wild type SRMS-mediated tyrosine phosphorylation of target 
proteins may possibly serve as binding sites for the SRMS SH2 domain which may partly explain 
the absence of a similar proportion of cytoplasmic puncta with the SH2 domain alone.   
 SH2 domains characteristically bind to tyrosine-phosphorylated sequences on proteins (Liu 
et al., 2012; Pawson et al., 2001).  We asked whether the cytoplasmic puncta localization displayed 
by the SRMS SH2 domain is due to the intermolecular interactions of this domain with native 
tyrosine-phosphorylated proteins in cells.  To test this possibility, colocalization of the SRMS SH2 
domain with endogenous tyrosine-phosphorylated proteins was assessed via immunofluorescence  
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Figure 4.31: Subcellular localization of SRMS functional domains.  HEK293 cells were seeded 
in glass coverslips in 6-well tissue culture dishes and transfected with vector encoding: A. GFP 
alone; B. GFP-SRMS SH3 domain, C. GFP-SRMS Kinase domain, D. GFP-SRMS SH2 domain 
and E. GFP-SRMS SH3-linker-SH2.  Transfected cells were fixed, permeabilized and the nuclei 
stained with DAPI.  Images were acquired at 40x magnification on a confocal microscope.  Scale 
bar = 20 nm.   
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Figure 4.32: Quantification of puncta localization displayed by SRMS variants .  HEK293 
cells were seeded in glass coverslips in 6-well tissue culture plates and transfected with vectors 
encoding either the GFP-tagged wild type SRMS (SRMS WT), GFP-SRMS K258M mutant, GFP-
SRMS SH3 domain, GFP-SRMS SH2 domain, GFP-SRMS SH3+SH2 domains or GFP-SRMS 
kinase domain.  Transfected cells were fixed, permeabilized and the nuclei stained with DAPI.     
The percent transfected cells displaying puncta-localization, in each transfected condition, are 
plotted on the y-axis.  200 transfected cells were counted and the number of cells displaying 
puncta-localization calculated as the percentage of total transfected cells and presented as mean ± 
SEM.  Data were obtained from 3 experimental replicates (n=3).   
 
analyses using HEK293 cells expressing ectopic GFP-SRMS SH2.  General phosphotyrosine 
antibodies were used to detect the localization of the total endogenous tyrosine-phosphorylated 
proteins in these cells.  Our immunofluorescence analyses revealed a generally diffuse localization 
pattern of total tyrosine-phosphorylated proteins in HEK293 cells indicating the presence 
oftyrosine phosphorylated proteins in both, the nucleus and cytoplasm (Figure 4.33A- 4.33C). 
Further, we observed that the cytoplasmic puncta produced by the SRMS SH2 domain only partly 
colocalized with total tyrosine-phosphorylated proteins in transfected cells (Figure 4.33C).  We 
next asked if the SRMS-SH2 domain-driven cytoplasmic puncta formation is exclusively 
dependent on the ability of the domain to bind tyrosine-phosphorylated proteins.  To do this, we 
sought to generate a mutant form of the SRMS SH2 domain that is defective in phospho-tyrosine 
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binding.  SH2 domains possess a highly conserved signature phosphotyrosine recognition motif 
namely, the “FLVRES” motif, that forms an integral part of the SH2 domain phosphotyrosine - 
binding pocket (Campbell and Jackson, 2003; Liu et al., 2012).  Previous studies have reported 
the involvement of various residues within this motif in contacting phosphotyrosyl residues 
(Mayer et al., 1992; O'Reilly et al., 2000; Safari et al., 2011).  Additionally, other residues, usually 
 
 
                 
 
Figure 4.33: Colocalization analyses of SRMS SH2 domain and native tyrosine -
phosphorylated proteins.  HEK293 cells were seeded in glass coverslips in 6-well tissue culture 
dishes.  A. Untransfected cells, or cells transfected with B. GFP alone or C. GFP-SRMS SH2 were 
fixed and processed for immunofluorescence analyses.  General phosphotyrosine antibodies and 
secondary goat anti-mouse IgG-Texas red (594 nm) antibodies were used to label total tyrosine 
phosphorylated proteins in cells.  DAPI was used to counter-stain the nucleus.  The cells were 
imaged at 40x magnification by confocal microscopy.  The SRMS cytoplasmic punctae are 
indicated in white arrows.  Scale bar = 20 nm. 
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E and S/T, positioned immediately after the FLVRES motif are also known to play a role in 
mediating interactions with the phosphotyrosyl residue (Amanchy et al., 2007; Campbell and 
Jackson, 2003).  The conserved phosphotyrosine-recognition motif in the SRMS SH2 domain 
corresponds to the sequence, FLIRPS (amino acids 144-149).  The SRMS S149 residue in the 
FLIRPS is succeeded by the residues ESS which are usually conserved and in other SH2 domains 
have been shown to be important for phosphotyrosyl-binding (Amanchy et al., 2007; Campbell 
and Jackson, 2003).  We generated a mutant SRMS SH2 domain where all residues in the FLIRPS-
ESS sequence were substituted with alanine residues.  We next determined the localization pattern 
of this SRMS SH2 domain mutant together with the wild type SRMS SH2 domain.  Vectors 
encoding GFP-tagged wild type SRMS SH2 or SH2 mutant were ectopically introduced in 
HEK293 cells and subcellular localization determined via fluorescence microscopy analyses.  We 
reasoned that if the cytoplasmic puncta localization displayed by the SRMS SH2 domain was 
dependent on the FLIRPS motif-mediated phosphotyrosine-protein binding, then disrupting the 
FLIRPS motif should impair the cytoplasmic puncta pattern of localization.  Contrary to our 
expectations, we observed that like the wild type SRMS SH2 domain, the SRMS SH2 domain 
mutant also localized to cytoplasmic punctae in the same proportion of transfected cells (Figure 
4.34A and 4.34B).  In both cases roughly 50-55% transfected cells displayed cytoplasmic puncta 
localization of the proteins (Figure 4.34 B).  This leads to the possible conclusions that (a) there 
may be structural cues, other than those involving the “FLVRES” phosphotyrosine-recognit ion 
motif, that dictate phosphotyrosine binding in the SRMS SH2 domain, or (b) there may be factors 
completely independent of the phosphotyrosine-binding ability of the SRMS SH2 domain that 
contribute to the formation of the cytoplasmic puncta.  Further studies on the characterization of 
the SRMS cytoplasmic puncta will form part of the future experiments in our laboratory. 
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Figure 4.34: Quantification of punctae localization displayed by the SRMS SH2 domain and 
the SH2-domain mutant.  A. HEK293 cells were seeded in glass coverslips in 6-well tissue 
culture plates and transfected with vectors encoding either the GFP-SRMS SH2 domain or the 
GFP-SRMS SH2 mutant harboring mutations in the FLIRPS-ESS sequence.  Transfected cells 
were fixed, permeabilized and the nuclei stained with DAPI. Images were acquired at 40x 
magnification on a confocal microscope.  Scale bar = 20 nm.  B. Cells displaying puncta-
localization were quantified.  The percent transfected cells displaying puncta-localization, in each 
transfected condition, are plotted on the y-axis.  200 transfected cells were counted and the number 
of cells displaying puncta-localization calculated as the percentage of total transfected cells and 
presented as mean ± SEM.  Data were obtained from 3 experimental replicates (n=3).    
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5.0 General Discussion 
 
5.1 Conclusions 
Non-receptor tyrosine kinases are key enzymes implicated in the regulation of mammalian growth 
and development.  These enzymes engage in interactions with and/or phosphorylation of target 
cellular proteins to regulate essential cellular processes in mammalian cell biology such as cell 
growth, proliferation and differentiation.  SRMS is a member of the BRK family of non-receptor 
tyrosine kinases whose other two members include BRK and FRK.  BRK and FRK represent well-
studied kinases in the context of their cellular substrates, signaling intermediates and overall 
cellular roles.  SRMS on the other hand is the least studied member of the BRK family.  Less is 
known about the cellular substrates, signaling intermediates and cellular functions played by the 
kinase.  Previous studies have shown that SRMS is, biochemically, an active tyrosine kinase which 
is able to associate with and phosphorylate its two known substrates, Dok1 and BRK(Goel et al., 
2013; Miah et al., 2014).  Other studies have reported SRMS protein expression in various 
mammalian tissues and immortalized cell lines (Goel et al., 2013).  Identification of the cellular 
substrates and signaling intermediates of SRMS would be important to understand the possible 
cellular roles played by the kinase in mammalian cells. 
 We employed quantitative mass spectrometry-based phosphoproteomics analyses to 
identify the candidate cellular substrates and signaling intermediates of SRMS.  Firstly, using an 
antibody-based phosphotyrosine-enrichment approach, we identified 663 candidate SRMS 
substrates, from cells expressing ectopic wild type SRMS.  Analyses of the sequences surrounding 
the phosphosites in the candidate substrates revealed novel SRMS substrate motifs, among which 
the KxY and KxxY motifs (where Y represents the phosphosite in the candidate SRMS substrates).  
were identified as the major consensus motifs.  We confirmed findings from our mass spectrometry 
analyses by using a high-throughput validation approach, employing customized peptide arrays 
comprised of peptides derived from the candidate SRMS substrates.  We further independently 
validated Vimentin and Sam68 as bonafide SRMS substrates by demonstrating that SRMS 
colocalized with and phosphorylated both targets in vitro and in vivo, through ectopic-expression 
studies in mammalian cell lines.  At the endogenous level, we also showed that SRMS promoted 
Sam68-tyrosine phosphorylation in EGF-dependent manner in MDA-MB 231 cells, thereby 
highlighting the significance of Sam68 as a potential physiological substrate of SRMS.    
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 Various studies have shown that by engaging in substrate-phosphorylation and/or protein-
protein interactions, tyrosine kinases can potentially influence the activation of serine/threonine 
kinases as part of the greater mammalian kinome.  Such events occurring downstream of tyrosine 
kinases constitute key tyrosine kinase signaling intermediaries.  We were interested in identifying 
the potential phosphoserine/phosphothreonine changes occurring in cells expressing ectopic 
SRMS.  Using a global phosphoproteomic-profiling approach, we identified 60 proteins that were 
hyperphosphorylated on phosphoserine/phosphothreonine sites.  Motif-enrichment analyses 
revealed that the phosphosites on these hyperphosphorylated proteins were candidate targets of 25 
different serine/threonine kinases.  Casein kinase 2 was identified as a major serine/threonine 
kinase.  Importantly, Casein kinase 2 was also identified as a candidate SRMS substrate from our 
phosphotyrosine enrichment-based MS analyses.  We specifically identified the activation loop 
Y182 site, the phosphorylation of which promotes CK2 activation, as a candidate target of SRMS.  
This implies that SRMS may potentially be involved in the positive regulation of Casein kinase 
activity and Casein kinase-dependent cellular functions in cells.  Further experiments are necessary 
to characterize the possible role of SRMS in the regulation of Casein kinase activity and functions.  
 Importantly, bioinformatics-based functional pathway analyses of both, the candidate 
SRMS substrates and signaling intermediates, revealed a major overlap in the types of cellular 
processes regulated by these proteins.  This indicates that the targets we identified in our mass 
spectrometry experiments at large, are not part of random cellular events but instead a part of a 
SRMS-regulated concerted group of proteins partaking in functionally-related cellular processes.  
 Our findings related to the characterization of the SRMS cytoplasmic puncta ruled out the 
possibility that SRMS is sequestered to specific subcellular organelles such as the mitochondr ia, 
endoplasmic reticulum, golgi bodies and lysosomes.  Our data, however, point to the possibility 
that the SH2 domain in the SRMS protein partially regulates the formation of the SRMS 
cytoplasmic punctae.  The composition of the SRMS cytoplasmic punctae and how the SRMS SH2 
domain potentially sequesters the SRMS protein to these cytoplasmic punctate structures is not 
clearly understood and will require further investigation. 
 Overall, by employing advanced mass-spectrometry techniques this project has identified 
numerous biologically-relevant mammalian cellular targets of SRMS.  This will serve as an 
important resource for future mechanistic studies aimed at understanding the cellular and 
physiological roles of SRMS.     
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5.2 Future Directions 
5.2.1 Investigating the cellular function of SRMS 
5.2.1.1 Characterizing the functional link between SRMS, Sam68 and vimentin 
Our phosphoproteomics analyses identified multiple candidate substrates and signaling 
intermediates of SRMS.  We identified and validated Sam68 as a novel SRMS substrate.  Sam68 
is an RNA-binding protein and tyrosine phosphorylation of Sam68 by BRK, for instance, has been 
shown to negatively regulate the RNA-binding properties of the protein (Derry et al., 2000; Lin et 
al., 1997).  It would be interesting to investigate whether SRMS affects the RNA-binding 
properties of Sam68 upon phosphorylation.  This is especially relevant since the SRMS-targeted 
site on Sam68 (Y167) lies in the nucleic acid-binding, KH domain of Sam68 and phosphorylation 
of the Y167 residue within the Sam68 KH domain may play a role in regulating the RNA-binding 
properties of this domain (Valverde et al., 2008).  Other studies have shown that Sam68 sequesters 
BRK to the nucleus in Sam68 nuclear bodies (SNBs) (Lukong et al., 2005).  The phosphorylation 
of Sam68 by BRK in the nucleus was shown to suppress cell cycle progression, as studied in rat 
astrocytes (Lukong et al., 2005).  Our findings here showed that SRMS colocalizes with Sam68 in 
the cytoplasm.  Cytoplasmic Sam68 has been previously found to be associated with polysomes 
indicating that in the cytoplasm, Sam68 is likely implicated in protein synthesis by promoting the 
translation of specific RNAs (Paronetto et al., 2006).  It may be possible that in contrast with BRK, 
SRMS plays a role in promoting the cytoplasmic localization of Sam68 where SRMS-targeted 
phosphorylation of Sam68 is potentially implicated in mRNA translation.  This may be worth 
investigating in future studies. 
 We also identified vimentin as another novel SRMS substrate.  Vimentin intermediate 
filaments are known to play a key role in cell migration and cell mitosis (Chou et al., 1990; Ivaska 
et al., 2007).  Site-specific phosphorylation of vimentin primarily on serine residues is functionally 
well characterized in the context of intermediate filament dynamics (Eriksson et al., 2004; Izawa 
and Inagaki, 2006).  For instance, phosphorylation of vimentin on S38 and S72 by PAK1 kinase 
leads to impaired intermediate filament assembly (Eriksson et al., 2004).  Tyrosine-
phosphorylation of vimentin, however, is not well-documented in the literature.  Given our 
findings here that SRMS colocalization with vimentin likely occurs in vimentin intermediate 
filaments, it would be interesting to investigate whether SRMS plays a role in the regulation of 
vimentin intermediate filament assembly/disassembly. 
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5.2.1.2 Studying the potential role of SRMS in the regulation of casein kinase activation  
Casein kinase 2 was identified in this work as a candidate SRMS target from two independent 
phosphoproteomic screens.  Specifically, the activating-autophosphorylation tyrosine residue, 
Y182 and the partial activating residue Y188, in casein kinase 2 were found to be 
hyperphosphorylated in SRMS-transfected cells (Donella-Deana et al., 2001; Sarno et al., 2002).  
Further, candidate casein-kinase substrates were also found to be hyperphosphorylated in these 
cells, collectively indicating that SRMS may function as an upstream activator of casein kinase.   
Casein kinase 2 is a ubiquitously-expressed protein implicated in essential cellular functions linked 
to, for instance, cell division, cell viability and damage-induced DNA-repair (Lebrin et al., 2001; 
Olsen et al., 2012; Ruhs et al., 2017; Yefi et al., 2011).  Further studies aimed at investigating 
Casein kinase 2 as a SRMS substrate and a key downstream target, would be important.  In the 
context of its role in cellular DNA-repair, Casein kinase 2-dependent regulation of DNA-repair 
through HMGA1 S102 phosphorylation (one of the CK2 targets identified in our 
phosphoproteomic screen) would be worth investigating under conditions of modulated SRMS 
expression.   
  
5.2.1.3 Characterizing the role of SRMS as a regulator of BRK activity in vivo 
Though BRK is not directly linked to the findings reported in this work, a previous published study 
identified BRK Y447 as a target site for phosphorylation by SRMS (Fan et al., 2015).  Given that 
pY447 is the c-Src pY530-equivalent negative regulatory site in BRK, it would be important to 
characterize the effect of SRMS-targeted Y447-phosphorylation on BRK enzymatic activation 
(Goel and Lukong, 2015; Okada, 2012).  This will help understand the potential role of SRMS as 
a regulator of BRK kinase-dependent functions in vivo.  BRK is highly expressed in breast cancer 
cells and we previously also reported SRMS expression in various breast cancer cell lines and  
tissues (Goel and Lukong, 2015; Goel et al., 2013; Miah et al., 2012).  Future studies aimed at 
investigating the effect of modulated SRMS expression on BRK activation in vivo may highlight 
a new mechanistic paradigm of BRK activation in breast cancer cells.  As such, by potentially 
negatively regulating BRK kinase activity, SRMS may play a tumor suppressor role in breast 
cancer cells where the enzyme suppresses the kinase-dependent oncogenic functions of BRK.  
Such impact of SRMS in breast cancer cells will require further investigations.  Additiona lly, 
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identifying the molecular cues underlying the potential spatio-temporal enzymatic regulation of 
BRK by SRMS in mammalian cells would also be important to study.  
 
5.2.2 Characterizing the SRMS cytoplasmic puncta 
Our findings in this work showed that a significant proportion of cells expressing ectopic SRMS 
SH2 domain displayed the punctate localization, characteristic of the wild-type full length SRMS 
protein.  This implied that the SRMS puncta may be driven at least in part by the SRMS SH2 
domain.  Future work would be necessary to characterize the mechanism by which SRMS is 
sequestered to these punctae.  To this end, an important direction of research may lie in studying 
the SRMS interactome.  It is possible that specific SRMS-interacting partners may represent key 
constituents of the SRMS cytoplasmic punctae and modulating the binding of SRMS with these 
interacting proteins may help characterize these punctate structures further.  In this context, the 
use of mass spectrometry-based proximity-dependent biotin identification (BioID) method may be 
well suited to identify the SRMS cellular interactors (Lambert et al., 2015).  The method involves 
the exogenous expression of a modified bait protein, fused to a promiscuous bacterial biotin ligase 
(BirA R118G mutant), that tethers to bonafide protein interactors in vivo upon biotinylat ion 
(achieved by adding biotin to the culture media).  The bait protein can then be immunoprecipitated 
and the bound proteins identified via LC-MS analyses.  Using this approach protein-protein 
associations/interactions, that are either weak or transient in nature, can be identified (Lambert et 
al., 2015).  It is expected that this approach may be better able to define the cellular constituents 
of the SRMS cytoplasmic punctate structures and further our understanding of how and perhaps 
why SRMS localizes to these punctate structures. 
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7.0 APPENDIX A 
 
SUPPLEMENTARY TABLES 1- 8:  
Supplementary Tables 1 to 8 are available as part of the published article Goel et al., MCP 2018. 
These Supplementary Tables and legends to these tables can be accessed freely on the Journal’s 
website as “Supplemental Data”, using the following weblink: 
http://www.mcponline.org/content/early/2018/03/01/mcp.RA118.000643/suppl/DC1 
SUPPLEMENTARY TABLES 9-11: 
Supplementary Tables 9 to 11 are part of a manuscript that has been accepted for publication by 
the journal, Proteome Science.  These Supplementary Tables have been compressed into a single 
file and uploaded as an “Additional File” to the University of Saskatchewan’s Thesis and 
Dissertation submittal system.  Accessibility to this file is governed by the University of 
Saskatchewan.  
 
The legends to Supplementary Tables 9 to11 are appended below: 
 
SUPPLEMENTARY TABLE 9: The table is organized in the following spreadsheets: 
• Spreadsheet “All Phosphopeptides”: This table lists all identified phosphopeptides from 
three independent replicates, via LC-MS/MS. Additional information corresponding to 
each phosphopeptide is also shown and includes peptide ID# (numerical ID), fraction 
(enriched; 1 or flowthrough; 2 fractions), Retention time, m/z, charge, measured mass, 
mass error, score, peptide sequence, modifications (type of PTM), UniProt accession, 
Phosphosite(s), sequence window, description of protein, use in quantitation (at least 2 
unique tryptic peptides were identified for the corresponding protein), ANOVA p-values 
corresponding to each phosphopeptide identified across the three independent replicates, 
normalized abundance (phosphopeptide intensity) of the identified phosphopeptides across 
each replicate, average phosphopeptide intensities of the peptide in the control cells or cells 
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expressing wild type SRMS, fold-change abundance of phosphopeptide intensities in 
SRMS-expressing cells (SRMS/Control) and Log2-scaled fold-change of SRMS/control 
values. 
• Spreadsheet “All unique phosphoproteins”: This table lists all the unique phosphoproteins 
mapped from the phosphopeptides quantified via LC-MS/MS in the Vector and SRMS-
expressing cells. Also shown are all associated phosphosites identified for each protein. 
• Spreadsheet “Phosphopeptides p-value ≤ 0.05”: This table lists all phosphopeptides filtered 
at an ANOVA p-value threshold of 0.05. Also shown is other relevant information 
corresponding to each phosphopeptide, as in Spreadsheet “All Phosphopeptides”.   
• Spreadsheet “Hyperphosphorylated proteins”: This table lists all the 
hyperphosphorylated/upregulated proteins identified in the SRMS-regulated 
phosphoproteome. These proteins were mapped from the 
hyperphosphorylated/upregulated peptides (Log2 SRMS/Control ≥ 1.58 and ANOVA p-
value ≤ 0.05). Therefore, only phosphosites identified at Log2 SRMS/Control ≥ 1.58 and 
ANOVA p-value ≤ 0.05, are shown for every protein. 
• Spreadsheet “Hypophosphorylated proteins”: Shown here is the 
hypophosphorylated/downregulated protein mapped from the 
hypophosphorylated/downregulated peptide (Log2 SRMS/Control ≤ -1 and ANOVA p-
value ≤ 0.05) identified in SRMS-expressing cells. 
    
SUPPLEMENTARY TABLE 10: The file is organized into the following spreadsheets: 
• Spreadsheet “Cell. & Biol. processes”: This table shows all the ce llular and biological 
processes identified by IPA analysis (www.ingenuity.com) enriched from the 
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upregulated/hyperphosphorylated proteins identified in the SRMS-regulated 
phosphoproteome. To minimize redundancy, the cellular and biological processes are 
categorized in specific functional “categories”. Also shown for every cellular and 
biological process are P-values (Fisher’s exact t-test), activation z-score, predicted 
activation state (based on a cut-off z-score= +/-2), protein names and the number of 
proteins enriched in the corresponding cellular and biological process.  
• Spreadsheet “Upstream regulators”: This table lists all the upstream regulators identified 
by IPA analysis for the SRMS-dependent upregulated/hyperphosphorylated proteins. Also 
shown are p-values, activation z-score, predicted activation state (based on a cut-off z-
score= +/-2), protein names and number of proteins for every upstream regulator identified 
by IPA analyses. 
• Spreadsheet “Signaling pathways”: Shown here are the canonical signaling pathways 
corresponding to the upregulated/hyperphosphorylated proteins, as identified by IPA 
analysis. Also shown are the -log p-values, ratio (the ratio estimates the representation of 
the proteins in each canonical pathway. This is calculated as the ratio of the number of 
proteins that are enriched in the pathway to the number of proteins in the Ingenuity database 
reference dataset that make up the pathway) and the protein names corresponding to each 
canonical pathway.    
 
SUPPLEMENTARY TABLE 11: This table lists all the candidate upstream kinases identified 
by NetworKIN analysis, for the upregulated phosphosites. Shown in the table is the substrate 
(phosphoprotein identified in the SRMS-regulated phosphoproteome), position (corresponding 
upregulated phosphosite), upstream kinase ID (candidate kinase known to target the corresponding 
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phosphosite), NetworKIN score, kinase group (NetPhorest-annotated kinase group), NetPhorest 
score, STRING identifier (the corresponding STRING-annotated identifier/ID for the interaction 
between the kinase and its substrate phosphoprotein), STRING score, Motif sequence (the specific 
motif corresponding to the phosphosite that is targeted by the candidate kinase) and STRING path.  
 
